
<!DOCTYPE html>
<html dir="ltr" lang="en">
<head>
 
<link rel="preconnect" href="https://cdn.cookielaw.org">
<link href="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js" rel="preload" as="script">
 <link href="https://www.googletagmanager.com/gtm.js?id=GTM-5MKXR9" rel="preload" as="script">
<!-- OneTrust Cookies Consent Notice start --> 
<script src="" type="text/javascript" charset="UTF-8" data-domain-script="7a4eae6f-1f57-4f7c-8a64-5aa159ee745e"></script>
<script type="text/javascript">
function OptanonWrapper() { }
</script>
<!-- OneTrust Cookies Consent Notice end -->
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta lang="en">
<meta http-equiv="content-type" content="text/html; charset=utf-8">
<meta http-equiv="content-language" content="en">
<meta name="viewport" content="width=device-width, height=device-height, initial-scale=1, minimum-scale=1, maximum-scale=5, user-scalable=1">
 <!-- Title and Description -->
 <title>Human Immunodeficiency Virus (HIV) Infection in Infants and Children - Pediatrics - MSD Manual Professional Edition</title>
 
 <!-- Schema.org/Additional markup -->
 
 
 
 
 
 
 
 
 
 
 
 
 
 <!-- Twitter Card data -->
 
 
 
 
 
 <!-- Open Graph data -->
 
 
 
 
 
 
 
 
 
 
 
 
 
<!-- Google Tag Manager --> <script></script> <!-- End Google Tag Manager -->
 <script type="text/javascript">
 // Way froward settings. Strongly typed for Typescript code.
 // Typescript definition file is in \src\Foundation\Presentation\code\Scripts\typings\Settings.d.ts
 MManual = window.MManual || {};
 MManual.Foundation = MManual.Foundation || {};
 MManual.Feature = MManual.Feature || {};
 MManual.Foundation.Logging = {
 Level : "WARN"
 }
 MManual.Foundation.Context = {
 Language: {
 Name: "en",
 Code: "en"
 },
 Edition: "Professional"
 }
 MManual.Foundation.Context.Item = {}
 
 MManual.Foundation.Context.Item.SitecoreId = "6ea530b9-c85e-4653-b466-245f2a0e10ea";
 MManual.Foundation.Context.Item.MediaId = "";
 MManual.Foundation.Context.Item.VasontId = "v1107293";
 MManual.Foundation.Context.Item.TemplateId = "9fe4ab09-1603-40e4-91f9-0ac01a474c58";
 
 
 MManual.Foundation.Context.Chapter = {
 SitecoreId : "323c3858-0888-45a6-a28f-0f7aa35180a3",
 VasontId : "v1107278"
 }
 MManual.Foundation.Context.Section = {
 SitecoreId : "b3de9005-316e-4c7c-a6f6-52a8bf0ea231",
 VasontId : "v878846"
 }
 
 MManual.Foundation.TemplateIds = {
 Topic : "9fe4ab09-1603-40e4-91f9-0ac01a474c58"
 }
 MManual.deferredScripts = [];
 // Below settings are obsolete. Please use MManual.Foundation.Context
 //////////////////
 // OBSOLETE START
 ///////////////////
 MManual.settings = MManual.settings || {};
 MManual.settings.edition = "Professional";
 MManual.settings.language = "en";
 MManual.settings.languageCode = "en";
 MManual.settings.displayDateFormat = "dd/MM/yy";
 MManual.settings.dateFormat = "dd/MM/yy";
 MManual.settings.loadLocationsGlobal = true;
 MManual.settings.LexicompEnabled = false;
 MManual.settings.topic = MManual.settings.topic || {};
 MManual.settings.topic.getTopicsForResourceUrl = "/Redesign/Topic/GetTopicsForResource";
 MManual.settings.topic.getTopicHelpfulUrl = "/Redesign/Topic/GetTopicHelpful";
 MManual.settings.topic.wasThisTopicHelpfulUrl = "/Redesign/Topic/WasThisTopicHelpful";
 MManual.settings.topic.getTableBodyUrl = "/Redesign/Topic/GetTableBody";
 MManual.settings.socialMedia = MManual.settings.socialMedia || {};
 MManual.settings.socialMedia.enableMultimediaPopupShareButton = true;
 MManual.CommonLetters = ['A', 'B', 'C', 'D', 'E', 'F', 'G', 'H', 'I', 'J', 'K', 'L', 'M', 'N', 'O', 'P', 'Q', 'R', 'S', 'T', 'U', 'V', 'W', 'X', 'Y', 'Z'];
 MManual.CommonNumbers = ['0', '1', '2', '3', '4', '5', '6', '7', '8', '9'];
 MManual.Context = MManual.settings;
 MManual.Context.Item = MManual.Foundation.Context.Item;
 /////////////////
 // OBSOLETE END
 /////////////////
 </script>
 <script src="./Content/Scripts/Redesign/Lib/jquery-3.5.1.min.js" type="text/javascript"></script>
 <script src="./Content/Scripts/Redesign/Lib/jquery-ui-1.13.1.custom/jquery-ui.min.js" type="text/javascript"></script>
 <script src="./Content/Scripts/Foundation/Presentation/Library/Knockout/knockout-3.5.1.js" type="text/javascript"></script>
 <script src="./Content/Scripts/Redesign/Lib/hammer.2.0.7.min.js" type="text/javascript"></script>
 <script src="./Content/Scripts/Redesign/Lib/polyfills/es5-shim.4.5.13.min.js" type="text/javascript"></script>
 <script src="./Content/Scripts/Redesign/Lib/polyfills/es6-shim.0.35.4.min.js" type="text/javascript"></script>
 <script src="./Content/Scripts/Redesign/Lib/slick-1.8.0/slick.1.8.0.min.js" type="text/javascript"></script>
<!--[if (gte IE 9)|!(IE)]><!-->
<script src="./bundles/redesign/libsjsv4.1.2.2-13178e13ca.js?v=9oeWsccS0AXvU_mpLneFQpk81D2qyviYAadBAspEdRc1"></script>
<!--<![endif]-->
<!--[if lt IE 9]>
 <script src="/bundles/redesign/ie8libsjsv4.1.2.2-13178e13ca.js?v=NYMKNIKPtdByxJkp3-a4OoxrVMsYmUh3Th334huO0BY1"></script>
<![endif]-->
<!-- Add custom class to categorize all cookies as functional. -->
<script src='./bundles/redesign/mmanualjsv4.1.2.2-13178e13ca.js?v=qZy1l8ugVchOqoSbrCHnQvB_O3jXnpspHrGZgwDHF0I1' class='optanon-category-C0002'></script>
<script defer="" src='./bundles/redesign/mmanualTopicjsv4.1.2.2-13178e13ca.js?v=kSA_yN8XuMyhoVC1QLzYxWJE66uhmC-mSc_-tgT27II1' class='optanon-category-C0002'></script>
<script defer="" src='./bundles/redesign/mmanualTopicResourceSearchjsv4.1.2.2-13178e13ca.js?v=iHsFLQRu7O1_jYYodP5cLz5m6_oggwQ97PNvPDyRMrw1' class='optanon-category-C0002'></script>
<!--Region information -->
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<link rel="preload" href="/Content/Fonts/Redesign/oldrambla/Rambla-Latin-webfont.woff2" as="font" type="font/woff2" crossorigin="anonymous">
<link rel="preload" href="/Content/Fonts/Redesign/OpenSans/OpenSans-700-Bold.woff2" as="font" type="font/woff2" crossorigin="anonymous">
<link rel="preload" href="/Content/Fonts/Redesign/OpenSans/OpenSans-700-Bold-Italic.woff2" as="font" type="font/woff2" crossorigin="anonymous">
<link rel="preload" href="/Content/Fonts/Redesign/OpenSans/OpenSans-400-Regular.woff2" as="font" type="font/woff2" crossorigin="anonymous">
<link rel="preload" href="/Content/Fonts/Redesign/OpenSans/OpenSans-400-Regular-Italic.woff2" as="font" type="font/woff2" crossorigin="anonymous">
<link rel="preload" href="/Content/Fonts/Redesign/OpenSans/OpenSans-300-Light.woff2" as="font" type="font/woff2" crossorigin="anonymous">
<link rel="preload" href="/Content/Fonts/Redesign/OpenSans/OpenSans-600-SemiBold.woff2" as="font" type="font/woff2" crossorigin="anonymous">
<link href="./bundles/redesign/mmanualcssv4.1.2.2-13178e13ca.css?v=RUczVKOp43QqHlIomZoV4XMWus4DZWBAeuESVt-1iCc1" rel="stylesheet" type="text/css" media="screen">
<link href="./bundles/redesign/jqueryuicssv4.1.2.2-13178e13ca.css?v=3k6hV5TZDiil7_Jv0lADrVVLB9hJfoX2PenhijDq_d81" rel="stylesheet" type="text/css" media="screen">
 <link href="./bundles/redesign/mmanualprofessionalcssv4.1.2.2-13178e13ca.css?v=mbUz3b7WGmUBumHpYEaEcWfHb1bxVAgvrA5uGMAlaJ81" rel="stylesheet" type="text/css">
<!--[if lt IE 9]><link href="/bundles/redesign/ie8cssv4.1.2.2-13178e13ca.css?v=" rel="stylesheet"/>
<![endif]-->
<link href="./bundles/redesign/mmanualcssprintv4.1.2.2-13178e13ca.css?v=2xJ7o27xwBLBtbGx65XzwLYcjgNEMec7qcBRi3GYAM01" rel="stylesheet" type="text/css" media="print">
<link href="./bundles/redesign/mmanualcsshybridv4.1.2.2-13178e13ca.css?v=LCUeOfwqiGi437ffhbWXxV6YW74rb9NUl93CESRStCs1" rel="stylesheet" type="text/css" media="hybrid">
<!--[if lt IE 9]>
 <script src="//html5shiv.googlecode.com/svn/trunk/html5.js"></script>
<![endif]-->
<script type="text/javascript">
 function msieversion() {
 var ua = window.navigator.userAgent;
 var msie = ua.indexOf("MSIE ");
 if (msie > 0 || !!navigator.userAgent.match(/Trident.*rv\:11\./) || msie == NaN)
 var test = $('li.no-children');
 test.addClass("noSpace");
 return false;
 };
 //msieversion();
</script>
<div style="display: none">
 <div class="confirmationpopup__container" id="access-confirmation-popup" style="z-index: 10000;">
 <div>
 <div>
 <div>
 <div class="confirmationpopup__container">
 <span class="confirmationpopup__logo"></span>
 <div class="confirmationpopup__title">
 <span class="confirmationpopup__text">MSD Manual</span>
 </div>
 <div class="confirmationpopup__description">
 <p>Please confirm that you are a health care professional</p>
 </div>
 <div class="confirmationpopup__answer">
 <a class="confirmationpopup__button confirmationpopup__button--yes" role="button">Yes</a>
 <a class="confirmationpopup__button confirmationpopup__button--no" role="button">No</a>
 </div>
 </div>
 </div>
 </div>
 </div>
 </div>
</div>
<div style="display: none">
 <div class="confirmationpopup__container" id="external-link-confirmation-popup" style="z-index: 10000;">
 <div>
 <div>
 <div>
 <div class="confirmationpopup__container">
 <span class="confirmationpopup__logo"></span>
 <div class="confirmationpopup__title">
 <span class="confirmationpopup__text">Leave this Site?</span>
 </div>
 <div class="confirmationpopup__description">
 <p>The link you have selected will take you to a third-party website. We do not control or have responsibility for the content of any third-party site.</p>
 </div>
 <div class="confirmationpopup__answer">
 <a class="confirmationpopup__button confirmationpopup__button--yes" role="button">Continue </a>
 <a class="confirmationpopup__button confirmationpopup__button--no" role="button">Cancel</a>
 </div>
 </div>
 </div>
 </div>
 </div>
 </div>
</div>
 <script> 
 var externalUrls = JSON.parse(atob('["www.cdc.gov/mmwr/preview/mmwrhtml/rr58e324a1.htm","www.cdc.gov/mmwr/preview/mmwrhtml/rr6403a1.htm","www.cdc.gov/vaccines/vpd/hepb/hcp/faqs-hcp-pediarix.html","cid.oxfordjournals.org/content/53/7/e25.full.pdf html?sid=67183860-0d8a-4d54-9d57-fd12d5682421","www.nature.com/articles/s41467-022-32936-3","pubmed.ncbi.nlm.nih.gov/35772465","pubmed.ncbi.nlm.nih.gov/31515408","www.ncbi.nlm.nih.gov/pmc/articles/PMC4028378","www.drugs-porphyria.org","porphyriafoundation.org/drugdatabase","aasldv2019stg.aasld.org/sites/default/files/2019-06/NAFLD Guidance 2018.pdf","aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.31060","academic.oup.com/cid/article/58/1/e1/374007","www.cdc.gov/hepatitis/hav/havfaq.htm","journals.lww.com/ajg/Fulltext/2018/02000/ACG_Clinical_Guideline__Alcoholic_Liver_Disease.9.aspx","www.cdc.gov/mmwr/preview/mmwrhtml/rr6007a1.htm","jama.jamanetwork.com/article.aspx?articleid=2492881","www.nhlbi.nih.gov/health-pro/guidelines/current/cardiovascular-health-pediatric-guidelines","gi.org/guideline/genetic-testing-and-management-of-hereditary-gastrointestinal-cancer-syndromes","rheumatology.oxfordjournals.org/content/42/2/235.full.pdf","onlinelibrary.wiley.com/doi/10.1002/14651858.CD003448.pub4/abstract?systemMessage=Wiley Online Library will be unavailable on Saturday 17th December 2016 at 09:00 GMT/ 04:00 EST/ 17:00 SGT for 4hrs due to essential maintenance.Apologies for the inconvenience","cid.oxfordjournals.org/content/early/2016/11/03/cid.ciw670.full","www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm","onlinelibrary.wiley.com/doi/10.1111/apt.13148/abstract","onlinelibrary.wiley.com/doi/10.1359/jbmr.06s204/abstract","onlinelibrary.wiley.com/doi/10.1002/jbmr.438/abstract","journals.lww.com/infectdis/Fulltext/2013/05000/New_Guidelines_for_Antimicrobial_Prophylaxis_in.10.aspx","jama.jamanetwork.com/article.aspx?articleid=1487498","cid.oxfordjournals.org/content/46/12/1801.full","www.cdc.gov/mmwr/volumes/67/wr/mm6703a5.htm","www.cdc.gov/mmwr/volumes/68/wr/mm6832a3.htm","www.onlinejacc.org/content/64/22/e77","jamanetwork.com/journals/jamasurgery/fullarticle/2623725","www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html#t-01","www.cdc.gov/mmwr/preview/mmwrhtml/rr5911a1.htm","www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm","www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html","www.cdc.gov/mmwr/volumes/65/rr/rr6503a1.htm","www.onlinejacc.org/content/56/22/1864","www.idsociety.org/practice-guideline/hap_vap","academic.oup.com/cid/article-lookup/doi/10.1086/649858","acp.silverchair-cdn.com/acp/content_public/journal/aim/937814/m183600ff3_panel_2.jpeg?Expires=1556744998&amp;Signature=Oc7aO8PzGrh4tsbJzhWwSTvws~WHIkN~BaNqycHCh1TDufduqpbjgojduPU-8q5Owv2tym0x3HekrEXjegtUiZ2C15Qag5cNuhdxGu84JMb5nLmefg~ofSQfhTAdRWr9ECrJt4a1nu0Rl2crQwlTdDcL4Q8k9MGLgeg6yqGHzJGmlul2E8fEWxiP1ivlR9GypBYLjQ-B3eUH4hi-SYVCDfitv2zjW01hFzUlZM6OSXb5yEGThsimV8yQSCxcSLwaaY~CnZZ96lrcrr87nkPmtyvM9iPUUs-ix3Be5lXTIDWuIRrY3xmWXTnpNu7fxROSemZYm5ESTXbpGdJH6gMyuA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA","www.cdc.gov/mmwr/preview/mmwrhtml/mm6203a3.htm","www.cdc.gov/mmwr/volumes/68/wr/mm6832a3.htm","www.ncbi.nlm.nih.gov/pubmed?term=Crit Care Med[Jour] AND 42[volume] AND 1157[page] AND 2014[pdat] AND Karvellas CJ[first author] AND Outcomes and complications of intracranial pressure monitoring in acute liver failure&amp;TransSchema=title&amp;cmd=detailssearch","www.ncbi.nlm.nih.gov/pubmed?term=\"Hepatology (Baltimore, Md.)\"[Jour] AND 66[volume] AND 1219[page] AND 2017[pdat] AND Albillos A[author] AND Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis. &amp;TransSchema=title&amp;cmd=detailssearch","fascrs.org/ascrs/media/files/downloads/Clinical Practice Guidelines/the-american-society-of-colon-practical-guideline-sinus-pilonidalis.pdf","fascrs.org/ascrs/media/files/downloads/Clinical Practice Guidelines/practice_parameters_for_the_management_of_hemorrhoids.pdf\"","www.cdc.gov/mmwr/preview/mmwrhtml/mm5803a4.htm","www.cdc.gov/mmwr/volumes/67/wr/mm6722a5.htm","pubmed.ncbi.nlm.nih.gov/21956720-evidence-report-genetic-and-metabolic-testing-on-children-with-global-developmental-delay-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology-society?from_term=\"Neurology\"[Jour] AND 2011[pdat]&amp;from_pos=7","www.nal.usda.gov/fnic/vitamins-and-minerals","www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management","www.willseye.org/doctor/melvin-roat-md-facs","faculty.mdanderson.org/profiles/pedro_ramirez.html","pharmacy.ucsf.edu/shalini-lynch","weillcornell.org/jwbarnhill","profiles.stanford.edu/david-spiegel","www.umc.edu/doctors/Huang_Juebin","www.chop.edu/doctors/moldenhauer-julie-s","www.urmc.rochester.edu/people/20996734-stephen-brian-sulkes","podiatry.temple.edu/kendrick-whitney","www.med.upenn.edu/apps/faculty/index.php/g275/p8178541","www.urmc.rochester.edu/people/21136627-ronald-rabinowitz","psychiatry.ubc.ca/person/rosemary-basson","profiles.utsouthwestern.edu/profile/48082/ravindra-sarode.html","sop.washington.edu/people/brian-werth","pharmacy.ucsd.edu/faculty/le","www.chop.edu/doctors/calabria-andrew-c","medicine.uiowa.edu/psychiatry/profile/william-coryell","www.chop.edu/doctors/mehta-jay","www.adelphi.edu/faculty/profiles/profile.php?PID=0649","www.ot.wustl.edu/about/our-people/peggy-barco-8","www.urmc.rochester.edu/people/21411717-jimena-cubillos","www.mlanet.org/resources/userguide.html","www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-vaccine-fact-sheet#how-effective-are-hpv-vaccines","www.ncbi.nlm.nih.gov/books/NBK25349","www.nichd.nih.gov/sites/default/files/2018-09/PRGLAC_Report.pdf","academic.oup.com/cid/article/45/7/941/544359","academic.oup.com/cid/article/55/10/e86/321183","aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.29800","aasldv2019stg.aasld.org/sites/default/files/2019-06/NAFLD Guidance 2018.pdf","www.cdc.gov/hepatitis/hav/havfaq.htm","www.nejm.org/doi/10.1056/NEJMoa1613512?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub  0www.ncbi.nlm.nih.gov","www.ncbi.nlm.nih.gov/pmc/articles/PMC5848239","pubmed.ncbi.nlm.nih.gov/29260225","aasldv2019stg.aasld.org/sites/default/files/2019-06/NAFLD Guidance 2018.pdf","www.cdc.gov/hepatitis/hav/havfaq.htm","aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.29800","jamanetwork.com/article.aspx?articleid=1487498","www.nejm.org/doi/10.1056/NEJMoa1613512?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub  0www.ncbi.nlm.nih.gov","circ.ahajournals.org/content/132/15/1435.long","www.porphyriafoundation.com","porphyriafoundation.org/for-healthcare-professionals/drug-safety","www.porphyria-europe.com","www.drugs-porphyria.org","profiles.stanford.edu/judith-prochaska","circ.ahajournals.org/content/132/15/1435.long","aasld.org/publications/practice-guidelines","www.uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/hepatitis-c-screening","aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.31065","www.ncbi.nlm.nih.gov/pubmed/22972059","aasldv2019stg.aasld.org/sites/default/files/2019-06/NAFLD Guidance 2018.pdf","academic.oup.com/cid/article/53/7/e25/424286","www.idsociety.org/practice-guideline/community-acquired-pneumonia-cap-in-adults","www.idsociety.org/practice-guideline/hap_vap","www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html","porphyriafoundation.org","www.ncbi.nlm.nih.gov/pmc/articles/PMC4695986","www.lajh.org/about/the-jewish-home-team/meet-our-clinicians","www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html","www.ncbi.nlm.nih.gov/pmc/articles/PMC7431966","www.the-scientist.com/news-opinion/vector-based-vaccines-come-to-the-fore-in-the-covid-19-pandemic-67915","www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext","www.med.upenn.edu/apps/faculty/index.php/g275/p8841440","www.cdc.gov/mmwr/volumes/70/rr/rr7001a1.htm","www.essentialaccessibility.com/merck","www.menopause.org/docs/default-source/2017/nams-2017-hormone-therapy-position-statement.pdf","www.ncbi.nlm.nih.gov/pmc/articles/PMC4028378","www.nejm.org/doi/10.1056/NEJMoa2112435?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub  0pubmed","www.ajog.org/article/S0002-9378(21)00963-7/fulltext","www.ajog.org/article/S0002-9378(20)30861-9/fulltext","ascopubs.org/doi/full/10.1200/JCO.21.00006","www.nejm.org/doi/10.1056/NEJMoa2112435?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub  0pubmed","www.ajog.org/article/S0002-9378(21)00963-7/fulltext","www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30020-8/fulltext","ascopubs.org/doi/full/10.1200/JCO.2014.58.3401?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub  0pubmed","ascopubs.org/doi/full/10.1200/JCO.2017.76.5966?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub  0pubmed","www.ajog.org/article/S0002-9378(20)30861-9/fulltext","www.nejm.org/doi/full/10.1056/NEJMoa1910962?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub  0pubmed","jamanetwork.com/journals/jamaoncology/fullarticle/2773114","ascopubs.org/doi/full/10.1200/JCO.21.00006","pubmed.ncbi.nlm.nih.gov/36107786","pubmed.ncbi.nlm.nih.gov/30304427","www.ncbi.nlm.nih.gov/pmc/articles/PMC5958910","www.ahajournals.org/doi/10.1161/HYP.0000000000000084","pubmed.ncbi.nlm.nih.gov/27195814","pubmed.ncbi.nlm.nih.gov/36130612","www.ncbi.nlm.nih.gov/pmc/articles/PMC9940918","pubmed.ncbi.nlm.nih.gov/36351458","pubmed.ncbi.nlm.nih.gov/36041474","pubmed.ncbi.nlm.nih.gov/29608107","pubmed.ncbi.nlm.nih.gov/35316839","pubmed.ncbi.nlm.nih.gov/36148880","pubmed.ncbi.nlm.nih.gov/37295445","www.ncbi.nlm.nih.gov/pmc/articles/PMC7652033","www.nejm.org/doi/10.1056/NEJMoa2032183?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub  0pubmed","www.ahajournals.org/doi/full/10.1161/CIR.0000000000000678?rfr_dat=cr_pub  0pubmed&url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org","diabetesjournals.org/care/article/42/1/126/36330/Racial-and-Ethnic-Differences-in-Anthropometric","agsjournals.onlinelibrary.wiley.com/doi/abs","www.ncbi.nlm.nih.gov/pubmed/31515408","opendata.ncats.nih.gov/covid19/variant/activity","opendata.ncats.nih.gov/variant/activity","diabetesjournals.org/care/article/41/12/2669/36544/Management-of-Hyperglycemia-in-Type-2-Diabetes","pubmed.ncbi.nlm.nih.gov/35772465","pubmed.ncbi.nlm.nih.gov/34004177","pubmed.ncbi.nlm.nih.gov/35973577","www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30925-9/fulltext","pubmed.ncbi.nlm.nih.gov/33349658","pubmed.ncbi.nlm.nih.gov/35834240","pubmed.ncbi.nlm.nih.gov/38319329","www.ncbi.nlm.nih.gov/pmc/articles/PMC10752259","pubmed.ncbi.nlm.nih.gov/35449407","pubmed.ncbi.nlm.nih.gov/19502645","pubmed.ncbi.nlm.nih.gov/35483753","pubmed.ncbi.nlm.nih.gov/3404868"]'));
 $(document).ready(function () {
 $("a").click(function() {
 var href = $(this).attr('href');
 if (MManual.Foundation.Url.IsAbsoluteUrl(href)) {
 var hrefWithoutProtocol = MManual.Foundation.Url.RemoveProtocol(href);
 var match = externalUrls.some(function(url) {
 return url.length > 0 && hrefWithoutProtocol.startsWith(url);
 });
 if (match) {
 externalLinkConfirmation.showConfirmationModal(href);
 } else {
 return true;
 }
 } else {
 return true;
 }
 return false;
 });
 });
 </script>
 <!-- AddToAny script remove-->
<script></script>
 
<script type="text/html" id="audio-player-template">
 <div class="multimedia multimedia--withdescription" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__audio hide-on-print">
 <div class="multimedia__audio--wrapper">
 <audio>
 <source data-bind="attr: { src: AudioUrl, type: MimeType }" />
 </audio>
 </div>
 </div>
 <div class="multimedia__description">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <div class="multimedia__description--wrapper">
 <!-- ko if: $data.Description -->
 <div class="multimedia__description--content">
 <p data-bind="html: Description"></p>
 </div>
 <!-- /ko -->
 <!-- ko if: $data.Credits -->
 <div class="multimedia__description--credits">
 <p data-bind="html: Credits"></p>
 </div>
 <!-- /ko -->
 </div>
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script>
<script type="text/html" id="inlinemedia-audio-template">
 <!-- ko if: isSideline-->
 <div class="inlinebox inlinebox--right inlinebox--clickable" data-bind="attr: {id: ItemId}, css: {'inlinebox--right': !IsInCarousel(), 'inlinebox--full': IsInCarousel}">
 <div class="inlinebox__wrapper">
 <!-- ko ifnot: IsInCarousel-->
 <div class="inlinebox__header">Audio</div>
 <!-- /ko -->
 <div class="inlinebox__content">
 <div class="multimedia__link" data-bind="component: { name: 'multimedia-link-text', params: multimediaLinkModel }"></div>
 <div class="inlinebox__button">
 <img loading="lazy" alt="icon" data-bind="attr: {src: ThumbnailUrl}">
 </div>
 </div>
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isInline -->
 <div data-bind="css: componentClasses(), attr: {id: ItemId}">
 <div class="inlinemedia__wrapper">
 <div class="inlinemedia__header">
 <div class="inlinemedia__title" data-bind="html: Title"></div>
 </div>
 <div class="inlinemedia__content">
 <audio>
 <source data-bind="attr: { src: AudioUrl, type: MimeType }" />
 </audio>
 <!-- ko if: detailsAvailable -->
 <div class="inlinemedia__more">
 <div class="inlinemedia__action inlinemedia__action--show" data-bind="event: {click: toggleDetailsFunction, keypress: toggleDetailsFunction}">
 <i class="inlinemedia__eye"></i>
 <span class="inlinemedia__details hide" role="button" tabindex="0">
 Show Details
 </span>
 <span class="inlinemedia__details show" role="button" tabindex="0">
 Hide Details
 </span>
 <div class="inlinemedia__information" data-bind="html: Description"></div>
 <div class="inlinemedia__credits" data-bind="html: Credits"></div>
 </div>
 </div>
 <!-- /ko -->
 </div>
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isText -->
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }"></div>
 <!-- /ko -->
</script>
<script type="text/html" id="biodigital-player-template">
 <div class="multimedia" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__iframe">
 <div class="multimedia__iframe--spacer"></div>
 <div class="multimedia__iframe--wrapper">
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="no" frameBorder="0" data-bind="attr: { src: IframeSrcComputed, title: Title }, iOSresizeIframeToParent : attachResizeCallback, swipe: {next: parentContext.showNext, prev: parentContext.showPrev}" sandbox="allow-modals allow-scripts allow-same-origin allow-forms allow-popups allow-top-navigation"></iframe>
 </div>
 <div class="multimedia__iframe--spacer"></div>
 </div>
 <div class="multimedia__description" data-bind="getDivRef : $parent.descriptionDivRef">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <!-- ko ifnot: parentContext.displaySingle -->
 <div class="multimedia__pager hide-on-print">
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showFirst">«</a>
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showPrev">‹</a>
 <span class="multimedia__pager--number" data-bind="text: $parent.activeEntry().index + 1"></span>/<span class="multimedia__pager--number" data-bind="text: $parent.activeList().length"></span>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showNext">›</a>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showLast">»</a>
 </div>
 <!-- /ko -->
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script><script type="text/html" id="inlinemedia-biodigital-template">
 <!-- ko ifnot: isText-->
 <div data-bind="css: componentClasses()">
 <div class="inlinemedia__wrapper">
 <div class="inlinemedia__header">
 <div class="inlinemedia__title" data-bind="html: Title"></div>
 <!-- ko if: isSideline() && !IsInCarousel() -->
 <div class="inlinemedia__open hide-on-print">
 <i class="inlinemedia__icon--open"></i>
 </div>
 <!-- /ko -->
 </div>
 <div class="inlinemedia__content">
 <!-- ko if: isSideline -->
 <figure class="box__figure">
 <img oncontextmenu="return false;" loading="lazy" class="box__picture" data-bind="attr: {src: ThumbnailUrl, alt: Title, width:ImageWidth, height:ImageHeight}" />
 <div class="box__action"></div>
 <div class="box__label">3D MODEL</div>
 </figure>
 <!-- /ko -->
 <!-- ko if: isInline -->
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="no" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrc, title: Title }"></iframe>
 <!-- /ko -->
 </div>
 <!-- ko ifnot: isInline -->
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }"></div>
 <!-- /ko -->
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isText -->
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }"></div>
 <!-- /ko -->
</script>
 
<script type="text/html" id="image-player-template">
 <div class="multimedia multimedia--withdescription" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__image" data-bind="css: zoomClass">
 <div class="multimedia__image--spacer hide-on-print"></div>
 <div class="multimedia__image--wrapper">
 <img oncontextmenu="return false;" loading="lazy" data-bind="attr: { src: ImageUrl, alt: Alt}, getImageDimensions: imageDimensions, pinchZoom: { pinchZoomActive: pinchZoomActive, isZoomed: isZoomed}">
 </div>
 <!-- ko if: zoomEnabled -->
 
 <!-- /ko -->
 <div class="multimedia__image--spacer hide-on-print"></div>
 </div>
 <div class="multimedia__description">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <!-- ko ifnot: parentContext.displaySingle -->
 <div class="multimedia__pager hide-on-print">
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showFirst">«</a>
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showPrev">‹</a>
 <span class="multimedia__pager--number" data-bind="text: $parent.activeEntry().index + 1"></span>/<span class="multimedia__pager--number" data-bind="text: $parent.activeList().length"></span>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showNext">›</a>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showLast">»</a>
 </div>
 <!-- /ko -->
 <div class="multimedia__description--wrapper">
 <!-- ko if: $data.Description -->
 <div class="multimedia__description--content" data-bind="html: Description"> </div>
 <!-- /ko -->
 <!-- ko if: $data.Credits -->
 <div class="multimedia__description--credits" data-bind="html: Credits"> </div>
 <!-- /ko -->
 </div>
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations" data-bind="modalLocations: topicsWithResource().length">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script>
<script type="text/javascript">
 (function (MManual) {
 var deferredScripts = [];
 
 deferredScripts.push("./bundles/redesign/imageplayerv4.1.2.2-13178e13ca.js?v=sWgoLvG7zFKbYfkOiaTYY5tBk5gefAsRS0qs0ENFdUc1");
 
 MManual.ImagePlayerScripts = deferredScripts;
 }(window.MManual = window.MManual || {}));
</script>
<script type="text/html" id="inlinemedia-photo-template">
 <!-- ko ifnot: isText-->
 <div data-bind="css: componentClasses()">
 <div class="inlinemedia__wrapper">
 <div class="inlinemedia__innerwrapper">
 <div class="inlinemedia__header">
 <div class="inlinemedia__title" data-bind="html: Title"></div>
 <div class="inlinemedia__open hide-on-print">
 <i class="inlinemedia__icon--open"></i>
 </div>
 </div>
 <div class="inlinemedia__content">
 <div class="inlinemedia__image--container">
 <img class="h-nocopy" loading="lazy" oncontextmenu="return false;" data-bind="attr: { src: ThumbnailUrl, alt: Alt, width:ImageWidth, height:ImageHeight }" />
 </div>
 <!-- ko if: isSideline -->
 <div class="inlinemedia__subtitle" data-bind="html: Credits"></div>
 <!-- /ko -->
 </div>
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }"></div>
 </div>
 <div class="inlinemedia__content">
 <!-- ko if: isInline() && detailsAvailable() -->
 <div class="inlinemedia__more">
 <div class="inlinemedia__action inlinemedia__action--show" data-bind="event: {click: toggleDetailsFunction, keypress: toggleDetailsFunction}">
 <i class="inlinemedia__eye"></i>
 <span class="inlinemedia__details hide" role="button" tabindex="0">
 Show Details
 </span>
 <span class="inlinemedia__details show" role="button" tabindex="0">
 Hide Details
 </span>
 <div class="inlinemedia__information" data-bind="html: Description"></div>
 <div class="inlinemedia__credits" data-bind="html: Credits"></div>
 </div>
 </div>
 <!-- /ko -->
 </div>
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isText -->
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }"></div>
 <!-- /ko -->
</script>
<script type="text/html" id="infographic-player-template">
 <div class="multimedia" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__image" data-bind="css: zoomClass">
 <div class="multimedia__image--spacer hide-on-print"></div>
 <div class="multimedia__image--wrapper h-nocopy">
 <img oncontextmenu="return false;" loading="lazy" data-bind="attr: { src: ImageUrl, alt: Title}, getImageDimensions: imageDimensions, pinchZoom: { pinchZoomActive: pinchZoomActive, isZoomed: isZoomed}">
 </div>
 <!-- ko if: zoomEnabled -->
 <div class="multimedia__image--actions hide-on-print">
 <div class="multimedia__image--actionzoom" data-bind="click: toggleZoom"></div>
 </div>
 <!-- /ko -->
 <div class="multimedia__image--spacer hide-on-print"></div>
 </div>
 <div class="multimedia__description">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <div class="multimedia__description--wrapper">
 <!-- ko if: CitationLink -->
 <div class="multimedia__description--source">
 <span class="multimedia__description--sourcetitle">Source:</span>
 <!-- ko if: CitationText -->
 <a href="#" class="multimedia__description--citation" data-bind="text: CitationText, attr: { href: CitationLink }"></a>
 <!-- /ko -->
 <!-- ko ifnot: CitationText -->
 <a href="#" class="multimedia__description--citation" data-bind="text: CitationLink, attr: { href: CitationLink }"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 </div>
 </div>
 </div>
</script>
<script type="text/html" id="inlinemedia-labtest-template">
 <!-- ko if: isSideline -->
 <div class="inlinebox inlinebox--clickable" data-bind="css: {'inlinebox--right': !IsInCarousel(), 'inlinebox--full': IsInCarousel}">
 <div class="inlinebox__wrapper">
 <!-- ko ifnot: IsInCarousel-->
 <div class="inlinebox__header">Lab Test</div>
 <!-- /ko -->
 <div class="inlinebox__content">
 <div class="multimedia__link" data-bind="component: { name: 'multimedia-link-text', params: multimediaLinkModel }"></div>
 <div class="inlinebox__button">
 <img class="labtest-icon" loading="lazy" alt="icon" data-bind="attr: {src: ThumbnailUrl }" width="55" height="55" />
 </div>
 </div>
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isInline -->
 <div data-bind="css: componentClasses()">
 <div class="inlinemedia__wrapper">
 <div class="inlinemedia__header">
 <div class="inlinemedia__title" data-bind="html: Title"></div>
 </div>
 <div class="inlinemedia__content">
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="yes" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrc, title: Title }"></iframe>
 </div>
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isText -->
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }"></div>
 <!-- /ko -->
</script><script type="text/html" id="labtest-player-template">
 <div class="multimedia" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__iframe">
 <div class="multimedia__iframe--spacer"></div>
 <div class="multimedia__iframe--wrapper h-ios-iframe-scroll">
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="auto" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrcComputed, title: Title }, setIframePrintTarget: setIframePrintTarget" sandbox="allow-modals allow-scripts allow-same-origin allow-forms allow-popups allow-top-navigation"></iframe>
 </div>
 <div class="multimedia__iframe--spacer"></div>
 </div>
 <div class="multimedia__description">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <!-- ko ifnot: parentContext.displaySingle -->
 <div class="multimedia__pager hide-on-print">
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showFirst">Â«</a>
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showPrev">â€¹</a>
 <span class="multimedia__pager--number" data-bind="text: $parent.activeEntry().index + 1"></span>/<span class="multimedia__pager--number" data-bind="text: $parent.activeList().length"></span>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showNext">â€º</a>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showLast">Â»</a>
 </div>
 <!-- /ko -->
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations" data-bind="modalLocations: topicsWithResource().length">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script>
<script type="text/html" id="mediawidget-labtest-template">
 <!-- ko component: {name: 'multimedia-link-text', params: { item: ko.mapping.fromJS({
 ItemId: ItemId,
 IframeSrc: MediaUrl,
 Title: Title,
 ShareUrlTitle: ShareUrlTitle,
 Description: Description,
 ThumbnailUrl: ThumbnailUrl,
 Credits: Credits,
 MediaType: 'labest',
 MediaNameTranslated: 'Lab Test' ,
 UniqueId: UniqueId
 }),
 linkText: Title,
 showTooltip: false,
 listName: 'LabTestResources' + $parent.key
 } } -->
 <!-- /ko -->
</script>
<script type="text/html" id="mediawidget-labtest-list-template">
 <!-- ko component: {name: 'multimedia-link-text', params: { item: ko.mapping.fromJS({
 ItemId: ItemId,
 IframeSrc: MediaUrl,
 Title: Title,
 ShareUrlTitle: ShareUrlTitle,
 Description: Description,
 ThumbnailUrl: ThumbnailUrl,
 Credits: Credits,
 MediaType: 'labtest',
 MediaNameTranslated: 'Lab Test',
 UniqueId: UniqueId
 }),
 linkText: Title,
 showTooltip: false,
 listName: 'LabTestResources' + $parent.key
 } } -->
 <!-- /ko -->
</script>
<script type="text/html" id="inlinemedia-featuredlink-template">
 <!-- ko ifnot: isText-->
 <!-- ko ifnot: isModal -->
 <a data-bind="attr: {href: IframeSrcComputed, target: Target}">
 <div data-bind="css: componentClasses()">
 <div class="inlinemedia__wrapper">
 <div class="inlinemedia__header">
 <div class="inlinemedia__title" data-bind="html: Title"></div>
 <!-- ko if: isSideline() && !IsInCarousel() -->
 <div class="inlinemedia__open hide-on-print">
 <i class="inlinemedia__icon--open"></i>
 </div>
 <!-- /ko -->
 </div>
 <div class="inlinemedia__content">
 <!-- ko if: isSideline -->
 <figure class="box__figure">
 <img oncontextmenu="return false;" loading="lazy" class="box__picture" data-bind="attr: {src: ThumbnailUrl, alt: Title}" />
 <div class="box__action"></div>
 <div class="box__label" data-bind="text:MediaNameTranslated"></div>
 </figure>
 <!-- /ko -->
 <!-- ko if: isInline -->
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="no" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrcComputed, title: Title }"></iframe>
 <!-- /ko -->
 </div>
 </div>
 </div>
 </a>
 <!-- /ko -->
 <!-- /ko -->
 <!-- ko if: isModal -->
 <div data-bind="css: componentClasses()">
 <div class="inlinemedia__wrapper">
 <div class="inlinemedia__header">
 <div class="inlinemedia__title" data-bind="html: Title"></div>
 <!-- ko if: isSideline() && !IsInCarousel() -->
 <div class="inlinemedia__open hide-on-print">
 <i class="inlinemedia__icon--open"></i>
 </div>
 <!-- /ko -->
 </div>
 <div class="inlinemedia__content">
 <!-- ko if: isSideline -->
 <figure class="box__figure">
 <img oncontextmenu="return false;" loading="lazy" class="box__picture" data-bind="attr: {src: ThumbnailUrl, alt: Title}" />
 <div class="box__action"></div>
 <div class="box__label" data-bind="text:MediaNameTranslated"></div>
 </figure>
 <!-- /ko -->
 <!-- ko if: isInline -->
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="no" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrcComputed, title: Title }"></iframe>
 <!-- /ko -->
 </div>
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }"></div>
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isText -->
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }">
 </div>
 <!-- /ko -->
</script><script type="text/html" id="featuredlink-player-template">
 <div class="multimedia" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__iframe">
 <div class="multimedia__iframe--spacer"></div>
 <div class="multimedia__iframe--wrapper">
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="yes" frameBorder="0" data-bind="attr: { src: IframeSrcComputed, title: Title }, iOSresizeIframeToParent : attachResizeCallback" sandbox="allow-modals allow-scripts allow-same-origin allow-forms allow-popups allow-top-navigation"></iframe>
 </div>
 <div class="multimedia__iframe--spacer"></div>
 </div>
 <div class="multimedia__description" data-bind="getDivRef : $parent.descriptionDivRef">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 </div>
 </div>
</script><script type="text/html" id="iframe-player-template">
 <div class="multimedia" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__iframe">
 <div class="multimedia__iframe--spacer"></div>
 <div class="multimedia__iframe--wrapper">
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="auto" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrcComputed, title: Title }" sandbox="allow-modals allow-scripts allow-same-origin allow-forms allow-popups allow-top-navigation"></iframe>
 </div>
 <div class="multimedia__iframe--spacer"></div>
 </div>
 <div class="multimedia__description">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <!-- ko ifnot: parentContext.displaySingle -->
 <div class="multimedia__pager hide-on-print">
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showFirst">«</a>
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showPrev">‹</a>
 <span class="multimedia__pager--number" data-bind="text: $parent.activeEntry().index + 1"></span>/<span class="multimedia__pager--number" data-bind="text: $parent.activeList().length"></span>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showNext">›</a>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showLast">»</a>
 </div>
 <!-- /ko -->
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script><script type="text/html" id="multimedia-thumbnail-template">
 <div class="modalcarousel__item" data-bind="event:{click: $parentContext.$parent.navToClick.bind($index()), keypress: $parentContext.$parent.navToClickKeyPress.bind($index())}, css: {'modalcarousel__item--active' : $parentContext.$parent.activeIndex() == $index()}, attr: { title: item.Title}, modalCarousel, css-static: 'modalcarousel__item--' + item.MediaType()" tabindex="0" role="button">
 <div class="modalcarousel__item--wrapper">
 <div class="modalcarousel__item--imagewrapper h-nocopy">
 <img oncontextmenu="return false;" data-bind="lazyload: {src: item.ThumbnailUrl, options: {loadOnlyInViewport: true} , updateTick: $parentContext.$parent.carouselScrollTick}, attr: {alt: item.Title }, scrollIntoView:$parentContext.$parent.activeIndex() == $index()" />
 </div>
 <div class="modalcarousel__item--text" data-bind="html: item.Title"> </div>
 </div>
 <div class="modalcarousel__item--number" data-bind="text: ($index() + 1)"></div>
 </div>
</script>
<script type="text/html" id="text-player-template">
 <div class="multimedia">
 <div class="multimedia__text" data-bind="html: Text"> </div>
 </div>
</script>
<script type="text/html" id="multimedia-link-block-template">
 <i class="inlinemedia__icon--open"
 data-bind="hoverVisible: enableHover, hoverTargetId: '.multimedia__link'"></i>
 <button class="multimedia__link--block" aria-expanded="false" data-bind="shortClick: showPlayer, attr : {'aria-label':'Expand the'+' '+ item.MediaNameTranslated()}"></button>
</script>
<script type="text/html" id="multimedia-link-text-template">
 <a class="multimedia__link--text" role="button" tabindex="0" aria-expanded="false" data-bind="shortClick: showPlayer, html: linkText, css: cssClass"></a>
</script><div class="multimedia__popup l-viewport" data-bind="component: { name: 'multimedia-popup'}">
 <!-- Placeholder for media players. -->
</div>
<script type="text/html" id="multimedia-popup-template">
 <!-- ko if: playerVisible -->
 <div class="modal" role="dialog" tabindex="-1" aria-labelledby="exampleModalLabel">
 <div class="modal--shade" data-bind="click: hidePopup"></div>
 <div class="modaldialog" data-bind=" arrowKeys: {left: showPrev, right: showNext}, css : {'h-expanded' : expanded }">
 <div class="modaldialog__header hide-on-print">
 <div class="modaldialog__header--wrapper">
 <div class="modaldialog__header--title modaldialog__header--element" data-bind="html: popupTitle(), scaleText: popupTitle"></div>
 <div tabindex="0" role="button" class="modaldialog__header--close modaldialog__header--element" data-bind="event: { click: hidePopup, keypress: hidePopupKeyPress }">
 Close
 </div>
 </div>
 </div>
 <div class="modaldialog__content">
 <div class="modaldialog__content--wrapper" data-bind="swipe: {next: showNext, prev: showPrev, canSwipe: canSwipe}">
 <div class="modaldialog__media" data-bind="css :{ 'modaldialog__media--withcarousel': !(displaySingle() || hideCarousel()), 'modaldialog__media--single': displaySingle }">
 <!-- ko ifnot: (displaySingle() || hideMainArrows()) -->
 <div class="modaldialog__media--sidemargin hide-on-print">
 <div class="modaldialog__media--nav modaldialog__media--prev" tabindex="0" role="button" aria-label="Previous" data-bind="event: { click: showPrev, keypress: showPrevKeyPress }">
 <div class="mm-icon" data-bind="css : showPrevClass()"></div>
 </div>
 </div>
 <!-- /ko -->
 <div class="modaldialog__media--wrapper">
 
 <!-- ko component: {name: activeEntry().item.MediaType() + '-player', params: activeEntry} -->
 <!-- /ko -->
 
 </div>
 <!-- ko ifnot: (displaySingle() || hideMainArrows()) -->
 <div class="modaldialog__media--sidemargin hide-on-print">
 <div class="modaldialog__media--nav modaldialog__media--next" tabindex="0" role="button" aria-label="Next" data-bind="event: { click: showNext, keypress: showNextKeyPress }">
 <div class="mm-icon" data-bind="css: showNextClass()"></div>
 </div>
 </div>
 <!-- /ko -->
 </div>
 <!-- ko ifnot: (displaySingle() || hideCarousel()) -->
 <div class="modaldialog__carousel hide-on-print">
 <div class="modaldialog__carousel--sidemargin modaldialog__carousel--prev" tabindex="0" role="button" data-bind="event:{click: carouselShowPrev, keypress:carouselShowPrevKeyPress}, css : { 'modaldialog__carousel--sidemargin--disabled' : isCarouselShowPrevDisabled() } "></div>
 <div class="modaldialog__carousel--wrapper">
 <div class="modalcarousel" data-bind="scrollTick : carouselScrollTick, scroll : carouselIsScrolled ">
 <!-- ko foreach: {data: activeList, as: 'entry'} -->
 <!-- ko template: {name: 'multimedia-thumbnail-template', data: entry} -->
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
 <div class="modaldialog__carousel--sidemargin modaldialog__carousel--next" tabindex="0" role="button" data-bind="event:{click: carouselShowNext, keypress:carouselShowNextKeyPress}, css : { 'modaldialog__carousel--sidemargin--disabled' : isCarouselShowNextDisabled() }"></div>
 </div>
 <!-- /ko -->
 <div class="modaldialog__toolbar hide-on-print">
 <!-- ko ifnot: displaySingle -->
 <div class="modaldialog__pager">
 <a class="modaldialog__pager--nav modaldialog__pager--navfirst" data-bind="click: showFirst">«</a>
 <a class="modaldialog__pager--nav modaldialog__pager--navleft" data-bind="click: showPrev">‹</a>
 <span class="modaldialog__pager--number" data-bind="text: activeEntry().index + 1"></span>/<span class="modaldialog__pager--number" data-bind="text: activeList().length"></span>
 <a class="modaldialog__pager--nav modaldialog__pager--navright" data-bind="click: showNext">›</a>
 <a class="modaldialog__pager--nav modaldialog__pager--navlast" data-bind="click: showLast">»</a>
 </div>
 <!-- /ko -->
 <div class="modaldialog__actions">
 <!-- ko if: detailsAvailable -->
 <div class="modaldialog__action modaldialog__action--description modaldialog__action--description-show" data-bind="click: toggleExpanded">
 <i class="modaldialog__icon--show"></i>
 <span class="modaldialog__action--text">
 Show Details
 </span>
 </div>
 <div class="modaldialog__action modaldialog__action--description modaldialog__action--description-hide" data-bind="click: toggleExpanded">
 <i class="modaldialog__icon--hide"></i>
 <span class="modaldialog__action--text">
 Hide Details
 </span>
 </div>
 <!-- /ko -->
 <!-- ko if: MManual.settings.socialMedia.enableMultimediaPopupShareButton -->
 <div class="modaldialog__action modaldialog__action--share a2a_kit" data-a2a-icon-color="transparent,transparent" data-bind="attr:{'data-a2a-url': shareUrl}">
 <a class="modaldialog__icon--share a2a_dd" href="https://www.addtoany.com/share" data-a2a-icon-color="transparent,transparent" role="button"></a>
 </div>
 <!-- /ko -->
 <div class="modaldialog__action modaldialog__action--print" data-bind="event:{click: printPopupContent, keypress:printPopupContentKeyPress}" tabindex="0" role="button" aria-label="print">
 <div class="modaldialog__icon--print"></div>
 </div>
 </div>
 </div>
 <div class="modaldialog__copyright-print">
 <div class="modaldialog__copyright-print--logo">
<img src="/Content/Images/msd_foot_logo.png" alt="" class="badge msd" loading="lazy" width="240" height="71" />
 </div>
 <div class="modaldialog__copyright-print--text">
 © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
 </div>
 </div>
 </div>
 </div>
 </div>
 </div>
 <!-- /ko -->
</script>
<script type="text/html" id="podcast-player-template">
 <div class="multimedia multimedia--withdescription" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__audio hide-on-print">
 <div class="multimedia__audio--wrapper">
 <audio>
 <source data-bind="attr: { src: AudioUrl, type: MimeType }" />
 </audio>
 </div>
 </div>
 <div class="multimedia__description">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <!-- ko ifnot: parentContext.displaySingle -->
 <div class="multimedia__pager hide-on-print">
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showFirst">«</a>
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showPrev">‹</a>
 <span class="multimedia__pager--number" data-bind="text: $parent.activeEntry().index + 1"></span>/<span class="multimedia__pager--number" data-bind="text: $parent.activeList().length"></span>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showNext">›</a>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showLast">»</a>
 </div>
 <!-- /ko -->
 <div class="multimedia__description--wrapper">
 <!-- ko if: $data.Description -->
 <div class="multimedia__description--content">
 <p data-bind="html: Description"></p>
 </div>
 <!-- /ko -->
 <!-- ko if: $data.Credits -->
 <div class="multimedia__description--credits">
 <p data-bind="html: Credits"></p>
 </div>
 <!-- /ko -->
 </div>
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations" data-bind="modalLocations: topicsWithResource().length">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script>
 <script type="text/html" id="quiz-player-template">
 <div class="multimedia" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <h3 class="multimedia__title" data-bind="html: Title"> </h3>
 <!-- /ko -->
 <div class="multimedia__iframe">
 <div class="multimedia__iframe--spacer"></div>
 <div class="multimedia__iframe--wrapper h-ios-iframe-scroll">
 <iframe frameBorder="0" scrolling="auto" data-bind="attr: { src: IframeSrcComputed, title: Title }" sandbox="allow-modals allow-scripts allow-same-origin allow-forms allow-popups allow-top-navigation, swipe: {left: parentContext.showNext, right: parentContext.showPrev}"></iframe>
 </div>
 <div class="multimedia__iframe--spacer"></div>
 </div>
 </div>
</script>
<script type="text/html" id="table-player-template">
 <div class="multimedia" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__table">
 <div class="multimedia__table--wrapper">
 <div data-bind="html: tableBody, stickyHeaderTable: tableBody" class="modaltable"> </div>
 </div>
 </div>
 <div class="multimedia__description">
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations" data-bind="modalLocations: topicsWithResource().length">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script><script type="text/html" id="m-link-text-template">
 <!-- ko if: isModal -->
 <a class="multimedia__link--text" tabindex="0" role="button" data-bind="shortClick: showPlayer, html: linkText, css: cssClass, attr: { title: item.Title }, mlinkToolTip: { thumbnail: item.ThumbnailUrl, title: item.Title, show: showTooltip, target: target }"></a>
 <!-- /ko -->
 <!-- ko ifnot: isModal -->
 <!--ko if: item.MediaType()=='podcast'-->
 <a class="multimedia__link--text" tabindex="0" role="button" data-bind="html: linkText, css: cssClass, attr: { title: item.Title, target: target, href: target=='_blank'? url :'https://www.msdmanuals.com/'+ url }, mlinkToolTip: { thumbnail: item.ThumbnailUrl, title: item.Title, show: showTooltip, target: target, url:url}"></a>
 <!-- /ko -->
 <!--ko ifnot: item.MediaType()=='podcast'-->
 <a class="multimedia__link--text" tabindex="0" role="button" data-bind="html: linkText, css: cssClass, attr: { title: item.Title, target: target, href: 'https://www.msdmanuals.com/'+'/professional/multimedia'+ url }, mlinkToolTip: { thumbnail: item.ThumbnailUrl, title: item.Title, show: showTooltip, target: target, url:'/professional/multimedia'+ url}"></a>
 <!-- /ko -->
 <!-- /ko -->
</script>
<script type="text/html" id="clinicalcalculator-player-template">
 <div class="multimedia" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__iframe">
 <div class="multimedia__iframe--spacer"></div>
 <div class="multimedia__iframe--wrapper h-ios-iframe-scroll">
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="auto" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrcComputed, title: Title }, setIframePrintTarget: setIframePrintTarget" sandbox="allow-modals allow-scripts allow-same-origin allow-forms allow-popups allow-top-navigation"></iframe>
 </div>
 <div class="multimedia__iframe--spacer"></div>
 </div>
 <div class="multimedia__description">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <!-- ko ifnot: parentContext.displaySingle -->
 <div class="multimedia__pager hide-on-print">
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showFirst">«</a>
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showPrev">‹</a>
 <span class="multimedia__pager--number" data-bind="text: $parent.activeEntry().index + 1"></span>/<span class="multimedia__pager--number" data-bind="text: $parent.activeList().length"></span>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showNext">›</a>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showLast">»</a>
 </div>
 <!-- /ko -->
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script><script type="text/html" id="inlinemedia-calculator-template">
 <!-- ko if: isSideline -->
 <div class="inlinebox inlinebox--clickable" data-bind="css: {'inlinebox--right': !IsInCarousel(), 'inlinebox--full': IsInCarousel}">
 <div class="inlinebox__wrapper">
 <!-- ko ifnot: IsInCarousel-->
 <div class="inlinebox__header">Clinical Calculator:</div>
 <!-- /ko -->
 <div class="inlinebox__content">
 <div class="multimedia__link" data-bind="component: { name: 'multimedia-link-text', params: multimediaLinkModel }"></div>
 <div class="inlinebox__button">
 <img class="labtest-icon" loading="lazy" alt="icon" data-bind="attr: {src: ThumbnailUrl }" width="48" height="48" />
 </div>
 </div>
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isInline -->
 <div data-bind="css: componentClasses()">
 <div class="inlinemedia__wrapper">
 <div class="inlinemedia__header">
 <div class="inlinemedia__title" data-bind="html: Title"></div>
 </div>
 <div class="inlinemedia__content">
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="no" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrc, title: Title }"></iframe>
 </div>
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isText -->
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }"></div>
 <!-- /ko -->
</script>
<script type="text/html" id="video-player-template">
 <div class="multimedia multimedia--withdescription" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__video">
 <div class="multimedia__video--spacer"></div>
 <div class="multimedia__video--wrapper">
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="no" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrcComputed, title: Title }"></iframe>
 <div class="multimedia__video--print" onclick="$(this).hide(); return true;">
 <img loading="lazy" data-bind="attr: { src: ThumbnailUrl, alt: Title }">
 </div>
 </div>
 <div class="multimedia__video--spacer"></div>
 </div>
 <div class="multimedia__description">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <!-- ko ifnot: parentContext.displaySingle -->
 <div class="multimedia__pager hide-on-print">
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showFirst">Â«</a>
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showPrev">â€¹</a>
 <span class="multimedia__pager--number" data-bind="text: $parent.activeEntry().index + 1"></span>/<span class="multimedia__pager--number" data-bind="text: $parent.activeList().length"></span>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showNext">â€º</a>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showLast">Â»</a>
 </div>
 <!-- /ko -->
 <div class="multimedia__description--wrapper">
 <!-- ko if: $data.Description -->
 <div class="multimedia__description--content" data-bind="html: Description"> </div>
 <!-- /ko -->
 <!-- ko if: $data.Credits -->
 <div class="multimedia__description--credits" data-bind="html: Credits"> </div>
 <!-- /ko -->
 </div>
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations" data-bind="modalLocations: topicsWithResource().length">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script>
<link rel="stylesheet" href="./Content/Styles/fa/fonts/font-awesome.css" type="text/css" media="screen"><link rel="stylesheet" href="./CustomCss/custom_mobile_styles.css"><script type="text/javascript" src="./customscript/videodetail.js?v=j6lqWQ_gaVddXSzk8oBfSqpw8iTwpNFAslFpddsSyrM1"></script><script type="text/javascript" src="./customscript/VideoPath.js?v=j6lqWQ_gaVddXSzk8oBfSqpw8iTwpNFAslFpddsSyrM1"></script><script type="text/javascript" src="./customscript/Appdetail.js?v=j6lqWQ_gaVddXSzk8oBfSqpw8iTwpNFAslFpddsSyrM1"></script><script type="text/javascript" src="./customscript/customscript.js?v=j6lqWQ_gaVddXSzk8oBfSqpw8iTwpNFAslFpddsSyrM1"></script></head>
<body class="professional msd ">
 <a href="/n3wbr@nds" rel="nofollow" style="display:none" arial-hidden="true">honeypot link</a>
 <!-- Google Tag Manager (noscript) --> <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-5MKXR9" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript> <!-- End Google Tag Manager (noscript) --> 
 <div id="testone"> <div class="l-viewport">
 
<input type="hidden" id="currentSitecoreItemId" value="6ea530b9-c85e-4653-b466-245f2a0e10ea">
<input type="hidden" id="wasThisTopicHelpfulUrl" value="/Custom/Topic/WasThisTopicHelpful">
<input type="hidden" id="getTopicHelpfulUrl" value="/Custom/Topic/GetTopicHelpful">
<input type="hidden" id="languageSwitchUrl" value="/professional/LanguageSwitch">
<input type="hidden" id="resourceServiceUrl" value="/custom/Topic/GetTopicsForResource">
<input type="hidden" id="tableBodyServiceUrl" value="/custom/Topic/GetTableBody">
<input type="hidden" id="getAlphabetUrl" value="/Redesign/Widgets/GetAlphabet">
<input type="hidden" id="landingPageUrl" value="https://www.msdmanuals.com/">
<input type="hidden" id="standaloneMultimediaBaseUrl" value="/professional/multimedia">
<input type="hidden" id="currentEdition" value="Professional">
<input type="hidden" id="currentLanguage" value="en">
<input type="hidden" id="currentLanguage2LetterISO" value="en">
<input type="hidden" id="oldRestrictedBrightcovePlayer" value="3851244774001">
<input type="hidden" id="restrictedBrightcovePlayer" value="5qrY5f1MK_default">
<input type="hidden" id="shareableBrightcovePlayer" value="6CaKiGXJD_default">
<input type="hidden" id="selectLanguageLabel" value="Select Language">
<input type="hidden" id="commonCloseText" value="close">
<input type="hidden" id="readAllText" value="Read All">
 
 <!-- New div groups for LetterSpine and Header has been created
 due to problems with existing styling
 ToDo rewrite whole header and letter spine as one component -->
 <div id="l-group--header-letterpine" class="main-header sticky-header">
 <div class="l-group l-group--header">
 <div id="l-layer--header" class="l-layer l-layer--header" data-header-element-position="static" data-header-element-order="0">
 
 
 
 </div>
 </div>
 </div>
 
 
<script>
 MManual.Feature = MManual.Feature || {};
 MManual.Feature.LetterSpine = MManual.Feature.LetterSpine || {};
 MManual.Feature.LetterSpine.Id = 'fde3f257-f752-43de-b5b3-5b932316c61f';
</script>
 <!-- <div id="l-group--header-letterpine--fixed" class="main-header l-group--header-letterpine-fixed l-group--header-letterpine-fixed--hidden l-group--header-letterpine-fixed--animate">
 <div class="l-group l-group--headerfixed hide-on-print">
 <div class="l-layer l-layer--header l-layer--fixed" data-header-element-position="fixed" data-header-element-order="0">
 
 
 </div>
 </div>
 <div class="l-group l-group--letterspinefixed"></div>
 </div>
 <div class="l-layer l-layer--underskirt">
 </div>-->
 
 
 
 <div class="l-layer l-layer--actiontoolbar">
 
 <div class="l-layer__content">
 <aside class="actiontoolbar hide-on-print">
 <!--<a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--bookmark" onclick="bookmarkPage(this);" href="#"></a>-->
 <a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--download" style="display: none" href="#"></a>
 
 <ul>
 <li class="a2a_kit a2a_kit_size_32 a2a_default_style" data-a2a-icon-color="transparent,transparent">
 <a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--share a2a_dd" href="https://www.addtoany.com/share" rel="noopener" role="button" aria-expanded="false" aria-label="Share in"></a>
 </li>
 <li>
 <a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--print" href="#" onclick="window.print(); MManual.analytics.notifyOpenModal(MManual.analytics.eventPrintAnArticle);" role="button" title="print"></a>
 </li>
 <li class="a2a_kit a2a_kit_size_32 a2a_default_style" data-a2a-icon-color="transparent,transparent">
 <a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--email a2a_button_email" href="#" role="button" title="Mail"></a>
 </li>
 <li class="scroll-to-top">
 <a href="#top" role="button" aria-label="Go To Top" title="Go To Top"><span class="scroll-to-top-img"></span></a>
 </li>
 <li class="scroll-to-bottom">
 <a href="#" role="button" aria-label="Go To Top"><span class="scroll-to-bottom-img"></span></a>
 </li>
 </ul>
 </aside>
 </div>
 
 </div>
 <main id="maincontent" class="l-layer l-layer--main">
 
 <section class="l-layer__content main">
 
 <div class="orderize"></div>
<div class="main__content">
 <div class="topic__wrapper">
 
<script type="text/javascript">
 var resources = [];
 var resourcesIdList = [];
 $.each(resources, function() {
 if (this.MultimediaItem != null) {
 resourcesIdList.push({"itemId": this.MultimediaItem.ItemId, "uniqueId": this.MultimediaItem.UniqueId});
 }
 });
 $('a[href="#also-of-interest-news"],a[href="#also-of-interest-video"],a[href="#also-of-interest-biodigital"],a[href="#also-of-interest-student-stories"]').click(function ()
 {
 window.scrollTo(0, $("#Ph-Item-Lazyloading").offset().top - 230);
 });
</script>
<div class="orderize__candidate" data-orderize="100" itemscope="" itemtype="http://schema.org/MedicalCondition" data-preview-container='.topic__article'>
 <input type="hidden" value="" id="hdnTopicTopTile">
 <div class="autoload-placeholder-top hide-on-print" style="display:none">
 <a class="pre-topic hide-on-print" role="button" aria-hidden="true"></a>
 </div>
 <div class="autoloadSettings" name="Up Next:">
 <a id="autoloadEnable" class="false" role="button" tabindex="-1"></a>
 <a id="autoloadChapter" class="false" role="button" tabindex="-1"></a>
 <a id="autoloadSection" class="false" role="button" tabindex="-1"></a>
 <a id="stopAutoloadChapterCircular" class="false" role="button" tabindex="-1"></a>
 </div>
 <article class="topic__article">
 
<div class="tablebox tablebox--headings">
 <div class="tablebox__cell tablebox__cell--headings">
 <div class="topic__headings">
 <span itemprop="code" itemscope="" itemtype="http://schema.org/MedicalCode">

 </span>
 <span itemprop="code" itemscope="" itemtype="http://schema.org/MedicalCode">

 </span>
 <div class="topic__header--container">
 <div class="topic__authors topic__authors--container">
 <a id="top" role="button" tabindex="-1"></a>
 <h1 class="topic__header__headermodify--title topic__header__headermodify--title--animate" itemprop="name">
 Human Immunodeficiency Virus (HIV) Infection in Infants and Children
 </h1>
 <div class="topic__authors-main-cont">
 <p class="topic__authors--description">By </p>
 
 <strong class="topic__label topic__label--author"><a href="./Contributors/weinberg-geoffrey.html">Geoffrey A. Weinberg</a></strong>
 <p class="topic__authors--description">, MD, Golisano Children’s Hospital</p>
 <div class="topic__revision">
 <div class="topic__authors">
 Reviewed/Revised Mar 2023 
 </div>
 </div>
 </div>
 </div>
 <div class="topic__buttons hide-on-print">
 <div class="topicswitch topic__patient-education topic__patient-education--top" data-icd9="042;795.71" tabindex="0" role="link">
 <div class="topic__patient-education--container">
 <div class="topic__patient-education--icon"></div>
 <div class="topic__patient-education--text">
 View PATIENT EDUCATION
 </div>
 </div>
 </div>
 </div>
 </div>
 </div>
 </div>
</div>
 <div class="box topicmenu hide-on-print">
 <div class="topic-section-heading-list">
 <ul>
 <li>
 <a href="#v1107319" class="topicmenu_mobile__paragraph">Epidemiology</a>
 </li>
 <li>
 <a href="#v77995632" class="topicmenu_mobile__paragraph">Transmission of HIV</a>
 </li>
 <li>
 <a href="#v49372990" class="topicmenu_mobile__paragraph">Classification</a>
 </li>
 <li>
 <a href="#v1107623" class="topicmenu_mobile__paragraph">Symptoms and Signs</a>
 </li>
 <li>
 <a href="#v1107648" class="topicmenu_mobile__paragraph">Diagnosis</a>
 </li>
 <li>
 <a href="#v1107694" class="topicmenu_mobile__paragraph">Treatment</a>
 </li>
 <li>
 <a href="#v9141114" class="topicmenu_mobile__paragraph">Transition to Adult Care</a>
 </li>
 <li>
 <a href="#v1107688" class="topicmenu_mobile__paragraph">Prognosis</a>
 </li>
 <li>
 <a href="#v1108218" class="topicmenu_mobile__paragraph">Prevention</a>
 </li>
 <li>
 <a href="#v9141133" class="topicmenu_mobile__paragraph">Key Points</a>
 </li>
 <li>
 <a href="#v37571419" class="topicmenu_mobile__paragraph">More Information</a>
 </li>
 </ul>
 </div>
 </div>
<div class="topic__resources--title hide-on-print">
 Topic Resources
</div>
<div id="topicResources" class="hero hide-on-print">
 <div class="hero__tabs">
 <ul class="hero__header">
 <li class="hero__cell hero__cell--empty" data-bind="css:{'hero__cell--active': $root.activeGroup() === 'Biodigitals'}">
 <a data-bind="" class="hero__link" tabindex="0" role="tab" aria-expanded="false" aria-disabled="true">
 <span class="hero__title">
 3D Models (0)
 </span>
 </a>
 <!-- ko if: $data.activeGroup() === "Biodigitals" -->
 <div class="hero__content" data-bind="css:{'hero__content--active': $root.activeGroup() === 'Biodigitals'}">
 <div class="floatbox">
 </div>
 <br class="floatbox__clear">
 </div>
 <!-- /ko -->
 </li>
 <li class="hero__cell hero__cell--empty" data-bind="css:{'hero__cell--active': $root.activeGroup() === 'Audios'}">
 <a data-bind="" class="hero__link" tabindex="0" role="tab" aria-expanded="false" aria-disabled="true">
 <span class="hero__title">
 Audios (0)
 </span>
 </a>
 <!-- ko if: $data.activeGroup() === "Audios" -->
 <div class="hero__content" data-bind="css:{'hero__content--active': $root.activeGroup() === 'Audios'}">
 <div class="floatbox">
 </div>
 <br class="floatbox__clear">
 </div>
 <!-- /ko -->
 </li>
 <li class="hero__cell hero__cell--empty" data-bind="css:{'hero__cell--active': $root.activeGroup() === 'Calculators'}">
 <a data-bind="" class="hero__link" tabindex="0" role="tab" aria-expanded="false" aria-disabled="true">
 <span class="hero__title">
 Calculators (0)
 </span>
 </a>
 <!-- ko if: $data.activeGroup() === "Calculators" -->
 <div class="hero__content" data-bind="css:{'hero__content--active': $root.activeGroup() === 'Calculators'}">
 <div class="floatbox">
 </div>
 <br class="floatbox__clear">
 </div>
 <!-- /ko -->
 </li>
 <li class="hero__cell " data-bind="css:{'hero__cell--active': $root.activeGroup() === 'Images'}">
 <a data-bind="event: { click: function() { $data.activateGroup('Images'); }, keypress: function() { $data.activateGroup('Images'); }}" class="hero__link" tabindex="0" role="tab" aria-expanded="false" false="">
 <span class="hero__title">
 Images (1)
 </span>
 </a>
 <!-- ko if: $data.activeGroup() === "Images" -->
 <div class="hero__content" data-bind="css:{'hero__content--active': $root.activeGroup() === 'Images'}">
 <div class="floatbox">
 <div class="floatbox__item floatbox__item--hero">
 
<a class="hero__figure hero__figure--image" data-group-name="image" title="Oral Candidiasis Due to HIV">
 <div class="hero__image--image">
 <div class="hero__container">
 <img class="hero__image--image" src="./~/media/manual/professional/images/4/1/5/415-candidiasis-tongue-slide-25-springer-high.jpg?mw=350&amp;thn=0&amp;sc_lang=en" width="1000" height="631" loading="lazy">
 </div>
 <span class="hero__description">
 Oral Candidiasis Due to HIV
 </span>
 </div>
 
<div class="multimedia__link" data-bind="component: { name: 'multimedia-link-block', params: {data: $data, root: $root, element: $element} }" data-popup-model='{"Alt":"Oral Candidiasis Due to HIV","Credits":"\u003cspan id=\u0022v85659979\u0022 class=\u0022anchor\u0022 \u003e\u003c/span\u003e\u003cdiv class=\u0022para\u0022 \u003e \u003cp \u003e© Springer Science+Business Media\u003c/p\u003e\u003c/div\u003e","IsRestricted":true,"ItemId":"31c77951-00f2-430b-8605-69c988e79a32","Title":"Oral%20Candidiasis%20Due%20to%20HIV","ShareUrlTitle":"oral-candidiasis-due-to-hiv","Description":"%3Cp%3EThis%20photo%20shows%20fluffy%20white%20exudate%20on%20the%20tongue%20of%20a%20child%20with%20HIV%20infection.%3C%2Fp%3E","ImageUrl":"./~/media/manual/professional/images/4/1/5/415-candidiasis-tongue-slide-25-springer-high.jpg?thn=0\u0026sc_lang=en","ThumbnailUrl":"./~/media/manual/professional/images/4/1/5/415-candidiasis-tongue-slide-25-springer-high.jpg?mw=350\u0026amp;thn=0\u0026amp;sc_lang=en","MediaType":"image","MediaNameTranslated":"Image","UniqueId":"v27716264","Placement":null,"IsInCarousel":false,"Edition":0,"ImageWidth":"1000","ImageHeight":"631","IframeSrc":null,"Target":null}' data-popup-options='{"ListName":"TopicResources","LinkText":"Oral%20Candidiasis%20Due%20to%20HIV","CssClass":null,"LoadLocations":true,"ShowTooltip":false,"SingleItem":false,"ExcludeFromBrand":null,"ShowCredits":true,"ShowDescription":true,"PopupTitle":"Topic%20Resources%20%3A%20Image","ShowTitle":true,"ShowIcon":false,"ShowModalIndicator":false,"ShowTitleInHeader":false,"HideCarousel":false,"Target":null,"Url":null,"HideMainArrows":false}'>
</div>
</a>
 </div>
 </div>
 <br class="floatbox__clear">
 </div>
 <!-- /ko -->
 </li>
 <li class="hero__cell " data-bind="css:{'hero__cell--active': $root.activeGroup() === 'Tables'}">
 <a data-bind="event: { click: function() { $data.activateGroup('Tables'); }, keypress: function() { $data.activateGroup('Tables'); }}" class="hero__link" tabindex="0" role="tab" aria-expanded="false" false="">
 <span class="hero__title">
 Tables (4)
 </span>
 </a>
 <!-- ko if: $data.activeGroup() === "Tables" -->
 <div class="hero__content" data-bind="css:{'hero__content--active': $root.activeGroup() === 'Tables'}">
 <div class="floatbox">
 <div class="floatbox__item floatbox__item--hero">
 
<a class="hero__figure hero__figure--table" data-group-name="table" title="Immunologic Categories (HIV Infection Stages) for Children 13 Years With HIV Infection Based on Age-Specific CD4+ T-Cell Count or Percentage">
 <div class="hero__table">
 <img class="hero__table--image" src="./Content/Images/Redesign/table/icon_table_red.png" loading="lazy">
 </div>
 <span class="hero__description">
 Immunologic Categories (HIV...
 </span>
 
<div class="multimedia__link" data-bind="component: { name: 'multimedia-link-block', params: {data: $data, root: $root, element: $element} }" data-popup-model='{"ItemId":"f95c6fa0-ba2c-48ca-b6fa-5e798b80914f","Title":"Immunologic%20Categories%20%28HIV%20Infection%20Stages%29%20for%20Children%20%3Cspan%20class%3D%27symbol%27%20%3E%3C%3C%2Fspan%3E%2013%20Years%20With%20HIV%20Infection%20Based%20on%20Age-Specific%20CD4%2B%20T-Cell%20Count%20or%20Percentage","ShareUrlTitle":"immunologic-categories-hiv-infection-stages-for-children-span-classsymbol-span-13-years-with-hiv-infection-based-on-age-specific-cd4-t-cell-count-or-percentage","Description":"","ImageUrl":null,"ThumbnailUrl":"./Content/Images/Redesign/table/icon_table_red.png","MediaType":"table","MediaNameTranslated":"Table","UniqueId":"v49373218","Placement":null,"IsInCarousel":false,"Edition":0,"ImageWidth":null,"ImageHeight":null,"IframeSrc":null,"Target":null,"Alt":null}' data-popup-options='{"ListName":"TopicResources","LinkText":"Immunologic%20Categories%20%28HIV%20Infection%20Stages%29%20for%20Children%20%3Cspan%20class%3D%27symbol%27%20%3E%3C%3C%2Fspan%3E%2013%20Years%20With%20HIV%20Infection%20Based%20on%20Age-Specific%20CD4%2B%20T-Cell%20Count%20or%20Percentage","CssClass":null,"LoadLocations":true,"ShowTooltip":false,"SingleItem":false,"ExcludeFromBrand":null,"ShowCredits":true,"ShowDescription":true,"PopupTitle":"Topic%20Resources%20%3A%20Table","ShowTitle":true,"ShowIcon":false,"ShowModalIndicator":false,"ShowTitleInHeader":false,"HideCarousel":false,"Target":null,"Url":null,"HideMainArrows":false}'>
</div>
</a>
 </div>
 <div class="floatbox__item floatbox__item--hero">
 
<a class="hero__figure hero__figure--table" data-group-name="table" title="Considerations for Use of Live Vaccines in Children With HIV Infection">
 <div class="hero__table">
 <img class="hero__table--image" src="./Content/Images/Redesign/table/icon_table_red.png" loading="lazy">
 </div>
 <span class="hero__description">
 Considerations for Use of...
 </span>
 
<div class="multimedia__link" data-bind="component: { name: 'multimedia-link-block', params: {data: $data, root: $root, element: $element} }" data-popup-model='{"ItemId":"ca02e767-48b1-472f-9d0a-b7ed22899500","Title":"Considerations%20for%20Use%20of%20Live%20Vaccines%20in%20Children%20With%20HIV%20Infection","ShareUrlTitle":"considerations-for-use-of-live-vaccines-in-children-with-hiv-infection","Description":"","ImageUrl":null,"ThumbnailUrl":"./Content/Images/Redesign/table/icon_table_red.png","MediaType":"table","MediaNameTranslated":"Table","UniqueId":"v1108117","Placement":null,"IsInCarousel":false,"Edition":0,"ImageWidth":null,"ImageHeight":null,"IframeSrc":null,"Target":null,"Alt":null}' data-popup-options='{"ListName":"TopicResources","LinkText":"Considerations%20for%20Use%20of%20Live%20Vaccines%20in%20Children%20With%20HIV%20Infection","CssClass":null,"LoadLocations":true,"ShowTooltip":false,"SingleItem":false,"ExcludeFromBrand":null,"ShowCredits":true,"ShowDescription":true,"PopupTitle":"Topic%20Resources%20%3A%20Table","ShowTitle":true,"ShowIcon":false,"ShowModalIndicator":false,"ShowTitleInHeader":false,"HideCarousel":false,"Target":null,"Url":null,"HideMainArrows":false}'>
</div>
</a>
 </div>
 <div class="floatbox__item floatbox__item--hero">
 
<a class="hero__figure hero__figure--table" data-group-name="table" title="Neonatal Antiretroviral Management According to Risk of HIV Infection">
 <div class="hero__table">
 <img class="hero__table--image" src="./Content/Images/Redesign/table/icon_table_red.png" loading="lazy">
 </div>
 <span class="hero__description">
 Neonatal Antiretroviral Managemen...
 </span>
 
<div class="multimedia__link" data-bind="component: { name: 'multimedia-link-block', params: {data: $data, root: $root, element: $element} }" data-popup-model='{"ItemId":"74086197-3239-4f45-b530-4a7161fe8cda","Title":"Neonatal%20Antiretroviral%20Management%20According%20to%20Risk%20of%20HIV%20Infection","ShareUrlTitle":"neonatal-antiretroviral-management-according-to-risk-of-hiv-infection","Description":"","ImageUrl":null,"ThumbnailUrl":"./Content/Images/Redesign/table/icon_table_red.png","MediaType":"table","MediaNameTranslated":"Table","UniqueId":"v49373411","Placement":null,"IsInCarousel":false,"Edition":0,"ImageWidth":null,"ImageHeight":null,"IframeSrc":null,"Target":null,"Alt":null}' data-popup-options='{"ListName":"TopicResources","LinkText":"Neonatal%20Antiretroviral%20Management%20According%20to%20Risk%20of%20HIV%20Infection","CssClass":null,"LoadLocations":true,"ShowTooltip":false,"SingleItem":false,"ExcludeFromBrand":null,"ShowCredits":true,"ShowDescription":true,"PopupTitle":"Topic%20Resources%20%3A%20Table","ShowTitle":true,"ShowIcon":false,"ShowModalIndicator":false,"ShowTitleInHeader":false,"HideCarousel":false,"Target":null,"Url":null,"HideMainArrows":false}'>
</div>
</a>
 </div>
 <div class="floatbox__item floatbox__item--hero">
 
<a class="hero__figure hero__figure--table" data-group-name="table" title="Antiretroviral Dosing for Neonates With Perinatal HIV Exposure">
 <div class="hero__table">
 <img class="hero__table--image" src="./Content/Images/Redesign/table/icon_table_red.png" loading="lazy">
 </div>
 <span class="hero__description">
 Antiretroviral Dosing for...
 </span>
 
<div class="multimedia__link" data-bind="component: { name: 'multimedia-link-block', params: {data: $data, root: $root, element: $element} }" data-popup-model='{"ItemId":"e0b2fa81-954d-4b00-931e-d0584b768e9a","Title":"Antiretroviral%20Dosing%20for%20Neonates%20With%20Perinatal%20HIV%20Exposure","ShareUrlTitle":"antiretroviral-dosing-for-neonates-with-perinatal-hiv-exposure","Description":"","ImageUrl":null,"ThumbnailUrl":"./Content/Images/Redesign/table/icon_table_red.png","MediaType":"table","MediaNameTranslated":"Table","UniqueId":"v49373475","Placement":null,"IsInCarousel":false,"Edition":0,"ImageWidth":null,"ImageHeight":null,"IframeSrc":null,"Target":null,"Alt":null}' data-popup-options='{"ListName":"TopicResources","LinkText":"Antiretroviral%20Dosing%20for%20Neonates%20With%20Perinatal%20HIV%20Exposure","CssClass":null,"LoadLocations":true,"ShowTooltip":false,"SingleItem":false,"ExcludeFromBrand":null,"ShowCredits":true,"ShowDescription":true,"PopupTitle":"Topic%20Resources%20%3A%20Table","ShowTitle":true,"ShowIcon":false,"ShowModalIndicator":false,"ShowTitleInHeader":false,"HideCarousel":false,"Target":null,"Url":null,"HideMainArrows":false}'>
</div>
</a>
 </div>
 </div>
 <br class="floatbox__clear">
 </div>
 <!-- /ko -->
 </li>
 <li class="hero__cell hero__cell--empty" data-bind="css:{'hero__cell--active': $root.activeGroup() === 'Videos'}">
 <a data-bind="" class="hero__link" tabindex="0" role="tab" aria-expanded="false" aria-disabled="true">
 <span class="hero__title">
 Videos (0)
 </span>
 </a>
 <!-- ko if: $data.activeGroup() === "Videos" -->
 <div class="hero__content" data-bind="css:{'hero__content--active': $root.activeGroup() === 'Videos'}">
 <div class="floatbox">
 </div>
 <br class="floatbox__clear">
 </div>
 <!-- /ko -->
 </li>
 </ul>
 </div>
</div>
<div class="topic__accordion">
 <span id="v1107299" class="anchor"></span><div class="para"> <p><div class='topic__explanation'>Human immunodeficiency virus (HIV) infection is caused by the retrovirus HIV-1 (and less commonly by the related retrovirus HIV-2). Infection leads to progressive immunologic deterioration and opportunistic infections and cancers. The end stage is acquired immunodeficiency syndrome (AIDS). Diagnosis is by viral antibodies in children <span class='symbol'>></span> 18 months and virologic nucleic acid amplification tests (such as polymerase chain reaction testing) in children <span class='symbol'>&lt</span> 18 months. Treatment is with combinations of antiretroviral medications.</div></p></div><span id="v1107297" class="anchor"></span><div class="para"> <p>(See also <a href="./{F74E7EDD-B57E-443C-AF88-E04A1F79DA48}.html" data-toggle="tooltip" title="Human Immunodeficiency Virus (HIV) Infection" data-id="90ffdf02-ca06-4ac1-a4f1-fa66c00f376a" data-itemid="f74e7edd-b57e-443c-af88-e04a1f79da48">Human Immunodeficiency Virus (HIV) Infection</a><span id="90ffdf02-ca06-4ac1-a4f1-fa66c00f376a" class="d-none xref"> <span class="tooltip-container"> <a href="./{F74E7EDD-B57E-443C-AF88-E04A1F79DA48}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Human Immunodeficiency Virus (HIV) Infection </span> Human immunodeficiency virus (HIV) infection results from 1 of 2 similar retroviruses (HIV-1 and HIV-2) that destroy CD4+ lymphocytes and impair cell-mediated immunity, increasing risk of certain... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/3/1/3/313_hiv_slide_3_springer_high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Human Immunodeficiency Virus (HIV) Infection" loading="lazy"> </span> </a> </span> </span> in adults.)</p></div><span id="v1107301" class="anchor"></span><div class="para"> <p>The general natural history and pathophysiology of pediatric HIV infection is similar to that in adults; however, the method of infection, clinical presentations, and treatments often differ. </p></div><span id="v77995614" class="anchor"></span><div class="para"> <p>Children with HIV infection may also have unique <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v49373375" data-toggle="tooltip" title="Psychosocial approach to children with HIV infection" data-id="babcb639-934c-4286-8499-4e6467267e38" data-itemid="6ea530b9-c85e-4653-b466-245f2a0e10ea">social integration issues</a><span id="babcb639-934c-4286-8499-4e6467267e38" class="d-none xref"> <span class="tooltip-container"> <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v49373375"> <span class="tooltip-content"> <span class="tooltip-heading"> Psychosocial approach to children with HIV infection </span> Human immunodeficiency virus (HIV) infection is caused by the retrovirus HIV-1 (and less commonly by the related retrovirus HIV-2). Infection leads to progressive immunologic deterioration and... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/4/1/5/415-candidiasis-tongue-slide-25-springer-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Psychosocial approach to children with HIV infection" loading="lazy"> </span> </a> </span> </span>.</p></div> <section id="v77995616" class="topic__section GHead"> <span></span> <h2 id="" class="topic__header--section"> <span id="v77995617" class="anchor"></span> General references </h2> <div class="topic__content"> <div class="list"> <ul data-mmanualobjecttype="List" class="nobulleted"><li class="topic__listitem"><span id="v77995620" class="anchor"></span><div class="para"> <p>ClinicalInfo.HIV.gov/Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV: <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines">Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection</a></p></div></li><li class="topic__listitem"><span id="v77995623" class="anchor"></span><div class="para"> <p>Weinberg GA, Siberry GK: Pediatric human immunodeficiency virus infection. In <i>Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases</i>, 9th ed., edited by JE Bennett, R Dolin, and MJ Blaser. Philadelphia, Elsevier, 2020, pp. 1732–1738.</p></div></li></ul></div> </div> </section> <section id="v1107319" class="topic__section FHead"> <h2 id="Epidemiology_v1107320" class="topic__header--section" data-originaltitle="Epidemiology"> <span id="v1107320" class="anchor"></span> Epidemiology of HIV Infection in Infants and Children </h2> <div class="topic__content"> <span id="v1107321" class="anchor"></span><div class="para"> <p>In the United States, since HIV infection was first recognized, more than 10,000 cases have been reported in children and young adolescents, but this number represents only 1% of total cases. In 2019, < 60 new cases were diagnosed in children < 13 years of age (<a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v37571257" data-toggle="tooltip" title="Epidemiology references" data-id="87d07376-61fe-40f1-b229-fd60d197084d" data-itemid="6ea530b9-c85e-4653-b466-245f2a0e10ea">1</a><span id="87d07376-61fe-40f1-b229-fd60d197084d" class="d-none xref"> <span class="tooltip-container"> <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v37571257"> <span class="tooltip-content"> <span class="tooltip-heading"> Epidemiology references </span> Human immunodeficiency virus (HIV) infection is caused by the retrovirus HIV-1 (and less commonly by the related retrovirus HIV-2). Infection leads to progressive immunologic deterioration and... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/4/1/5/415-candidiasis-tongue-slide-25-springer-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Epidemiology references" loading="lazy"> </span> </a> </span> </span>).</p></div><span id="v1107322" class="anchor"></span><div class="para"> <p>More than 95% of US children with HIV infection acquired the infection from their mother, through either antenatal or perinatal transmission (also called vertical transmission or mother-to-child transmission [MTCT]). Most of the remainder (including children with hemophilia or other coagulation disorders) received contaminated blood or blood products. Some cases were the result of sexual abuse. </p></div><span id="v77995624" class="anchor"></span><div class="para"> <p>MTCT has declined significantly in the United States from approximately 25% in 1991 (resulting in > 1600 infected children annually) to ≤ 1% in 2019 (resulting in approximately 50 children infected annually). MTCT has been reduced by using comprehensive serologic screening and treating of infected pregnant women during both pregnancy and delivery and by providing short-term antiretroviral prophylaxis to exposed newborns. Approximately 3000 to 5000 pregnant women with HIV infection give birth annually in the United States, so attention to preventing MTCT remains critical in preventing HIV infection in infants and children.</p></div><span id="v9140437" class="anchor"></span><div class="para"> <p>Although the number of children infected annually has decreased, the total number of US adolescents and young adults (13 to 24 years of age) with HIV infection continues to increase despite the marked success in decreasing perinatal HIV infection. In 2019, about 36,000 new cases of HIV infection in the United States were diagnosed; 20% of these were among adolescents and young adults 13 to 24 years of age (the majority of whom were 18 years of age or older) (<a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v37571257" data-toggle="tooltip" title="Epidemiology references" data-id="a183d4aa-1fc7-4ed2-bd55-2e8cf11ad5e1" data-itemid="6ea530b9-c85e-4653-b466-245f2a0e10ea">1</a><span id="a183d4aa-1fc7-4ed2-bd55-2e8cf11ad5e1" class="d-none xref"> <span class="tooltip-container"> <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v37571257"> <span class="tooltip-content"> <span class="tooltip-heading"> Epidemiology references </span> Human immunodeficiency virus (HIV) infection is caused by the retrovirus HIV-1 (and less commonly by the related retrovirus HIV-2). Infection leads to progressive immunologic deterioration and... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/4/1/5/415-candidiasis-tongue-slide-25-springer-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Epidemiology references" loading="lazy"> </span> </a> </span> </span>). This paradoxical increase in the number of children and adolescents with HIV infection is a result of both greater survival rates among perinatally infected children and new cases of HIV infection acquired via sexual transmission among other adolescents and young adults (in particular, among young men who have sex with men). Reducing transmission of HIV among young men who have sex with men continues to be an important focus of domestic HIV control efforts as is continuing the reduction of MTCT.</p></div><span id="v1107323" class="anchor"></span><div class="para"> <p>Worldwide, in 2021, about 1.7 million children < 14 years old had HIV infection (4% of the total caseload worldwide) (<a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v37571257" data-toggle="tooltip" title="Epidemiology references" data-id="e4623733-4ee1-48dc-9eee-e0ed1620afe5" data-itemid="6ea530b9-c85e-4653-b466-245f2a0e10ea">2</a><span id="e4623733-4ee1-48dc-9eee-e0ed1620afe5" class="d-none xref"> <span class="tooltip-container"> <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v37571257"> <span class="tooltip-content"> <span class="tooltip-heading"> Epidemiology references </span> Human immunodeficiency virus (HIV) infection is caused by the retrovirus HIV-1 (and less commonly by the related retrovirus HIV-2). Infection leads to progressive immunologic deterioration and... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/4/1/5/415-candidiasis-tongue-slide-25-springer-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Epidemiology references" loading="lazy"> </span> </a> </span> </span>). Each year, about 160,000 more children are infected (10% of all new infections), and about 100,000 children die. </p></div><span id="v77995626" class="anchor"></span><div class="para"> <p>Although these numbers represent a daunting amount of illness, new programs created to deliver antiretroviral therapy (ART) to pregnant women and children have reduced the annual number of new childhood infections and childhood deaths by 33 to 50% in the past few years (<a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v37571257" data-toggle="tooltip" title="Epidemiology references" data-id="e808610b-281d-4cfa-a0f2-04cf3fc02156" data-itemid="6ea530b9-c85e-4653-b466-245f2a0e10ea">1</a><span id="e808610b-281d-4cfa-a0f2-04cf3fc02156" class="d-none xref"> <span class="tooltip-container"> <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v37571257"> <span class="tooltip-content"> <span class="tooltip-heading"> Epidemiology references </span> Human immunodeficiency virus (HIV) infection is caused by the retrovirus HIV-1 (and less commonly by the related retrovirus HIV-2). Infection leads to progressive immunologic deterioration and... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/4/1/5/415-candidiasis-tongue-slide-25-springer-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Epidemiology references" loading="lazy"> </span> </a> </span> </span>). However, infected children still do not receive ART nearly as often as adults, and <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v1108223" data-toggle="tooltip" title="Prevention of perinatal transmission" data-id="81a50f35-6bc8-41a1-ab05-5096128c34f4" data-itemid="6ea530b9-c85e-4653-b466-245f2a0e10ea">interrupting vertical transmission</a><span id="81a50f35-6bc8-41a1-ab05-5096128c34f4" class="d-none xref"> <span class="tooltip-container"> <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v1108223"> <span class="tooltip-content"> <span class="tooltip-heading"> Prevention of perinatal transmission </span> Human immunodeficiency virus (HIV) infection is caused by the retrovirus HIV-1 (and less commonly by the related retrovirus HIV-2). Infection leads to progressive immunologic deterioration and... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/4/1/5/415-candidiasis-tongue-slide-25-springer-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Prevention of perinatal transmission" loading="lazy"> </span> </a> </span> </span> (MTCT) and providing treatment to children with HIV infection remain the two most important goals of global pediatric HIV medicine.</p></div> <section id="v37571256" class="topic__section GHead"> <span></span> <h3 id="Epidemiology_v1107320_v37571257" class="topic__header--subsection"> <span id="v37571257" class="anchor"></span> Epidemiology references </h3> <div class="topic__content"> <div class="list"> <ul data-mmanualobjecttype="List" class="nobulleted"><li class="topic__listitem"><span id="v49372988" class="anchor"></span><div class="para"> <p>1. <a rel="nofollow" target="_blank" href="https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html">Centers for Disease Control and Prevention</a>: HIV Surveillance Report, 2020. Vol. 33. Published May 2022. Accessed 11/29/2022.</p></div></li><li class="topic__listitem"><span id="v77995630" class="anchor"></span><div class="para"> <p>2. <a rel="nofollow" target="_blank" href="https://www.unaids.org/en/resources/fact-sheet">UNAIDS</a>: Global HIV & AIDS statistics—Fact sheet. Accessed 12/19/2022.</p></div></li></ul></div> </div> </section> </div> </section> <section id="v77995632" class="topic__section FHead"> <h2 id="" class="topic__header--section" data-originaltitle="Transmission of HIV"> <span id="v77995633" class="anchor"></span> Transmission of HIV Infection in Infants and Children </h2> <div class="topic__content"> <span id="v77995635" class="anchor"></span><div class="para"> <p>The infection risk for an infant born to a mother with HIV infection who did not receive ART during pregnancy is estimated at 25%. </p></div><span id="v77995636" class="anchor"></span><div class="para"> <p><b>Risk factors</b> for MTCT include </p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v77995639" class="anchor"></span><div class="para"> <p>Seroconversion during pregnancy or breastfeeding (major risk)</p></div></li><li class="topic__listitem"><span id="v77995641" class="anchor"></span><div class="para"> <p>High plasma viral RNA concentrations (major risk)</p></div></li><li class="topic__listitem"><span id="v77995643" class="anchor"></span><div class="para"> <p>Advanced maternal disease</p></div></li><li class="topic__listitem"><span id="v77995645" class="anchor"></span><div class="para"> <p>Low maternal peripheral CD4+ T-cell counts</p></div></li></ul></div><span id="v77995646" class="anchor"></span><div class="para"> <p>Prolonged rupture of membranes is no longer thought to be an important risk factor. </p></div><span id="v77995647" class="anchor"></span><div class="para"> <p>Cesarean delivery before onset of active labor reduces the risk of MTCT. However, it is clear that MTCT is reduced most significantly by giving combination ART, usually including <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>zidovudine</span> (ZDV), to the mother and neonate (see <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v1108219" data-toggle="tooltip" title="Prevention" data-id="cfaa5105-c702-4015-9058-ec85b578575e" data-itemid="6ea530b9-c85e-4653-b466-245f2a0e10ea">Prevention of HIV Infection in Infants and Children</a><span id="cfaa5105-c702-4015-9058-ec85b578575e" class="d-none xref"> <span class="tooltip-container"> <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v1108219"> <span class="tooltip-content"> <span class="tooltip-heading"> Prevention </span> Human immunodeficiency virus (HIV) infection is caused by the retrovirus HIV-1 (and less commonly by the related retrovirus HIV-2). Infection leads to progressive immunologic deterioration and... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/4/1/5/415-candidiasis-tongue-slide-25-springer-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Prevention" loading="lazy"> </span> </a> </span> </span>). ZDV monotherapy reduces MTCT from 25% to about 8%, and current combination ART reduces it to ≤ 1%.</p></div><span id="v77995649" class="anchor"></span><div class="para"> <p>HIV has been detected in both the cellular and cell-free fractions of human breast milk. Estimates of the overall risk of transmission through breastfeeding are 12 to 14%, reflecting varying durations of breastfeeding. Transmission by breastfeeding is greatest in mothers with high plasma viral RNA concentrations (eg, women who become infected during pregnancy or during the period of breastfeeding).</p></div><span id="v77995650" class="anchor"></span><div class="para"> <p>Early in the HIV pandemic, HIV was transmitted to young children via contaminated blood products (eg, whole blood or cellular or plasma blood components such as packed red blood cells, intravenous immune globulin); however, transmission via this route no longer occurs when blood products are screened for HIV (and, in the case of immune globulin, also prepared with viral inactivation steps).</p></div><span id="v77995651" class="anchor"></span><div class="para"> <p>Transmission of HIV via sexual activity of adolescents is similar to that of adults (see <a href="./{F74E7EDD-B57E-443C-AF88-E04A1F79DA48}.html#v1021294" data-toggle="tooltip" title="Transmission" data-id="8d3b2b5f-3a63-4370-807c-5bd2c127a180" data-itemid="f74e7edd-b57e-443c-af88-e04a1f79da48">Transmission of HIV Infection</a><span id="8d3b2b5f-3a63-4370-807c-5bd2c127a180" class="d-none xref"> <span class="tooltip-container"> <a href="./{F74E7EDD-B57E-443C-AF88-E04A1F79DA48}.html#v1021294"> <span class="tooltip-content"> <span class="tooltip-heading"> Transmission </span> Human immunodeficiency virus (HIV) infection results from 1 of 2 similar retroviruses (HIV-1 and HIV-2) that destroy CD4+ lymphocytes and impair cell-mediated immunity, increasing risk of certain... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/3/1/3/313_hiv_slide_3_springer_high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Transmission" loading="lazy"> </span> </a> </span> </span> in adults).</p></div> </div> </section> <section id="v49372990" class="topic__section FHead"> <h2 id="Epidemiology_v49372991" class="topic__header--section" data-originaltitle="Classification"> <span id="v49372991" class="anchor"></span> Classification of HIV Infection in Infants and Children </h2> <div class="topic__content"> <span id="v49372992" class="anchor"></span><div class="para"> <p>HIV infection causes a broad spectrum of disease, of which AIDS is the most severe. Past classification schemes established by the Centers for Disease Control and Prevention (CDC) defined the progression of clinical and immunologic decline. These clinical and immunologic categories have become much less relevant in the era of combination ART, because when ART is taken as prescribed, it almost invariably decreases symptoms and increases CD4+ T-cell counts. However, immunologic staging based on CD4+ T-cell counts remains valuable for planning opportunistic pathogen prophylaxis. </p></div><span id="v49372994" class="anchor"></span><div class="para"> <p>The clinical categories in children <span class='symbol'>&lt</span> 13 years are available from ClinicalInfo.HIV.gov's <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/appendix-c-cdc-pediatric-hiv-cd4-cell?view=full">Appendix C: CDC Pediatric HIV CD4 Cell Count/Percentage and HIV-Related Diseases Categorization</a> table and are shown in table <span class="multimedia__link mlinkBlock" data-bind="component: { name: 'm-link-text', params: $data }" data-popup-model='{"ItemId":"f95c6fa0-ba2c-48ca-b6fa-5e798b80914f","Title":"Immunologic%20Categories%20%28HIV%20Infection%20Stages%29%20for%20Children%20%2013%20Years%20With%20HIV%20Infection%20Based%20on%20Age-Specific%20CD4%2B%20T-Cell%20Count%20or%20Percentage","ShareUrlTitle":"immunologic-categories-hiv-infection-stages-for-children-span-classsymbol-span-13-years-with-hiv-infection-based-on-age-specific-cd4-t-cell-count-or-percentage","Description":"","ImageUrl":null,"ThumbnailUrl":"/Content/Images/Redesign/table/icon_table_red.png","MediaType":"table","MediaNameTranslated":"Table","UniqueId":"v49373218","Placement":null,"IsInCarousel":false,"Edition":0,"ImageWidth":null,"ImageHeight":null,"IframeSrc":null,"Target":null,"Alt":null}' data-popup-options='{"ListName":"TopicMultimedia","LinkText":"%3Cspan%20%3EImmunologic%20Categories%20%28HIV%20Infection%20Stages%29%20for%20Children%20%3C%2013%20Years%20With%20HIV%20Infection%20Based%20on%20Age-Specific%20CD4%2B%20T-Cell%20Count%20or%20Percentage%3C%2Fspan%3E","CssClass":null,"LoadLocations":true,"ShowTooltip":true,"SingleItem":true,"ExcludeFromBrand":"","ShowCredits":true,"ShowDescription":true,"PopupTitle":"Table","ShowTitle":true,"ShowIcon":false,"ShowModalIndicator":false,"ShowTitleInHeader":false,"HideCarousel":false,"Target":"modal","Url":null,"HideMainArrows":false}'></span>. In infants and children, HIV infection and disease may progress more rapidly than in adolescents and adults.</p></div> <span id="v49373217"></span> <div data-mmanualobjecttype="illustrativeMaterial" class="inlinebox--full inlinebox--table inlinebox--clickable illustrativeMaterialTable "> <div class="inlinebox__wrapper" id="v49373219"> <div class="inlinebox__header">Table</div> <div class="inlinebox__content"> <div class="multimedia__link" data-bind="component: { name: 'multimedia-link-text', params: $data }" data-popup-model='{"ItemId":"f95c6fa0-ba2c-48ca-b6fa-5e798b80914f","Title":"Immunologic%20Categories%20%28HIV%20Infection%20Stages%29%20for%20Children%20%3Cspan%20class%3D%27symbol%27%20%3E%3C%3C%2Fspan%3E%2013%20Years%20With%20HIV%20Infection%20Based%20on%20Age-Specific%20CD4%2B%20T-Cell%20Count%20or%20Percentage","ShareUrlTitle":"immunologic-categories-hiv-infection-stages-for-children-span-classsymbol-span-13-years-with-hiv-infection-based-on-age-specific-cd4-t-cell-count-or-percentage","Description":"","ImageUrl":null,"ThumbnailUrl":"./Content/Images/Redesign/table/icon_table_red.png","MediaType":"table","MediaNameTranslated":"Table","UniqueId":"v49373218","Placement":null,"IsInCarousel":false,"Edition":0,"ImageWidth":null,"ImageHeight":null,"IframeSrc":null,"Target":null,"Alt":null}' data-popup-options='{"ListName":"","LinkText":"Immunologic%20Categories%20%28HIV%20Infection%20Stages%29%20for%20Children%20%3Cspan%20class%3D%27symbol%27%20%3E%3C%3C%2Fspan%3E%2013%20Years%20With%20HIV%20Infection%20Based%20on%20Age-Specific%20CD4%2B%20T-Cell%20Count%20or%20Percentage","CssClass":null,"LoadLocations":false,"ShowTooltip":false,"SingleItem":true,"ExcludeFromBrand":null,"ShowCredits":true,"ShowDescription":true,"PopupTitle":"Table","ShowTitle":true,"ShowIcon":false,"ShowModalIndicator":false,"ShowTitleInHeader":false,"HideCarousel":true,"Target":null,"Url":null,"HideMainArrows":false}'> </div> <div class="inlinebox__button"> <img src="./Content/Images/Redesign/table/icon_table_red.png" alt="" loading="lazy" width="55" height="42"> </div> <div class="inlinebox__content--print" id="f95c6fa0-ba2c-48ca-b6fa-5e798b80914f"> </div> </div> </div> <!-- Type: Table --> </div> <script type="text/javascript"> $(document).ready(function () { var url = window.location; if (url.search.includes("media=print")) { $.ajax({ url: '/Redesign/Topic/GetTableBody', type: "GET", dataType: "json", data: { tableId: 'f95c6fa0-ba2c-48ca-b6fa-5e798b80914f' }, async: true, success: function (data) { $('#f95c6fa0-ba2c-48ca-b6fa-5e798b80914f').html('<div class="modaldialog">'+ data.TableBody + '</div>'); }, error: function (jqxhr, textStatus, errorThrown) { console.error(errorThrown); } }); } }); </script> </div> </section> <section id="v1107623" class="topic__section FHead" itemprop="signOrSymptom" itemscope="" itemtype="http://schema.org/MedicalSignOrSymptom"> <h2 id="SymptomsAndSigns_v1107624" class="topic__header--section" data-originaltitle="Symptoms and Signs"> <span id="v1107624" class="anchor"></span> Symptoms and Signs of HIV Infection in Infants and Children </h2> <div class="topic__content"> <section id="v1107645" class="topic__section GHead"> <span></span> <h3 id="SymptomsAndSigns_v1107624_v1107646" class="topic__header--subsection"> <span id="v1107646" class="anchor"></span> Children receiving combination antiretroviral therapy (ART) </h3> <div class="topic__content"> <span id="v1107647" class="anchor"></span><div class="para"> <p>Combination ART has significantly changed the clinical manifestations of pediatric HIV infection. Although bacterial pneumonia and other bacterial infections (eg, bacteremia, recurrent otitis media) still occur more often in children with HIV infection, opportunistic infections and growth failure are much less frequent than in the pre-ART era. New problems, such as alterations in serum lipids, hyperglycemia, fat maldistribution (lipodystrophy and lipoatrophy), nephropathy, and osteonecrosis, are reported; however, the incidence is lower in children than in adults with HIV infection. </p></div><span id="v9140465" class="anchor"></span><div class="para"> <p>Although combination ART clearly improves neurodevelopmental outcome, there seems to be an increased rate of behavioral, developmental, and cognitive problems in treated children with HIV infection. It is unclear whether these problems are caused by HIV infection itself, medications, or other biopsychosocial factors that occur among children with HIV infection. It is unknown whether any additional effects of HIV infection or ART during critical periods of growth and development will manifest later in life. However, no such effects have been noted in perinatally infected children who were treated with ART and are now young adults. To detect such adverse effects, providers will need to monitor children with HIV infection over time.</p></div> </div> </section> <section id="v1107625" class="topic__section GHead"> <span></span> <h3 id="SymptomsAndSigns_v1107624_v1107626" class="topic__header--subsection"> <span id="v1107626" class="anchor"></span> Natural history in untreated children </h3> <div class="topic__content"> <span id="v1107627" class="anchor"></span><div class="para"> <p>Infants infected perinatally usually are asymptomatic during the first few months of life, even if no combination ART is begun. Although the median age at symptom onset is about 3 years, some children remain asymptomatic for <span class='symbol'>></span> 5 years and, with appropriate ART, are expected to survive to adulthood. </p></div><span id="v77995656" class="anchor"></span><div class="para"> <p>In the pre-ART era, about 10 to 15% of children had rapid disease progression, with symptoms occurring in the first year of life and death occurring by 18 to 36 months; these children were thought to have acquired HIV infection earlier in utero. However, most children likely acquire infection at or near birth and have slower disease progression (surviving beyond 5 years even before ART was used routinely).</p></div> <div class="inlinemedia-component " data-ko-rebind="v27716264" data-bind="component: {name: 'inlinemedia-photo', params: $data}" data-inline-model='{"Alt":"Oral Candidiasis Due to HIV","Credits":"\u003cspan id=\u0022v85659979\u0022 class=\u0022anchor\u0022 \u003e\u003c/span\u003e\u003cdiv class=\u0022para\u0022 \u003e \u003cp \u003e© Springer Science+Business Media\u003c/p\u003e\u003c/div\u003e","IsRestricted":true,"ItemId":"31c77951-00f2-430b-8605-69c988e79a32","Title":"Oral Candidiasis Due to HIV","ShareUrlTitle":"oral-candidiasis-due-to-hiv","Description":"\u003cul\u003e\u003cspan id=\u0022v88847152\u0022 class=\u0022anchor\u0022\u003e\u003c/span\u003e\u003cdiv class=\u0022para\u0022\u003e \u003cp\u003eThis photo shows fluffy white exudate on the tongue of a child with HIV infection.\u003c/p\u003e\u003c/div\u003e\u003c/ul\u003e","ImageUrl":"./~/media/manual/professional/images/4/1/5/415-candidiasis-tongue-slide-25-springer-high.jpg?thn=0\u0026sc_lang=en","ThumbnailUrl":"./~/media/manual/professional/images/4/1/5/415-candidiasis-tongue-slide-25-springer-high.jpg?mw=350\u0026amp;thn=0\u0026amp;sc_lang=en","MediaType":"image","MediaNameTranslated":"Image","UniqueId":"v27716264","Placement":"sideline","IsInCarousel":false,"Edition":0,"ImageWidth":"1000","ImageHeight":"631","IframeSrc":null,"Target":null}'> </div><span id="v77995657" class="anchor"></span><div class="para"> <p>In infants who are not receiving ART, disease manifestations include failure to thrive, neurologic problems (eg, loss or delay in motor skills, irritability, poor head growth), failure to thrive, and <i>Pneumocystis</i> pneumonia. </p></div><span id="v77995658" class="anchor"></span><div class="para"> <p>Older children who are not receiving ART frequently have recurrent otitis media, sinusitis, bacterial pneumonia, bacteremia, herpes zoster, and lymphoid interstitial pneumonitis. Older children and adolescents whose disease manifests late in childhood (called slow progressors or nonprogressors) may present with persistent generalized lymphadenopathy, esophageal candidiasis, and lymphoma of the brain or other sites, which is similar to manifestations in adults who are not receiving ART. </p></div><span id="v77995659" class="anchor"></span><div class="para"> <p>All of these manifestations, including opportunistic infections, occur only rarely in people who are receiving combination ART.</p></div> </div> </section> <section id="v1107629" class="topic__section GHead"> <span></span> <h3 id="SymptomsAndSigns_v1107624_v1107630" class="topic__header--subsection"> <span id="v1107630" class="anchor"></span> Complications of HIV in children </h3> <div class="topic__content"> <span id="v9140463" class="anchor"></span><div class="para"> <p>When complications occur, they typically involve opportunistic infections (and rarely cancer). Combination ART has made such infections uncommon, and they now occur mainly in undiagnosed children who have not yet received ART or in children who are not adherent to ART. </p></div><span id="v1107634" class="anchor"></span><div class="para"> <p>When opportunistic infections occur, <a href="./{158ED3D8-7B77-490A-98EE-E29670D7E361}.html" data-toggle="tooltip" title="Pneumocystis jirovecii Pneumonia" data-id="ac3d9c00-1896-4d01-aedc-ade60d0b7b06" data-itemid="158ed3d8-7b77-490a-98ee-e29670d7e361"><i>Pneumocystis jirovecii </i>pneumonia</a><span id="ac3d9c00-1896-4d01-aedc-ade60d0b7b06" class="d-none xref"> <span class="tooltip-container"> <a href="./{158ED3D8-7B77-490A-98EE-E29670D7E361}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> <i>Pneumocystis jirovecii</i> Pneumonia </span> <i>Pneumocystis jirovecii</i>, an atypical fungus, is a common cause of pneumonia in immunosuppressed patients, especially in those infected with human immunodeficiency virus (HIV) and in those... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="/-/media/manual/professional/images/p/n/e/pneumocystis_pneumonia_high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="<i>Pneumocystis jirovecii</i> Pneumonia" loading="lazy"> </span> </a> </span> </span> is the most common and serious and has high mortality. <i>Pneumocystis</i> pneumonia can occur as early as age 4 to 6 weeks but occurs mostly in infants aged 3 to 6 months who acquired infection before or at birth. Infants and older children with <i>Pneumocystis</i> pneumonia characteristically develop a subacute, diffuse pneumonitis with dyspnea at rest, tachypnea, oxygen desaturation, nonproductive cough, and fever (in contrast to non–HIV-infected immunocompromised children and adults, in whom onset is often more acute and fulminant).</p></div><span id="v1107638" class="anchor"></span><div class="para"> <p>Other opportunistic infections in immunosuppressed children include <a href="./{D3F93532-BAC5-4EDF-A805-C33116F1E3CD}.html#v88073961" data-toggle="tooltip" title="Candida Esophagitis" data-id="162915b0-16eb-4c3e-bb46-4d5e12630b39" data-itemid="d3f93532-bac5-4edf-a805-c33116f1e3cd"><i>Candida</i> esophagitis</a><span id="162915b0-16eb-4c3e-bb46-4d5e12630b39" class="d-none xref"> <span class="tooltip-container"> <a href="./{D3F93532-BAC5-4EDF-A805-C33116F1E3CD}.html#v88073961"> <span class="tooltip-content"> <span class="tooltip-heading"> <i>Candida</i> Esophagitis </span> Esophageal infection occurs mainly in patients with impaired host defenses. Primary agents include <i>Candida albicans</i>, herpes simplex virus, and cytomegalovirus. Symptoms are odynophagia... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="/-/media/manual/professional/images/c/a/n/candida-esophagitis-lynch-crop-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="<i>Candida</i> Esophagitis" loading="lazy"> </span> </a> </span> </span>, disseminated <a href="./{9885C1BA-1CEF-43F4-B6A7-537D038A2E61}.html" data-toggle="tooltip" title="Cytomegalovirus (CMV) Infection" data-id="e49675e0-3bbc-4682-a912-100784cede4d" data-itemid="9885c1ba-1cef-43f4-b6a7-537d038a2e61">cytomegalovirus infection</a><span id="e49675e0-3bbc-4682-a912-100784cede4d" class="d-none xref"> <span class="tooltip-container"> <a href="./{9885C1BA-1CEF-43F4-B6A7-537D038A2E61}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Cytomegalovirus (CMV) Infection </span> Cytomegalovirus (CMV, human herpesvirus type 5) can cause infections that have a wide range of severity. A syndrome of infectious mononucleosis that lacks severe pharyngitis is common. Severe... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>, chronic or disseminated <a href="./{A3767F9E-B465-4A68-B382-5EE496A3BB3C}.html" data-toggle="tooltip" title="Neonatal Herpes Simplex Virus (HSV) Infection" data-id="ddca4f27-1267-4520-8899-1d0b6eb3dc0e" data-itemid="a3767f9e-b465-4a68-b382-5ee496a3bb3c">herpes simplex virus infection</a><span id="ddca4f27-1267-4520-8899-1d0b6eb3dc0e" class="d-none xref"> <span class="tooltip-container"> <a href="./{A3767F9E-B465-4A68-B382-5EE496A3BB3C}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Neonatal Herpes Simplex Virus (HSV) Infection </span> Neonatal herpes simplex virus infection is usually transmitted during delivery. A typical sign is vesicular eruption, which may be accompanied by or progress to disseminated disease. Diagnosis... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/1/7/m1700184-localized-hsv-in-a-neonate-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Neonatal Herpes Simplex Virus (HSV) Infection" loading="lazy"> </span> </a> </span> </span> and <a href="./{655DB737-A38D-4B7E-8D82-325DFD38136E}.html" data-toggle="tooltip" title="Chickenpox" data-id="cc0cbaba-d7f4-48f3-bc58-621640770ea3" data-itemid="655db737-a38d-4b7e-8d82-325dfd38136e">varicella-zoster virus infection</a><span id="cc0cbaba-d7f4-48f3-bc58-621640770ea3" class="d-none xref"> <span class="tooltip-container"> <a href="./{655DB737-A38D-4B7E-8D82-325DFD38136E}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Chickenpox </span> Chickenpox is an acute, systemic, usually childhood infection caused by the varicella-zoster virus (human herpesvirus type 3). It usually begins with mild constitutional symptoms (eg, fever... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/1/5/1/15142_chickenpox_back_public_health_image_library_high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Chickenpox" loading="lazy"> </span> </a> </span> </span>, and, less commonly, <a href="./{A8714A3D-4F14-4D70-982B-78165645C2F4}.html" data-toggle="tooltip" title="Perinatal Tuberculosis (TB)" data-id="db875bd6-d053-4b15-95ae-9e585b38c4ad" data-itemid="a8714a3d-4f14-4d70-982b-78165645c2f4"><i>Mycobacterium tuberculosis</i></a><span id="db875bd6-d053-4b15-95ae-9e585b38c4ad" class="d-none xref"> <span class="tooltip-container"> <a href="./{A8714A3D-4F14-4D70-982B-78165645C2F4}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Perinatal Tuberculosis (TB) </span> Tuberculosis can be acquired during the perinatal period. Symptoms and signs are nonspecific. Diagnosis is by culture and sometimes x-ray and biopsy. Treatment is with isoniazid and other antituberculous... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span> and <i>M. avium</i> complex infections, chronic enteritis caused by <a href="./{FB0B4149-8217-43A3-9A33-F266554EA123}.html" data-toggle="tooltip" title="Cryptosporidiosis" data-id="78f9d780-1643-4bc0-9588-e233c7fec0b1" data-itemid="fb0b4149-8217-43a3-9a33-f266554ea123"><i>Cryptosporidium</i></a><span id="78f9d780-1643-4bc0-9588-e233c7fec0b1" class="d-none xref"> <span class="tooltip-container"> <a href="./{FB0B4149-8217-43A3-9A33-F266554EA123}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Cryptosporidiosis </span> Cryptosporidiosis is infection with the protozoan <i>Cryptosporidium</i>. The primary symptom is watery diarrhea, often with other signs of gastrointestinal distress. Illness is typically self-limited... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/c/r/y/cryptosporidium-lifecycle-lg-cdc-sized.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Cryptosporidiosis" loading="lazy"> </span> </a> </span> </span> or other organisms, and disseminated or CNS cryptococcal or <a href="./{1B76FB97-4740-4B09-BCD6-96F9FF75D841}.html" data-toggle="tooltip" title="Toxoplasmosis" data-id="50069b3e-0b43-420e-b2ef-a26fe3e8bf28" data-itemid="1b76fb97-4740-4b09-bcd6-96f9ff75d841"><i>Toxoplasma gondii </i>infection</a><span id="50069b3e-0b43-420e-b2ef-a26fe3e8bf28" class="d-none xref"> <span class="tooltip-container"> <a href="./{1B76FB97-4740-4B09-BCD6-96F9FF75D841}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Toxoplasmosis </span> Toxoplasmosis is infection with <i>Toxoplasma gondii</i>. Symptoms range from none to benign lymphadenopathy, a mononucleosis-like illness, to life-threatening central nervous system (CNS) disease... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/c/0/2/c0271978-retinitis-toxoplasmosis-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Toxoplasmosis" loading="lazy"> </span> </a> </span> </span>.</p></div><span id="v1107644" class="anchor"></span><div class="para"> <p>Cancers in immunocompromised children with HIV infection are relatively uncommon, but leiomyosarcomas and certain lymphomas, including CNS lymphomas and non-Hodgkin B-cell lymphomas (Burkitt type), occur much more often than in immunocompetent children. Kaposi sarcoma is very rare in children with HIV infection. (See <a href="./{839FFABF-D3AE-4FF1-A927-D818CD6E8279}.html" data-toggle="tooltip" title="Cancers Common in Patients with HIV Infection" data-id="650710cc-a778-4b7b-96dd-853649a05647" data-itemid="839ffabf-d3ae-4ff1-a927-d818cd6e8279">Cancers Common Among Patients with HIV Infection</a><span id="650710cc-a778-4b7b-96dd-853649a05647" class="d-none xref"> <span class="tooltip-container"> <a href="./{839FFABF-D3AE-4FF1-A927-D818CD6E8279}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Cancers Common in Patients with HIV Infection </span> AIDS-defining cancers in patients infected with HIV are Kaposi sarcoma Lymphoma, Burkitt (or equivalent term) Lymphoma, immunoblastic (or equivalent term) Lymphoma, primary, of central nervous system <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>.)</p></div> </div> </section> </div> </section> <section id="v1107648" class="topic__section FHead"> <h2 id="Diagnosis_v1107649" class="topic__header--section" data-originaltitle="Diagnosis"> <span id="v1107649" class="anchor"></span> Diagnosis of HIV Infection in Infants and Children </h2> <div class="topic__content"> <div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v1107654" class="anchor"></span><div class="para"> <p>Serum antibody tests</p></div></li><li class="topic__listitem"><span id="v1107656" class="anchor"></span><div class="para"> <p>Virologic nucleic acid tests (includes HIV RNA/DNA or HIV RNA assays)</p></div></li></ul></div> <section id="v1107657" class="topic__section GHead"> <span></span> <h3 id="Diagnosis_v1107649_v1107658" class="topic__header--subsection"> <span id="v1107658" class="anchor"></span> HIV-specific tests </h3> <div class="topic__content"> <span id="v1107660" class="anchor"></span><div class="para"> <p><b>Children <span class='symbol'>&lt</span> 18 months</b> retain maternal antibody, causing false-positive results even with the 4th-generation HIV-1/2 antigen/antibody combination immunoassay. Therefore, in these children, the diagnosis must be made by <i>HIV virologic assays, or nucleic acid tests (NATs)</i> as they are known collectively, such as <i>qualitative RNA or RNA/DNA assays</i>. Newer real-time RNA or RNA/DNA assays can be used to diagnose about 30 to 50% of cases at birth and nearly 100% of cases by 4 to 6 months of age, including children with non-subtype B and group O strains of HIV more commonly found outside of the United States. HIV viral culture has acceptable sensitivity and specificity but has been replaced by NATs because it is technically more demanding and hazardous. (See also ClinicalInfo.HIV.gov's <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/diagnosis-hiv-infection-infants-and-children?view=full">Diagnosis of HIV Infection in Infants and Children</a>.)</p></div><span id="v1107659" class="anchor"></span><div class="para"> <p>In <b>children <span class='symbol'>></span> 18 months,</b> the diagnosis of HIV infection is made using a series of tests: a serum <i>4th-generation HIV-1/2 antigen/antibody combination immunoassay</i>, followed by a <i>2nd-generation HIV-1/2 antibody differentiation assay</i>, and, if required, an <i>HIV-1 qualitative RNA assay</i>. This diagnostic testing algorithm has supplanted the previous sequential testing by serum immunoassay and Western blot confirmation. Only very rarely does an older child with HIV infection lack HIV antibody because of significant hypogammaglobulinemia.</p></div><span id="v1107662" class="anchor"></span><div class="para"> <p>The <i>quantitative HIV RNA assay</i> is most commonly used to determine HIV plasma viral load for monitoring efficacy of treatment. It may also be used for infant diagnostic testing; however, care must be taken because test specificity is uncertain at very low RNA concentrations (<span class='symbol'>&lt</span> 5000 copies/mL) and sensitivity is unknown in infants of mothers with complete treatment-mediated viral suppression at the time of delivery.</p></div><span id="v1107665" class="anchor"></span><div class="para"> <p><b>Rapid point-of-care tests</b> may be done using <i>rapid immunoassay tests for HIV antibody</i> because these tests may provide results in minutes to hours using oral secretions, whole blood, or serum. In the United States, these tests are most useful in labor and delivery units to test women of unknown HIV serostatus, thus allowing perinatal counseling, commencement of ART to prevent MTCT, and testing of the infant by virologic NATs to be arranged during the birth visit. These tests provide similar advantages in other episodic care settings (eg, emergency departments, adolescent medicine clinics, sexually transmitted infection clinics) and in medically underserved areas of the world. </p></div><span id="v77995661" class="anchor"></span><div class="para"> <p>However, rapid assays typically require confirmatory tests, such as a second antigen/antibody assay, an HIV-1/2 antibody differentiation assay, or a NAT. These confirmatory tests are especially important because in areas where the expected HIV prevalence is low, even a specific rapid assay yields mostly false-positive results (low positive predictive value by <a href="./{FFD8C031-7081-4310-8529-525752F52179}.html#v1124370" data-toggle="tooltip" title="Bayes Theorem" data-id="2b9a9e2a-b5c3-462b-8423-cc94200910d0" data-itemid="ffd8c031-7081-4310-8529-525752f52179">Bayes theorem</a><span id="2b9a9e2a-b5c3-462b-8423-cc94200910d0" class="d-none xref"> <span class="tooltip-container"> <a href="./{FFD8C031-7081-4310-8529-525752F52179}.html#v1124370"> <span class="tooltip-content"> <span class="tooltip-heading"> Bayes Theorem </span> Test results may help make a diagnosis in symptomatic patients (diagnostic testing) or identify occult disease in asymptomatic patients (screening). If the tests were appropriately ordered on... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>). The higher the pre-test probability of HIV (ie, seroprevalence), the higher the positive predictive value of the test. </p></div><span id="v77995663" class="anchor"></span><div class="para"> <p>As more laboratories are able to do same-day testing using 4th-generation HIV-1/2 antigen/antibody combination immunoassays, there will be less need for the comparatively less sensitive and less specific rapid immunoassays. Again, neither rapid immunoassays nor 4th generation HIV1/2 antigen/antibody assays are sensitive enough for HIV diagnosis in a child < 18 months of age.</p></div><span id="v1107668" class="anchor"></span><div class="para"> <p><b>Pre-test counseling</b> before HIV testing of a child involves discussing the possible psychosocial risks and benefits of testing with the mother or primary caregiver (and the child, if old enough). Most US jurisdictions (and CDC recommendations) now follow an opt-out, oral discussion rather than requiring formal oral (or written) consent. Providers should act in accordance with their state, local, and hospital laws and regulations. Counseling and consent requirements should not deter testing if it is medically indicated; refusal of a patient or guardian to give consent does not relieve providers of their professional and legal responsibilities, and sometimes authorization for testing must be obtained by other means (eg, court order). </p></div><span id="v77995664" class="anchor"></span><div class="para"> <p>Test results should be discussed in person with the family, the primary caregiver, and, if old enough, the child. If the child is HIV-positive, appropriate counseling and subsequent follow-up care must be provided. In all cases, maintaining confidentiality is essential.</p></div><span id="v1107669" class="anchor"></span><div class="para"> <p>Children and adolescents with HIV infection or AIDS must be reported to the appropriate public health department in accordance with state, local, and hospital laws. </p></div><span id="v37571282" class="anchor"></span><div class="para"> <p>(For questions regarding neonatal diagnosis, clinicians can call the Perinatal HIV Consultation and Referral Services Hotline: 1-888-HIV-8765 [1-888-448-8765].)</p></div> </div> </section> <section id="v49373314" class="topic__section GHead"> <span></span> <h3 id="Diagnosis_v1107649_v49373315" class="topic__header--subsection"> <span id="v49373315" class="anchor"></span> HIV testing schedules for pregnant women and newborns </h3> <div class="topic__content"> <span id="v49373316" class="anchor"></span><div class="para"> <p>(See also the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV's <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new-guidelines">Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States</a> and <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/maternal-hiv-testing-and-identification-perinatal-hiv-exposure?view=full">Maternal HIV Testing and Identification of Perinatal HIV Exposure</a> and the U.S. Preventive Services Task Force's <a rel="nofollow" target="_blank" href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/human-immunodeficiency-virus-hiv-infection-screening">2019 Human Immunodeficiency Virus (HIV) Infection: Screening</a> recommendation statement.)</p></div><span id="v77995667" class="anchor"></span><div class="para"> <p><b>HIV infection testing for all pregnant women</b> should be done before pregnancy or early in pregnancy so that combination antiretroviral (ARV) medications may be given for their own health and to prevent MTCT. Current recommendations suggest repeat testing in the third trimester to detect newly acquired HIV infection—the treatment of which even late in pregnancy will still improve the woman's health and help lessen MTCT (<a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v77995675" data-toggle="tooltip" title="Diagnosis reference" data-id="26c73276-fd3e-44ba-a28d-7ebac894ec4c" data-itemid="6ea530b9-c85e-4653-b466-245f2a0e10ea">1</a><span id="26c73276-fd3e-44ba-a28d-7ebac894ec4c" class="d-none xref"> <span class="tooltip-container"> <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v77995675"> <span class="tooltip-content"> <span class="tooltip-heading"> Diagnosis reference </span> Human immunodeficiency virus (HIV) infection is caused by the retrovirus HIV-1 (and less commonly by the related retrovirus HIV-2). Infection leads to progressive immunologic deterioration and... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/4/1/5/415-candidiasis-tongue-slide-25-springer-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Diagnosis reference" loading="lazy"> </span> </a> </span> </span>).</p></div><span id="v49373319" class="anchor"></span><div class="para"> <p><b>HIV infection testing for newborns</b> is done on varying schedules, depending on whether an infant perinatally exposed to HIV by a mother living with HIV infection is considered at low or higher risk of transmission; higher-risk infants are tested more frequently.</p></div><span id="v49373320" class="anchor"></span><div class="para"> <p>Low risk of perinatal HIV transmission is defined by the following:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v49373323" class="anchor"></span><div class="para"> <p>The mother received antiretroviral therapy (ART) during pregnancy.</p></div></li><li class="topic__listitem"><span id="v49373325" class="anchor"></span><div class="para"> <p>The mother had sustained virologic suppression as shown by plasma HIV viral RNA of < 50 copies/mL near delivery.</p></div></li><li class="topic__listitem"><span id="v49373327" class="anchor"></span><div class="para"> <p>There were no concerns about the mother's adherence to ART.</p></div></li></ul></div><span id="v49373328" class="anchor"></span><div class="para"> <p><b>Testing of infants at low risk</b> is recommended at the following ages:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v49373331" class="anchor"></span><div class="para"> <p>14 to 21 days</p></div></li><li class="topic__listitem"><span id="v49373333" class="anchor"></span><div class="para"> <p>1 to 2 months (at least 2 weeks after cessation of <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v1108219" data-toggle="tooltip" title="Prevention" data-id="0d3b8f6e-83d1-499f-8c8d-c352e9c6c917" data-itemid="6ea530b9-c85e-4653-b466-245f2a0e10ea">ARV prophylaxis</a><span id="0d3b8f6e-83d1-499f-8c8d-c352e9c6c917" class="d-none xref"> <span class="tooltip-container"> <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v1108219"> <span class="tooltip-content"> <span class="tooltip-heading"> Prevention </span> Human immunodeficiency virus (HIV) infection is caused by the retrovirus HIV-1 (and less commonly by the related retrovirus HIV-2). Infection leads to progressive immunologic deterioration and... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/4/1/5/415-candidiasis-tongue-slide-25-springer-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Prevention" loading="lazy"> </span> </a> </span> </span>)</p></div></li><li class="topic__listitem"><span id="v49373336" class="anchor"></span><div class="para"> <p>4 to 6 months</p></div></li></ul></div><span id="v49373337" class="anchor"></span><div class="para"> <p>Higher risk of perinatal HIV transmission is defined as a mother living with HIV infection who has one or more of the following factors:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v49373340" class="anchor"></span><div class="para"> <p>Did not receive prenatal care</p></div></li><li class="topic__listitem"><span id="v49373342" class="anchor"></span><div class="para"> <p>Did not receive ART during pregnancy, or received only intrapartum ART</p></div></li><li class="topic__listitem"><span id="v49373348" class="anchor"></span><div class="para"> <p>Initiated ART late in pregnancy (during the late second or third trimester)</p></div></li><li class="topic__listitem"><span id="v49373350" class="anchor"></span><div class="para"> <p>Diagnosed with acute HIV infection during pregnancy</p></div></li><li class="topic__listitem"><span id="v49373352" class="anchor"></span><div class="para"> <p>Had an unknown or a detectable (≥ 50 copies/mL) HIV plasma viral load near delivery (particularly when delivery was vaginal)</p></div></li><li class="topic__listitem"><span id="v49373354" class="anchor"></span><div class="para"> <p>Had acute or primary HIV infection during pregnancy or is breastfeeding (in which case breastfeeding should be stopped)</p></div></li></ul></div><span id="v49373355" class="anchor"></span><div class="para"> <p><b>Testing of infants at higher risk</b> is recommended at the following ages:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v49373358" class="anchor"></span><div class="para"> <p>Birth (blood sample should be from newborn, not from umbilical cord blood)</p></div></li><li class="topic__listitem"><span id="v49373360" class="anchor"></span><div class="para"> <p>14 to 21 days </p></div></li><li class="topic__listitem"><span id="v49373362" class="anchor"></span><div class="para"> <p>1 to 2 months</p></div></li><li class="topic__listitem"><span id="v49373364" class="anchor"></span><div class="para"> <p>2 to 3 months (2 to 6 weeks after cessation of <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v1108219" data-toggle="tooltip" title="Prevention" data-id="9acb5a27-beea-446b-9cf7-4e3c32d53293" data-itemid="6ea530b9-c85e-4653-b466-245f2a0e10ea">ARV prophylaxis</a><span id="9acb5a27-beea-446b-9cf7-4e3c32d53293" class="d-none xref"> <span class="tooltip-container"> <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v1108219"> <span class="tooltip-content"> <span class="tooltip-heading"> Prevention </span> Human immunodeficiency virus (HIV) infection is caused by the retrovirus HIV-1 (and less commonly by the related retrovirus HIV-2). Infection leads to progressive immunologic deterioration and... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/4/1/5/415-candidiasis-tongue-slide-25-springer-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Prevention" loading="lazy"> </span> </a> </span> </span>)</p></div></li><li class="topic__listitem"><span id="v49373367" class="anchor"></span><div class="para"> <p>4 to 6 months</p></div></li></ul></div><span id="v49373368" class="anchor"></span><div class="para"> <p>A positive test should be confirmed immediately using the same or another virologic test; two positive tests confirm HIV infection.</p></div><span id="v49373369" class="anchor"></span><div class="para"> <p>If the serial HIV virologic tests are negative at ≥ 2 weeks and at ≥ 4 weeks and in the absence of any AIDS-defining illness, the infant is considered presumptively uninfected (ie, with <span class='symbol'>></span> 95% accuracy). If HIV virologic tests are also negative at ≥ 4 weeks and at ≥ 4 months, and again in the absence of any AIDS-defining illness, the infant is considered definitively uninfected.</p></div><span id="v77995669" class="anchor"></span><div class="para"> <p>Some experts continue to recommend follow-up antibody tests (1 antigen/antibody combination assay at <span class='symbol'>></span> 18 months or, alternatively, 2 such assays done between 6 months and 18 months) to definitively exclude HIV infection and confirm seroreversion (loss of passively acquired HIV antibodies), especially if the infant was not in the low-risk category or was suspected to have exposure after birth (eg, from breast milk, percutaneous exposure, or sexual abuse). Seroreversion occurs at a median of 14 months of age; late seroreversion occasionally occurs up to 18 to 24 months of age, complicating the interpretation of antibodies in perinatally exposed infants. Expert consultation should be sought, and repeated testing (along with virologic NATs) is indicated for the perinatally exposed toddler with positive antibodies. </p></div><span id="v77995670" class="anchor"></span><div class="para"> <p>If an infant <span class='symbol'>&lt</span> 18 months with a positive antibody test but negative virologic tests develops an AIDS-defining illness (see ClinicalInfo.HIV.gov's <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/appendix-c-cdc-pediatric-hiv-cd4-cell?view=full">Appendix C: CDC Pediatric HIV CD4 Cell Count/Percentage and HIV-Related Diseases Categorization</a> table), HIV infection is diagnosed.</p></div> </div> </section> <section id="v1107670" class="topic__section GHead"> <span></span> <h3 id="Diagnosis_v1107649_v1107671" class="topic__header--subsection"> <span id="v1107671" class="anchor"></span> Additional tests after HIV diagnosis </h3> <div class="topic__content"> <span id="v1107672" class="anchor"></span><div class="para"> <p>Once infection is diagnosed, other tests are done:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v1107675" class="anchor"></span><div class="para"> <p>CD4+ T-cell count</p></div></li><li class="topic__listitem"><span id="v1107677" class="anchor"></span><div class="para"> <p>CD8+ T-cell count</p></div></li><li class="topic__listitem"><span id="v1107679" class="anchor"></span><div class="para"> <p>Plasma viral RNA concentration</p></div></li></ul></div><span id="v1107680" class="anchor"></span><div class="para"> <p>Infected children require measurement of CD4+ and CD8+ T-cell counts and plasma viral RNA concentration (viral load) to help determine their degree of illness, prognosis, and the effects of therapy. CD4+ counts may be normal (eg, above the age-specific cutoffs of category 1 in table <span class="multimedia__link mlinkBlock" data-bind="component: { name: 'm-link-text', params: $data }" data-popup-model='{"ItemId":"f95c6fa0-ba2c-48ca-b6fa-5e798b80914f","Title":"Immunologic%20Categories%20%28HIV%20Infection%20Stages%29%20for%20Children%20%2013%20Years%20With%20HIV%20Infection%20Based%20on%20Age-Specific%20CD4%2B%20T-Cell%20Count%20or%20Percentage","ShareUrlTitle":"immunologic-categories-hiv-infection-stages-for-children-span-classsymbol-span-13-years-with-hiv-infection-based-on-age-specific-cd4-t-cell-count-or-percentage","Description":"","ImageUrl":null,"ThumbnailUrl":"/Content/Images/Redesign/table/icon_table_red.png","MediaType":"table","MediaNameTranslated":"Table","UniqueId":"v49373218","Placement":null,"IsInCarousel":false,"Edition":0,"ImageWidth":null,"ImageHeight":null,"IframeSrc":null,"Target":null,"Alt":null}' data-popup-options='{"ListName":"TopicMultimedia","LinkText":"%3Cspan%20%3EImmunologic%20Categories%20%28HIV%20Infection%20Stages%29%20for%20Children%20%3C%2013%20Years%20With%20HIV%20Infection%20Based%20on%20Age-Specific%20CD4%2B%20T-Cell%20Count%20or%20Percentage%3C%2Fspan%3E","CssClass":null,"LoadLocations":true,"ShowTooltip":true,"SingleItem":true,"ExcludeFromBrand":"","ShowCredits":true,"ShowDescription":true,"PopupTitle":"Table","ShowTitle":true,"ShowIcon":false,"ShowModalIndicator":false,"ShowTitleInHeader":false,"HideCarousel":false,"Target":"modal","Url":null,"HideMainArrows":false}'></span>) initially but fall eventually. CD8+ counts usually increase initially and do not fall until late in the infection. These changes in cell populations result in a decrease in the CD4+:CD8+ cell ratio, a characteristic of HIV infection (although sometimes occurring in other infections). Plasma viral RNA concentrations in untreated children <span class='symbol'>&lt</span> 12 months are typically very high (mean of about 200,000 RNA copies/mL). By 24 months, viral concentrations in untreated children decrease (to a mean of about 40,000 RNA copies/mL). </p></div><span id="v77995673" class="anchor"></span><div class="para"> <p>Although the wide range of HIV RNA concentrations in children make the data less predictive of morbidity and mortality than in adults, determining plasma viral concentrations in conjunction with CD4+ counts still yields more accurate prognostic information than does determining either marker alone. Less expensive alternative surrogate markers such as total lymphocyte counts and serum <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>albumin</span> levels may also predict AIDS mortality in children, which may be useful in areas where more sophisticated testing is not available.</p></div><span id="v1107684" class="anchor"></span><div class="para"> <p>Although not routinely measured, serum immunoglobulin concentrations, particularly IgG and IgA, often are markedly elevated, but occasionally some children develop panhypogammaglobulinemia. Patients may be anergic to skin test antigens.</p></div> </div> </section> <section id="v77995674" class="topic__section GHead"> <span></span> <h3 id="Diagnosis_v1107649_v77995675" class="topic__header--subsection"> <span id="v77995675" class="anchor"></span> Diagnosis reference </h3> <div class="topic__content"> <div class="list"> <ul data-mmanualobjecttype="List" class="nobulleted"><li class="topic__listitem"><span id="v77995678" class="anchor"></span><div class="para"> <p>1. <a rel="nofollow" target="_blank" href="https://pubmed.ncbi.nlm.nih.gov/30575656/">Pollock L, Cohan D, Pecci CC, Mittal P</a>: ACOG Committee opinion no. 752: Prenatal and perinatal human immunodeficiency virus testing. <i>Obstet Gynecol</i> 133(1):187, 2019. doi: 10.1097/AOG.0000000000003048</p></div></li></ul></div> </div> </section> </div> </section> <section id="v1107694" class="topic__section FHead" itemprop="possibleTreatment" itemscope="" itemtype="http://schema.org/MedicalTherapy"> <h2 id="Treatment_v1107695" class="topic__header--section" data-originaltitle="Treatment"> <span id="v1107695" class="anchor"></span> Treatment of HIV Infection in Infants and Children </h2> <div class="topic__content"> <div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v1107701" class="anchor"></span><div class="para"> <p>Combinations of antiretroviral (ARV) medications (antiretroviral therapy [ART])</p></div></li><li class="topic__listitem"><span id="v1107703" class="anchor"></span><div class="para"> <p>Supportive care</p></div></li></ul></div><span id="v77995680" class="anchor"></span><div class="para"> <p>Combination ART is individualized to the child but most commonly includes 3 medications:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v77995683" class="anchor"></span><div class="para"> <p>Two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) <i>plus</i></p></div></li><li class="topic__listitem"><span id="v77995685" class="anchor"></span><div class="para"> <p>One integrase strand transfer inhibitor (INSTI) <i>or</i> one protease inhibitor</p></div></li></ul></div><span id="v77995686" class="anchor"></span><div class="para"> <p>Sometimes a non-nucleoside reverse transcriptase inhibitor (NNRTI) is given with 2 NRTIs.</p></div><span id="v1107704" class="anchor"></span><div class="para"> <p>Because of the success of combination ART, much of the current focus is on the management of HIV infection as a chronic disease, addressing both medical and social issues. Important long-term medical issues include the need to manage HIV-related and drug-related metabolic complications and to account for age-related changes in drug pharmacokinetics and pharmacodynamics. Social issues include the need to cope with peer pressure, ensure school success and appropriate career choice, and educate children about transmission risk. Adolescents often have difficulty seeking and following health care advice and need particular help with treatment adherence. </p></div><span id="v77995687" class="anchor"></span><div class="para"> <p>Challenges for infants and younger children include lack of pediatric pharmacokinetic data for newer compounds, palatability and tolerability of liquid formulations, and lack of fixed-dosed combination tablets. </p></div><span id="v77995688" class="anchor"></span><div class="para"> <p>Children and adolescents should be managed in collaboration with experts who have experience in the management of pediatric HIV infection.</p></div> <section id="v37571283" class="topic__section GHead"> <span></span> <h3 id="Treatment_v1107695_v37571284" class="topic__header--subsection"> <span id="v37571284" class="anchor"></span> Indications for ART in children </h3> <div class="topic__content"> <span id="v37571285" class="anchor"></span><div class="para"> <p>(For a discussion of some ARV medications and dosages, see <a href="./{74B30271-8B50-4566-A065-33B80B68A8EF}.html" data-toggle="tooltip" title="Antiretroviral Therapy in Children" data-id="4a58ca3e-a8dd-441f-b280-a1ad51d725e5" data-itemid="74b30271-8b50-4566-a065-33b80b68a8ef">Antiretroviral Therapy in Children</a><span id="4a58ca3e-a8dd-441f-b280-a1ad51d725e5" class="d-none xref"> <span class="tooltip-container"> <a href="./{74B30271-8B50-4566-A065-33B80B68A8EF}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Antiretroviral Therapy in Children </span> There are > 40 antiretroviral (ARV) medications, including multidrug combination products, available in the United States, each of which may have adverse effects and drug interactions with... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span> and see the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV's <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines">Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection</a> and see <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/overview-0?view=full">Appendix A: Pediatric Antiretroviral Drug Information</a>.)</p></div><span id="v37571287" class="anchor"></span><div class="para"> <p>Initiation of ART for children is similar to that in adults; essentially, all children with HIV infection should be given ART as soon as possible (rapid initiation, within 1 to 2 weeks of diagnosis). There is both strong consensus and clinical trial evidence for early initiation of ART in infants with HIV infection. </p></div><span id="v77995691" class="anchor"></span><div class="para"> <p>The goal of therapy at all ages is similar to that in adults:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v77995694" class="anchor"></span><div class="para"> <p>Suppress HIV replication (as measured by HIV plasma viral load).</p></div></li><li class="topic__listitem"><span id="v77995696" class="anchor"></span><div class="para"> <p>Maintain or achieve age-normal CD4+ counts and percentages with the least amount of drug toxicity.</p></div></li></ul></div><span id="v77995697" class="anchor"></span><div class="para"> <p>Before making the decision to initiate therapy, the practitioner should fully assess the readiness of the caregiver and child to adhere with ARV medication administration and discuss the potential benefits and risks of therapy. Because expert opinions on therapeutic strategies change rapidly, consultation with experts is strongly advised.</p></div> </div> </section> <section id="v1108081" class="topic__section GHead"> <span></span> <h3 id="Treatment_v1107695_v1108082" class="topic__header--subsection"> <span id="v1108082" class="anchor"></span> Adherence to ART </h3> <div class="topic__content"> <span id="v1108083" class="anchor"></span><div class="para"> <p>ART is successful only if the family and child are able to adhere to a possibly complex medical regimen. Nonadherence not only leads to failure to control HIV but also selects drug-resistant HIV strains, which reduces future therapeutic choices. </p></div><span id="v77995698" class="anchor"></span><div class="para"> <p>Barriers to adherence should be addressed before starting treatment. Barriers include availability and palatability of pills or suspensions, adverse effects (including those due to drug interactions with current therapy), pharmacokinetic factors such as the need to take some medications with food or in a fasted state, and a child’s dependence on others to give medications (and parents with HIV infection may have problems with remembering to take their own medications). Newer once- or twice-daily combination regimens and more palatable pediatric formulations help improve adherence, and the growing availability of once-daily fixed-dose combination tablets for older children and adults has helped many youth living with HIV infection.</p></div><span id="v9141092" class="anchor"></span><div class="para"> <p>Adherence may be especially problematic in adolescents regardless of whether they have been infected perinatally or have acquired HIV infection later on through sexual activity or injection drug use. Adolescents have complex biopsychosocial issues, such as low self-esteem, chaotic and unstructured lifestyles, fear of being singled out because of illness, and sometimes a lack of family support, all of which may reduce ART adherence. In addition, adolescents may not be developmentally able to understand why ARV medications are necessary during periods of asymptomatic infection and they may worry greatly about adverse effects. </p></div><span id="v77995699" class="anchor"></span><div class="para"> <p>Despite frequent contact with the medical system, perinatally infected adolescents may fear or deny their HIV infection, distrust information provided by the health care team, and poorly make the transition to the adult health care system (see <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v9141115" data-toggle="tooltip" title="Transition to Adult Care" data-id="f7f3d72f-eafe-45c2-abb4-5775253da660" data-itemid="6ea530b9-c85e-4653-b466-245f2a0e10ea">Transition to Adult Care</a><span id="f7f3d72f-eafe-45c2-abb4-5775253da660" class="d-none xref"> <span class="tooltip-container"> <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v9141115"> <span class="tooltip-content"> <span class="tooltip-heading"> Transition to Adult Care </span> Human immunodeficiency virus (HIV) infection is caused by the retrovirus HIV-1 (and less commonly by the related retrovirus HIV-2). Infection leads to progressive immunologic deterioration and... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/4/1/5/415-candidiasis-tongue-slide-25-springer-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Transition to Adult Care" loading="lazy"> </span> </a> </span> </span>). Treatment regimens for adolescents must be made in consideration of these issues. Although the goal is to have the adolescent adhere to a maximally potent regimen of ARV medications, a realistic assessment of the adolescent's maturity and support systems may suggest that the treatment plan begin by focusing on avoidance of opportunistic illness and providing information about reproductive health services, housing, and how to succeed in school. Once care team members are confident the adolescent is receiving proper support, they can decide exactly which ARV medications are best.</p></div> </div> </section> <section id="v1108084" class="topic__section GHead"> <span></span> <h3 id="Treatment_v1107695_v1108085" class="topic__header--subsection"> <span id="v1108085" class="anchor"></span> Monitoring </h3> <div class="topic__content"> <span id="v1108086" class="anchor"></span><div class="para"> <p>Clinical and laboratory monitoring are important for identifying drug toxicity and therapeutic failure.</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v1108089" class="anchor"></span><div class="para"> <p>At entry into care and at initiation of ART (and if changing ART regimen): Physical examination, adherence evaluation, complete blood count, serum chemistry values including electrolytes, liver and kidney tests, HIV plasma viral load, CD4+ lymphocyte counts, and, for adolescent girls, a pregnancy test</p></div></li><li class="topic__listitem"><span id="v37571373" class="anchor"></span><div class="para"> <p>Every 3 to 4 months: Physical examination, adherence evaluation, complete blood count, serum chemistry values, including electrolytes, liver and kidney tests, HIV plasma viral load, and CD4+ lymphocyte counts</p></div></li><li class="topic__listitem"><span id="v1108091" class="anchor"></span><div class="para"> <p>Every 6 to 12 months: Lipid profiles and urinalysis; complete blood count and serum chemistry values including electrolytes, and liver and kidney tests if not done already in those with a stable clinical status; adherence evaluation</p></div></li></ul></div><span id="v37571374" class="anchor"></span><div class="para"> <p>HIV genotypic resistance testing should be done at entry into care and upon ART changes due to presumed virologic failure. </p></div><span id="v37571375" class="anchor"></span><div class="para"> <p>If <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>abacavir</span> is to be given, HLA-B*5701 status must be tested; <span class="genericDrug" data-showrollover="false">abacavir</span> should be given only to patients who are HLA-B*5701–negative. This testing is most often done at entry into care so that safety of possible future use of <span class="genericDrug" data-showrollover="false">abacavir</span> is known.</p></div><span id="v9141094" class="anchor"></span><div class="para"> <p>If children have a stable treatment status, ie, nondetectable HIV RNA and normal age-adjusted CD4+ lymphocyte counts without clinical signs of toxicity for at least 12 months, and a stable family support system, many clinicians will extend the interval of laboratory evaluations to every 6 to 12 months. However, clinical care visits every 3 months with measurement of HIV plasma viral load are valuable because clinicians have the opportunity to review adherence, monitor growth and clinical symptoms, and update weight-based dosing of ARV medications as needed.</p></div> </div> </section> <section id="v77995703" class="topic__section GHead"> <span itemscope="" itemtype="http://schema.org/MedicalTherapy"></span> <h3 id="Treatment_v1107695_v77995704" class="topic__header--subsection"> <span itemprop="name" id="v77995704" class="anchor"></span> Prevention of opportunistic infections </h3> <div class="topic__content"> <span id="v77995705" class="anchor"></span><div class="para"> <p>Prophylactic treatment is recommended in certain children with HIV infection for prevention of <a href="./{158ED3D8-7B77-490A-98EE-E29670D7E361}.html" data-toggle="tooltip" title="Pneumocystis jirovecii Pneumonia" data-id="8ac37720-179d-4669-a2a7-a8791a13d55f" data-itemid="158ed3d8-7b77-490a-98ee-e29670d7e361"><i>Pneumocystis</i> pneumonia</a><span id="8ac37720-179d-4669-a2a7-a8791a13d55f" class="d-none xref"> <span class="tooltip-container"> <a href="./{158ED3D8-7B77-490A-98EE-E29670D7E361}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> <i>Pneumocystis jirovecii</i> Pneumonia </span> <i>Pneumocystis jirovecii</i>, an atypical fungus, is a common cause of pneumonia in immunosuppressed patients, especially in those infected with human immunodeficiency virus (HIV) and in those... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="/-/media/manual/professional/images/p/n/e/pneumocystis_pneumonia_high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="<i>Pneumocystis jirovecii</i> Pneumonia" loading="lazy"> </span> </a> </span> </span> and <i>M. avium</i> complex infections. Data are limited on the use of prophylaxis for opportunistic infection by other organisms, such as cytomegalovirus, fungi, and <i>Toxoplasma</i>. Guidance on prophylaxis of these and other opportunistic infections is also available at <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new-guidelines?view=full">ClinicalInfo.HIV.gov</a>.</p></div><span id="v77995709" class="anchor"></span><div class="para"> <p><b>Prophylaxis against <i>Pneumocystis</i> pneumonia</b> is indicated for</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v77995712" class="anchor"></span><div class="para"> <p>Children with HIV infection who are <span class='symbol'>≥</span> 6 years of age with CD4+ count <span class='symbol'>&lt</span> 200 cells/mcL or CD4+ percentage <span class='symbol'>&lt</span> 14%</p></div></li><li class="topic__listitem"><span id="v77995714" class="anchor"></span><div class="para"> <p>Children with HIV infection who are 1 to < 6 years of age with CD4+ count <span class='symbol'>&lt</span> 500 cells/mcL or CD4+ percentage <span class='symbol'>&lt</span> 22%</p></div></li><li class="topic__listitem"><span id="v77995716" class="anchor"></span><div class="para"> <p>Infants with HIV infection who are <span class='symbol'>&lt</span> 12 months of age regardless of CD4+ count or percentage</p></div></li><li class="topic__listitem"><span id="v77995718" class="anchor"></span><div class="para"> <p>Infants born to women with HIV infection (beginning at 4 to 6 weeks of age) until HIV infection is either presumptively excluded by documentation of 2 negative virologic test results (1 at <span class='symbol'>≥</span> 2 weeks of age and 1 at <span class='symbol'>≥</span> 4 weeks of age) or definitively excluded by documentation of 2 negative virologic test results (1 at <span class='symbol'>≥</span> 1 month of age and 1 at <span class='symbol'>≥</span> 4 months of age) (NOTE: For these definitions of HIV exclusion to be valid, the infant must not be breastfeeding.)</p></div></li></ul></div><span id="v77995719" class="anchor"></span><div class="para"> <p>Once immune reconstitution with combination ART occurs, discontinuation of <i>Pneumocystis</i> pneumonia prophylaxis may be considered for children with HIV infection who have received combination ART for <span class='symbol'>></span> 6 months and whose CD4+ percentage and CD4+ count have remained higher than the previously described treatment thresholds for <span class='symbol'>></span> 3 consecutive months. Subsequently, the CD4+ percentage and count should be reevaluated at least every 3 months, and prophylaxis should be reinstituted if the original criteria are reached.</p></div><span id="v77995721" class="anchor"></span><div class="para"> <p>The medication of choice for <i>Pneumocystis</i> prophylaxis at any age is <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>trimethoprim</span>/sulfamethoxazole (TMP/SMX). The dosage is TMP 75 mg/SMX 375 mg/m<sup>2</sup> orally 2 times a day on 3 consecutive days/week (eg, Monday-Tuesday-Wednesday); alternative schedules include the same dose 2 times a day every day, the same dose 2 times a day on alternate days, or twice the dose (TMP 150 mg/SMX 750 mg/m<sup>2</sup>) once a day for 3 consecutive days/week. Some experts find it easier to use weight-based dosing (TMP 2.5 to 5 mg/SMX 12.5 to 25 mg/kg orally 2 times a day). </p></div><span id="v77995723" class="anchor"></span><div class="para"> <p>For patients who cannot tolerate TMP/SMX, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>dapsone</span> 2 mg/kg (not to exceed 100 mg) orally once a day is an alternative, especially for those <span class='symbol'>&lt</span> 5 years of age. Oral <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>atovaquone</span> given daily or aerosolized <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>pentamidine</span> (300 mg via specially designed inhaler for children ≥ 5 years) given once a month is an additional alternative. IV <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>pentamidine</span> has also been used but is less effective and more toxic.</p></div><span id="v77995724" class="anchor"></span><div class="para"> <p><b>Prophylaxis against <i>M. avium</i> complex</b> infection is indicated in</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v77995728" class="anchor"></span><div class="para"> <p>Children <span class='symbol'>≥</span> 6 years with CD4+ count <span class='symbol'>&lt</span> 50 cells/mcL</p></div></li><li class="topic__listitem"><span id="v77995730" class="anchor"></span><div class="para"> <p>Children 2 to 6 years with CD4+ count <span class='symbol'>&lt</span> 75 cells/mcL</p></div></li><li class="topic__listitem"><span id="v77995732" class="anchor"></span><div class="para"> <p>Children 1 to 2 years with CD4+ count <span class='symbol'>< </span>500 cells/mcL</p></div></li><li class="topic__listitem"><span id="v77995734" class="anchor"></span><div class="para"> <p>Children <span class='symbol'>&lt</span> 1 year with CD4+ count <span class='symbol'>&lt</span> 750 cells/mcL</p></div></li></ul></div><span id="v77995735" class="anchor"></span><div class="para"> <p>Weekly <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>azithromycin</span> or daily <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>clarithromycin</span> is the medication of choice, and daily <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifabutin</span> is an alternative.</p></div> </div> </section> <section id="v49373374" class="topic__section GHead"> <span></span> <h3 id="Treatment_v1107695_v49373375" class="topic__header--subsection"> <span id="v49373375" class="anchor"></span> Psychosocial approach to children with HIV infection </h3> <div class="topic__content"> <span id="v49373376" class="anchor"></span><div class="para"> <p>HIV infection in a child affects the entire family. Serologic testing of siblings and parents is recommended for those families with a child with perinatally acquired infection. This may not be necessary for those families without known HIV infection who adopt a child with HIV infection. The physician must provide education and ongoing counseling.</p></div><span id="v49373377" class="anchor"></span><div class="para"> <p>Children with HIV infection should be taught good hygiene and behavior to reduce risk to others. How much and when children are told about the illness depends on age and maturity. Older children and adolescents should be made aware of their diagnosis and the possibility of sexual transmission and should be counseled appropriately. Families may be unwilling to share the diagnosis with people outside the immediate family because it can create social isolation. Feelings of guilt are common. Family members, including children, can become clinically depressed and require counseling.</p></div><span id="v49373378" class="anchor"></span><div class="para"> <p>Because HIV infection is not acquired through the typical types of contact that occur among children (eg, through saliva or tears), children with HIV infection should be allowed to attend school without restrictions. Similarly, there are no inherent reasons to restrict foster care, adoptive placement, or child care of children with HIV infection. Conditions that may pose an increased risk to others (eg, aggressive biting or the presence of exudative, weeping skin lesions that cannot be covered) may require special precautions.</p></div><span id="v49373379" class="anchor"></span><div class="para"> <p>The number of school personnel aware of the child’s condition should be kept to the minimum needed to ensure proper care. The family has the right to inform the school, but people involved in the care and education of a child with HIV infection must respect the child’s right to privacy. Disclosures of information should be made only with the informed consent of the parents or legal guardians and age-appropriate assent of the child.</p></div> </div> </section> <section id="v1108092" class="topic__section GHead"> <span></span> <h3 id="Treatment_v1107695_v1108093" class="topic__header--subsection"> <span id="v1108093" class="anchor"></span> Routine vaccinations </h3> <div class="topic__content"> <span id="v1108096" class="anchor"></span><div class="para"> <p> <a href="./{4B587529-6EBC-4349-ABC8-3F78E4E81AE9}.html#v82347972" data-toggle="tooltip" title="Childhood Vaccination Schedules" data-id="31e58629-773c-44f1-a2a7-21e65b000448" data-itemid="4b587529-6ebc-4349-abc8-3f78e4e81ae9">Routine pediatric vaccination protocols</a><span id="31e58629-773c-44f1-a2a7-21e65b000448" class="d-none xref"> <span class="tooltip-container"> <a href="./{4B587529-6EBC-4349-ABC8-3F78E4E81AE9}.html#v82347972"> <span class="tooltip-content"> <span class="tooltip-heading"> Childhood Vaccination Schedules </span> Vaccination has been extremely effective in preventing serious disease and in improving health worldwide. Because of vaccines, infections that were once very common and/or fatal (eg, smallpox... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span> (including for <a href="./{15803A40-86F8-457C-9891-8DE8532EDB52}.html" data-toggle="tooltip" title="COVID-19 Vaccine" data-id="4885b50f-73e6-4707-9034-60e4a0286f3c" data-itemid="15803a40-86f8-457c-9891-8de8532edb52">COVID-19</a><span id="4885b50f-73e6-4707-9034-60e4a0286f3c" class="d-none xref"> <span class="tooltip-container"> <a href="./{15803A40-86F8-457C-9891-8DE8532EDB52}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> COVID-19 Vaccine </span> COVID-19 vaccines provide protection against COVID-19, the disease caused by infection with the SARS-CoV-2 virus. Vaccination is the most effective strategy to prevent severe illness and death... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>) are recommended for children with HIV infection, with several exceptions. </p></div><span id="v77995738" class="anchor"></span><div class="para"> <p>The main exception is that <b>live-virus vaccines and live-bacteria vaccines</b> (eg, bacille Calmette–Guérin [BCG]) should be avoided or used only in certain circumstances (see table <span class="multimedia__link mlinkBlock" data-bind="component: { name: 'm-link-text', params: $data }" data-popup-model='{"ItemId":"ca02e767-48b1-472f-9d0a-b7ed22899500","Title":"Considerations%20for%20Use%20of%20Live%20Vaccines%20in%20Children%20With%20HIV%20Infection","ShareUrlTitle":"considerations-for-use-of-live-vaccines-in-children-with-hiv-infection","Description":"","ImageUrl":null,"ThumbnailUrl":"/Content/Images/Redesign/table/icon_table_red.png","MediaType":"table","MediaNameTranslated":"Table","UniqueId":"v1108117","Placement":null,"IsInCarousel":false,"Edition":0,"ImageWidth":null,"ImageHeight":null,"IframeSrc":null,"Target":null,"Alt":null}' data-popup-options='{"ListName":"TopicMultimedia","LinkText":"%3Cspan%20%3EConsiderations%20for%20Use%20of%20Live%20Vaccines%20in%20Children%20With%20HIV%20Infection%3C%2Fspan%3E","CssClass":null,"LoadLocations":true,"ShowTooltip":true,"SingleItem":true,"ExcludeFromBrand":"","ShowCredits":true,"ShowDescription":true,"PopupTitle":"Table","ShowTitle":true,"ShowIcon":false,"ShowModalIndicator":false,"ShowTitleInHeader":false,"HideCarousel":false,"Target":"modal","Url":null,"HideMainArrows":false}'></span>). </p></div><span id="v1108099" class="anchor"></span><div class="para"> <p>Live oral poliovirus vaccine (which is not available in the United States but is still used in other parts of the world) and live-attenuated influenza vaccine are not recommended; however, inactivated polio vaccine should be given according to the routine schedule, and <a href="./{C3C97683-4BCF-46EE-9AAF-16CD253B0B2D}.html" data-toggle="tooltip" title="Influenza Vaccine" data-id="eb5b84b8-3c91-40a1-88ac-43f1fffbdf8d" data-itemid="c3c97683-4bcf-46ee-9aaf-16cd253b0b2d">inactivated influenza vaccination</a><span id="eb5b84b8-3c91-40a1-88ac-43f1fffbdf8d" class="d-none xref"> <span class="tooltip-container"> <a href="./{C3C97683-4BCF-46EE-9AAF-16CD253B0B2D}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Influenza Vaccine </span> Based on recommendations by the World Health Organization and the Centers for Disease Control and Prevention (CDC), vaccines for influenza are modified annually to include the most prevalent... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span> should be given yearly.</p></div><span id="v1108100" class="anchor"></span><div class="para"> <p>The live <a href="./{9B13E380-5C42-4321-9C85-6675F98829E3}.html" data-toggle="tooltip" title="Measles, Mumps, and Rubella (MMR) Vaccine" data-id="7b8b3736-9b7f-4f13-bde2-7639ddbb1295" data-itemid="9b13e380-5c42-4321-9c85-6675f98829e3">measles-mumps-rubella (MMR) vaccine</a><span id="7b8b3736-9b7f-4f13-bde2-7639ddbb1295" class="d-none xref"> <span class="tooltip-container"> <a href="./{9B13E380-5C42-4321-9C85-6675F98829E3}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Measles, Mumps, and Rubella (MMR) Vaccine </span> The measles/mumps/rubella vaccines (MMR vaccines) effectively protect against all 3 infections ( measles, mumps, rubella). Historically, people who are given the MMR vaccine according to the... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span> and <a href="./{41F4A30E-1F06-47DD-9164-627B28C74977}.html" data-toggle="tooltip" title="Varicella Vaccine" data-id="a8194703-9798-4c06-9622-13c44a990750" data-itemid="41f4a30e-1f06-47dd-9164-627b28c74977">varicella vaccine</a><span id="a8194703-9798-4c06-9622-13c44a990750" class="d-none xref"> <span class="tooltip-container"> <a href="./{41F4A30E-1F06-47DD-9164-627B28C74977}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Varicella Vaccine </span> Varicella vaccination provides effective protection against varicella (chickenpox). It is not known how long protection against varicella lasts. But, live-virus vaccines, like the varicella... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span> should not be given to children with manifestations of severe immunosuppression. However, the MMR and varicella-zoster virus (VZV) vaccines (separately; not combined as MMRV vaccine, which has a higher titer of attenuated varicella virus, the safety of which has not been shown in this population) <i>can</i> be given to asymptomatic patients following the routine schedule and to patients who have had HIV symptoms but who are not severely immunocompromised (ie, not in category 3 [see table <span class="multimedia__link mlinkBlock" data-bind="component: { name: 'm-link-text', params: $data }" data-popup-model='{"ItemId":"f95c6fa0-ba2c-48ca-b6fa-5e798b80914f","Title":"Immunologic%20Categories%20%28HIV%20Infection%20Stages%29%20for%20Children%20%2013%20Years%20With%20HIV%20Infection%20Based%20on%20Age-Specific%20CD4%2B%20T-Cell%20Count%20or%20Percentage","ShareUrlTitle":"immunologic-categories-hiv-infection-stages-for-children-span-classsymbol-span-13-years-with-hiv-infection-based-on-age-specific-cd4-t-cell-count-or-percentage","Description":"","ImageUrl":null,"ThumbnailUrl":"/Content/Images/Redesign/table/icon_table_red.png","MediaType":"table","MediaNameTranslated":"Table","UniqueId":"v49373218","Placement":null,"IsInCarousel":false,"Edition":0,"ImageWidth":null,"ImageHeight":null,"IframeSrc":null,"Target":null,"Alt":null}' data-popup-options='{"ListName":"TopicMultimedia","LinkText":"%3Cspan%20%3EImmunologic%20Categories%20%28HIV%20Infection%20Stages%29%20for%20Children%20%3C%2013%20Years%20With%20HIV%20Infection%20Based%20on%20Age-Specific%20CD4%2B%20T-Cell%20Count%20or%20Percentage%3C%2Fspan%3E","CssClass":null,"LoadLocations":true,"ShowTooltip":true,"SingleItem":true,"ExcludeFromBrand":"","ShowCredits":true,"ShowDescription":true,"PopupTitle":"Table","ShowTitle":true,"ShowIcon":false,"ShowModalIndicator":false,"ShowTitleInHeader":false,"HideCarousel":false,"Target":"modal","Url":null,"HideMainArrows":false}'></span>], including having a CD4+ T-cell percentage of <span class='symbol'>≥</span> 15%). If possible, the MMR and VZV vaccines should be given starting at age 12 months in symptomatic patients to enhance the likelihood of an immune response, ie, before the immune system deteriorates. The second dose of each may be given as soon as 4 weeks later in an attempt to induce seroconversion as early as possible, although typically a 3-month interval between varicella vaccine doses is preferred in noninfected children <span class='symbol'>&lt</span> 13 years. If the risk of exposure to measles is increased, such as during an outbreak, the measles vaccine should be given at an earlier age, such as 6 to 9 months.</p></div><span id="v1108104" class="anchor"></span><div class="para"> <p>The live oral <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rotavirus vaccine</span> may be given to infants who are exposed to HIV or who are infected with HIV according to the <a href="./{4B587529-6EBC-4349-ABC8-3F78E4E81AE9}.html#v82347972" data-toggle="tooltip" title="Childhood Vaccination Schedules" data-id="cbd11add-58fe-451b-b1bc-f8c1e527d05b" data-itemid="4b587529-6ebc-4349-abc8-3f78e4e81ae9">routine schedule</a><span id="cbd11add-58fe-451b-b1bc-f8c1e527d05b" class="d-none xref"> <span class="tooltip-container"> <a href="./{4B587529-6EBC-4349-ABC8-3F78E4E81AE9}.html#v82347972"> <span class="tooltip-content"> <span class="tooltip-heading"> Childhood Vaccination Schedules </span> Vaccination has been extremely effective in preventing serious disease and in improving health worldwide. Because of vaccines, infections that were once very common and/or fatal (eg, smallpox... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>. Safety and efficacy data are limited in symptomatic infants but there very likely is overall benefit to immunization, particularly in areas where rotavirus causes significant mortality.</p></div><span id="v1108105" class="anchor"></span><div class="para"> <p>The BCG vaccine is not recommended in the United States because it is an area of low tuberculosis (TB) prevalence. However, elsewhere in the world, especially in countries where TB prevalence is high, BCG is routinely used; many of these countries also have high HIV prevalence among childbearing women. BCG as a live bacterial vaccine has caused some harm in children with HIV infection but likely protects children who do not have HIV infection and even some children who do have HIV infection from acquiring TB. The World Health Organization (WHO) now recommends that children who are known to be HIV-infected, even if asymptomatic, should no longer be immunized with BCG vaccine. However, BCG may be given to asymptomatic infants of unknown HIV infection status born to women with HIV infection, depending on the relative incidence of TB and HIV in the particular area. BCG also may be given to asymptomatic infants born to women of unknown HIV infection status. </p></div><span id="v9141096" class="anchor"></span><div class="para"> <p>In some areas of the world, children are routinely given the <a href="./{AA0BEA68-7496-4D03-BF9F-2F7E60014103}.html#v1021110" data-toggle="tooltip" title="Prevention" data-id="233a53fd-76b7-46e7-be61-9b05922b574f" data-itemid="aa0bea68-7496-4d03-bf9f-2f7e60014103"><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>yellow fever vaccine</span></a><span id="233a53fd-76b7-46e7-be61-9b05922b574f" class="d-none xref"> <span class="tooltip-container"> <a href="./{AA0BEA68-7496-4D03-BF9F-2F7E60014103}.html#v1021110"> <span class="tooltip-content"> <span class="tooltip-heading"> Prevention </span> Yellow fever is a mosquito-borne flavivirus infection endemic in tropical South America and sub-Saharan Africa. Symptoms may include sudden onset of fever, relative bradycardia, headache, and... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span> or the <a href="./{0190EDFF-3A85-438E-9447-18CCBF49E062}.html#v1020824" data-toggle="tooltip" title="Prevention" data-id="ec2e616e-875b-40f3-9faf-913372200a6f" data-itemid="0190edff-3a85-438e-9447-18ccbf49e062">dengue virus vaccine</a><span id="ec2e616e-875b-40f3-9faf-913372200a6f" class="d-none xref"> <span class="tooltip-container"> <a href="./{0190EDFF-3A85-438E-9447-18CCBF49E062}.html#v1020824"> <span class="tooltip-content"> <span class="tooltip-heading"> Prevention </span> Dengue is a mosquito-borne disease caused by a flavivirus. Dengue fever usually results in abrupt onset of high fever, headache, myalgias, arthralgias, and generalized lymphadenopathy, followed... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>; these live virus vaccines should be given only to those without severe immunosuppression.</p></div><span id="v1108107" class="anchor"></span><div class="para"> <p>Because children with symptomatic HIV infection generally have poor immunologic responses to vaccines, they should be considered susceptible when they are exposed to a vaccine-preventable disease (eg, measles, tetanus, varicella) regardless of their vaccination history. Such children should receive passive immunization with IV immune globulin. IV immune globulin also should be given to any nonimmunized household member who is exposed to measles.</p></div><span id="v1108108" class="anchor"></span><div class="para"> <p><i>Seronegative children living with a person with symptomatic HIV infection</i> should receive <a href="./{B1673C7B-7F18-40EA-B742-954408B58A4A}.html" data-toggle="tooltip" title="Poliomyelitis Vaccine" data-id="f668247e-48ef-422c-9fd3-c7ec2446fcb1" data-itemid="b1673c7b-7f18-40ea-b742-954408b58a4a">inactivated poliovirus vaccine</a><span id="f668247e-48ef-422c-9fd3-c7ec2446fcb1" class="d-none xref"> <span class="tooltip-container"> <a href="./{B1673C7B-7F18-40EA-B742-954408B58A4A}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Poliomyelitis Vaccine </span> Extensive vaccination has almost eradicated polio worldwide. But cases still occur in areas with incomplete immunization, such as sub-Saharan Africa and southern Asia. There are 3 serotypes... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span> rather than oral polio vaccine. Influenza (inactivated or live), MMR, varicella, and rotavirus vaccines may be given normally because these vaccine viruses are not commonly transmitted by the vaccinee. Adult household contacts should receive annual influenza vaccination (inactivated or live) to reduce the risk of transmitting influenza to the person with HIV infection.</p></div><span id="v77995742" class="anchor"></span><div class="para"> <p><b>Additional recommendations for children with HIV infection</b> are</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v77995745" class="anchor"></span><div class="para"> <p>1 to 2 months after the last dose of the <a href="./{1AD058B8-EED6-4FC4-AB2D-E7B8BF1297E5}.html" data-toggle="tooltip" title="Hepatitis B (HepB) Vaccine" data-id="34e8449b-5626-43a4-98bf-e0d7541444d2" data-itemid="1ad058b8-eed6-4fc4-ab2d-e7b8bf1297e5"><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>hepatitis B vaccine</span></a><span id="34e8449b-5626-43a4-98bf-e0d7541444d2" class="d-none xref"> <span class="tooltip-container"> <a href="./{1AD058B8-EED6-4FC4-AB2D-E7B8BF1297E5}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Hepatitis B (HepB) Vaccine </span> The hepatitis B vaccine is 80 to 100% effective in preventing infection or clinical hepatitis B in people who complete the vaccine series. For more information, see Hepatitis B Advisory Committee... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span> series, children with HIV infection should be tested to determine whether the level of antibodies to hepatitis B surface antigen (anti-HBs) is protective (<span class='symbol'>≥</span> 10 mIU/mL). </p></div></li><li class="topic__listitem"><span id="v77995748" class="anchor"></span><div class="para"> <p>Children and adolescents with HIV infection who are < 18 years of age should be given the <a href="./{4CBAC8F6-1075-42ED-9391-C044CE443EB5}.html" data-toggle="tooltip" title="Pneumococcal Vaccine" data-id="4aa694c3-ed08-49d7-94a9-a787965fa994" data-itemid="4cbac8f6-1075-42ed-9391-c044ce443eb5">pneumococcal conjugate vaccine</a><span id="4aa694c3-ed08-49d7-94a9-a787965fa994" class="d-none xref"> <span class="tooltip-container"> <a href="./{4CBAC8F6-1075-42ED-9391-C044CE443EB5}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Pneumococcal Vaccine </span> Pneumococcal disease (eg, otitis media, pneumonia, sepsis, meningitis) is caused by some of the > 90 serotypes of <i>Streptococcus pneumoniae</i> (pneumococci). Vaccines are directed against... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>. (See also <a rel="nofollow" target="_blank" href="https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html">Pneumococcal Advisory Committee on Immunization Practices [ACIP] Vaccine Recommendations</a>.)</p></div></li></ul></div><span id="v77995752" class="anchor"></span><div class="para"> <p>Certain postexposure treatment recommendations also differ. <a href="./{509A3135-C16D-4D29-9F8B-C2526A49BB59}.html" data-toggle="tooltip" title="Meningococcal Vaccine" data-id="1038a22a-708f-4a6e-8172-711ac53118ce" data-itemid="509a3135-c16d-4d29-9f8b-c2526a49bb59">Quadrivalent meningococcal conjugate immunization</a><span id="1038a22a-708f-4a6e-8172-711ac53118ce" class="d-none xref"> <span class="tooltip-container"> <a href="./{509A3135-C16D-4D29-9F8B-C2526A49BB59}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Meningococcal Vaccine </span> The meningococcal serogroups that most often cause meningococcal disease in the United States are serogroups B, C, and Y. Serogroups A and W cause disease outside the United States. Current... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span> has been recommended for routine and catch-up use in children, adolescents, and adults with HIV infection (see also ACIP <a rel="nofollow" target="_blank" href="https://www.cdc.gov/mmwr/volumes/65/wr/mm6543a3.htm">recommendations for the use of meningococcal conjugate vaccines in people who have HIV</a>).</p></div> <span id="v1108109"></span> <div data-mmanualobjecttype="illustrativeMaterial" class="inlinebox--full inlinebox--table inlinebox--clickable illustrativeMaterialTable "> <div class="inlinebox__wrapper" id="v1108119"> <div class="inlinebox__header">Table</div> <div class="inlinebox__content"> <div class="multimedia__link" data-bind="component: { name: 'multimedia-link-text', params: $data }" data-popup-model='{"ItemId":"ca02e767-48b1-472f-9d0a-b7ed22899500","Title":"Considerations%20for%20Use%20of%20Live%20Vaccines%20in%20Children%20With%20HIV%20Infection","ShareUrlTitle":"considerations-for-use-of-live-vaccines-in-children-with-hiv-infection","Description":"","ImageUrl":null,"ThumbnailUrl":"./Content/Images/Redesign/table/icon_table_red.png","MediaType":"table","MediaNameTranslated":"Table","UniqueId":"v1108117","Placement":null,"IsInCarousel":false,"Edition":0,"ImageWidth":null,"ImageHeight":null,"IframeSrc":null,"Target":null,"Alt":null}' data-popup-options='{"ListName":"","LinkText":"Considerations%20for%20Use%20of%20Live%20Vaccines%20in%20Children%20With%20HIV%20Infection","CssClass":null,"LoadLocations":false,"ShowTooltip":false,"SingleItem":true,"ExcludeFromBrand":null,"ShowCredits":true,"ShowDescription":true,"PopupTitle":"Table","ShowTitle":true,"ShowIcon":false,"ShowModalIndicator":false,"ShowTitleInHeader":false,"HideCarousel":true,"Target":null,"Url":null,"HideMainArrows":false}'> </div> <div class="inlinebox__button"> <img src="./Content/Images/Redesign/table/icon_table_red.png" alt="" loading="lazy" width="55" height="42"> </div> <div class="inlinebox__content--print" id="ca02e767-48b1-472f-9d0a-b7ed22899500"> </div> </div> </div> <!-- Type: Table --> </div> <script type="text/javascript"> $(document).ready(function () { var url = window.location; if (url.search.includes("media=print")) { $.ajax({ url: '/Redesign/Topic/GetTableBody', type: "GET", dataType: "json", data: { tableId: 'ca02e767-48b1-472f-9d0a-b7ed22899500' }, async: true, success: function (data) { $('#ca02e767-48b1-472f-9d0a-b7ed22899500').html('<div class="modaldialog">'+ data.TableBody + '</div>'); }, error: function (jqxhr, textStatus, errorThrown) { console.error(errorThrown); } }); } }); </script> </div> </section> <section id="v77995756" class="topic__section GHead"> <span itemscope="" itemtype="http://schema.org/MedicalTherapy"></span> <h3 id="Treatment_v1107695_v77995757" class="topic__header--subsection"> <span itemprop="name" id="v77995757" class="anchor"></span> Treatment reference </h3> <div class="topic__content"> <div class="list"> <ul data-mmanualobjecttype="List" class="nobulleted"><li class="topic__listitem"><span id="v77995760" class="anchor"></span><div class="para"> <p>1. <a rel="nofollow" target="_blank" href="https://pubmed.ncbi.nlm.nih.gov/36107786/">Kobayashi M, Farrar JL, Gierke R, et al</a>: Use of 15-valent pneumococcal conjugate vaccine among U.S. children: Updated recommendations of the Advisory Committee on Immunization Practices—United States, 2022. <i>MMWR Morb Mortal Wkly Rep</i> 71(37):1174–1181, 2022. doi: 10.15585/mmwr.mm7137a3</p></div></li></ul></div> </div> </section> </div> </section> <section id="v9141114" class="topic__section FHead"> <h2 id="" class="topic__header--section"> <span id="v9141115" class="anchor"></span> Transition to Adult Care </h2> <div class="topic__content"> <span id="v9141116" class="anchor"></span><div class="para"> <p>Transition of youth with HIV infection from the pediatric health care model to the adult health care model takes time and advance planning. This process is active and ongoing and does not simply involve a one-time referral to an adult care clinic or office. The pediatric health care model tends to be family-centered, and the care team includes a multidisciplinary team of physicians, nurses, social workers, and mental health professionals; perinatally infected youth may have been cared for by such a team for their entire life. </p></div><span id="v37571404" class="anchor"></span><div class="para"> <p>In contrast, the typical adult health care model tends to be individual-centered, and the health care practitioners involved may be located in separate offices requiring multiple visits. Health care practitioners at adult care clinics and offices are often managing high patient volumes, and the consequences of lateness or missed appointments (which may be more common among adolescents) are stricter. Finally, changes in insurance coverage in adolescence or young adulthood can complicate transition of medical care as well. </p></div><span id="v77995762" class="anchor"></span><div class="para"> <p>Planning transition over several months and having adolescents have discussions or joint visits with the pediatric and adult health care practitioners can lead to a smoother and more successful transition. A resource for transition of youth with HIV infection into adult health care is available from the American Academy of Pediatrics (see <a rel="nofollow" target="_blank" href="https://pubmed.ncbi.nlm.nih.gov/23796739/">Transitioning HIV-Infected Youth Into Adult Health Care</a>).</p></div> </div> </section> <section id="v1107688" class="topic__section FHead"> <h2 id="Prognosis_v1107689" class="topic__header--section" data-originaltitle="Prognosis"> <span id="v1107689" class="anchor"></span> Prognosis for HIV Infection in Infants and Children </h2> <div class="topic__content"> <span id="v1107690" class="anchor"></span><div class="para"> <p>In the pre-ART era, 10 to 15% of children from high-resource countries and perhaps 50 to 80% of children from low-resource countries died before age 4 years; however, with appropriate combination ART regimens, most perinatally infected children survive well into adulthood. Increasing numbers of these perinatally infected young adults have given birth to or fathered their own children.</p></div><span id="v1107691" class="anchor"></span><div class="para"> <p>Nevertheless, if opportunistic infections occur, particularly <i>Pneumocystis</i> pneumonia, progressive neurologic disease, or severe wasting, the prognosis is poor unless virologic and immunologic control is regained with combination ART. Mortality due to <i>Pneumocystis</i> pneumonia ranges from 5 to 40% if treated and is almost 100% if untreated. Prognosis is also poor for children in whom virus is detected early (ie, by 7 days of life) or who develop symptoms in the first year of life.</p></div><span id="v9140470" class="anchor"></span><div class="para"> <p>There have been several reported cases of adults in whom replication-competent HIV was eradicated (ie, these people were "cured" for > 5 years). These adults each required a hematopoietic stem cell transplant for leukemia. The donor cells were homozygous for the CCR5-delta 32 mutation, which made the engrafted lymphocytes resistant to infection with CCR5-tropic HIV; subsequently, HIV has remained undetectable. It is likely that ART, bone marrow ablation, and graft-vs-host disease also contributed to these cures. </p></div><span id="v77995764" class="anchor"></span><div class="para"> <p>At least one infant born to a mother with HIV infection who had not received prenatal care or prenatal (or intrapartum) ART was preliminarily thought to have been cured but upon further clinical follow-up was found to have persistent HIV infection. This infant was given combination ART at high doses (not yet known to be safe and effective for general use) beginning on day 2 of life through 15 months of age, after which time it was inadvertently interrupted. Nevertheless, at 24 months of age the infant had no detectable replicating virus RNA (a "functional cure") but did have detectable proviral DNA. Subsequently, however, HIV replication ensued. No infants or children have been permanently cured of their HIV infection, and it is not yet known if cure is possible. </p></div><span id="v77995765" class="anchor"></span><div class="para"> <p>What is known, however, is that HIV infection is a treatable infection that is already compatible with long-term survival if effective ART is given. Future research will undoubtedly uncover ways to improve ART tolerance and efficacy and perhaps help achieve the goal of curative therapy. <b>At present, interruption of ART in either infancy, childhood, or adulthood is not recommended</b>.</p></div> </div> </section> <section id="v1108218" class="topic__section FHead" itemprop="primaryPrevention" itemscope="" itemtype="http://schema.org/MedicalTherapy"> <h2 id="Prevention_v1108219" class="topic__header--section" data-originaltitle="Prevention"> <span id="v1108219" class="anchor"></span> Prevention of HIV Infection in Infants and Children </h2> <div class="topic__content"> <span id="v77995766" class="anchor"></span><div class="para"> <p>For pre-exposure prevention, see <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v77995803" data-toggle="tooltip" title="Pre-exposure prophylaxis (PrEP)" data-id="f40501b3-1cc5-41b9-8ee3-b9d610fc291b" data-itemid="6ea530b9-c85e-4653-b466-245f2a0e10ea">Pre-exposure prophylaxis (PrEP)</a><span id="f40501b3-1cc5-41b9-8ee3-b9d610fc291b" class="d-none xref"> <span class="tooltip-container"> <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v77995803"> <span class="tooltip-content"> <span class="tooltip-heading"> Pre-exposure prophylaxis (PrEP) </span> Human immunodeficiency virus (HIV) infection is caused by the retrovirus HIV-1 (and less commonly by the related retrovirus HIV-2). Infection leads to progressive immunologic deterioration and... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/4/1/5/415-candidiasis-tongue-slide-25-springer-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Pre-exposure prophylaxis (PrEP)" loading="lazy"> </span> </a> </span> </span>.</p></div><span id="v1108220" class="anchor"></span><div class="para"> <p>For postexposure prevention, see <a href="./{F74E7EDD-B57E-443C-AF88-E04A1F79DA48}.html#v1022631" data-toggle="tooltip" title="Postexposure prophylaxis (PEP)" data-id="8e29e5c8-8990-4032-8b20-3d6f9b9503da" data-itemid="f74e7edd-b57e-443c-af88-e04a1f79da48">Postexposure prophylaxis (PEP)</a><span id="8e29e5c8-8990-4032-8b20-3d6f9b9503da" class="d-none xref"> <span class="tooltip-container"> <a href="./{F74E7EDD-B57E-443C-AF88-E04A1F79DA48}.html#v1022631"> <span class="tooltip-content"> <span class="tooltip-heading"> Postexposure prophylaxis (PEP) </span> Human immunodeficiency virus (HIV) infection results from 1 of 2 similar retroviruses (HIV-1 and HIV-2) that destroy CD4+ lymphocytes and impair cell-mediated immunity, increasing risk of certain... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/3/1/3/313_hiv_slide_3_springer_high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Postexposure prophylaxis (PEP)" loading="lazy"> </span> </a> </span> </span>. </p></div> <section id="v1108222" class="topic__section GHead"> <span itemscope="" itemtype="http://schema.org/MedicalTherapy"></span> <h3 id="Prevention_v1108219_v1108223" class="topic__header--subsection"> <span itemprop="name" id="v1108223" class="anchor"></span> Prevention of perinatal transmission </h3> <div class="topic__content"> <span id="v1108227" class="anchor"></span><div class="para"> <p>Appropriate prenatal ART attempts to optimize maternal health, interrupt MTCT, and minimize in utero drug toxicity. In the United States and other countries where ARV medications and HIV testing are readily available, treatment with ARV medications is standard for all pregnant women with HIV infection (see <a href="./{F74E7EDD-B57E-443C-AF88-E04A1F79DA48}.html#v1022162" data-toggle="tooltip" title="Treatment" data-id="b855776c-bade-4405-b3a7-bc2698ae4578" data-itemid="f74e7edd-b57e-443c-af88-e04a1f79da48">treatment of HIV infection in adults</a><span id="b855776c-bade-4405-b3a7-bc2698ae4578" class="d-none xref"> <span class="tooltip-container"> <a href="./{F74E7EDD-B57E-443C-AF88-E04A1F79DA48}.html#v1022162"> <span class="tooltip-content"> <span class="tooltip-heading"> Treatment </span> Human immunodeficiency virus (HIV) infection results from 1 of 2 similar retroviruses (HIV-1 and HIV-2) that destroy CD4+ lymphocytes and impair cell-mediated immunity, increasing risk of certain... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/3/1/3/313_hiv_slide_3_springer_high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Treatment " loading="lazy"> </span> </a> </span> </span>). Rapid HIV testing of pregnant women who present in labor without documentation of their HIV serostatus may allow immediate institution of such measures.</p></div><span id="v1108229" class="anchor"></span><div class="para"> <p><b><i>All pregnant women with HIV infection</i></b> should initiate combination ART to prevent MTCT, as well as for their own health, as soon as the diagnosis of HIV infection is made and they are ready to adhere to ART. Combination ART is continued throughout pregnancy. Pregnancy is not a contraindication to combination ART regimens; specifically, neither <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>dolutegravir</span> nor <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>efavirenz</span> is contraindicated during the first trimester. Although a clinical trial in Botswana initially showed a link between periconceptional exposure to <span class="genericDrug" data-showrollover="false">dolutegravir</span> and a small increase in infant neural tube defects, the apparent increase was not present after further study, and it is unknown whether this increase was truly due to <span class="genericDrug" data-showrollover="false">dolutegravir</span> or to another factor, such as folate deficiency. The majority of experts believe that women with HIV infection already receiving combination ART who become pregnant should continue that therapy, even early during the first trimester.</p></div><span id="v49373386" class="anchor"></span><div class="para"> <p>Elective cesarean delivery before onset of labor is recommended if the maternal HIV plasma viral load is > 1000 copies/mL. If labor has already begun, it is less certain whether cesarean delivery reduces MTCT. </p></div><span id="v49373387" class="anchor"></span><div class="para"> <p><b>When patients present in labor,</b> <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>zidovudine</span> (ZDV) is given at 2 mg/kg IV for the first hour and then at 1 mg/kg/hour IV until delivery to women who have ≥ 1 of the following: </p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v49373390" class="anchor"></span><div class="para"> <p>Recent HIV plasma viral load > 1000 copies/mL</p></div></li><li class="topic__listitem"><span id="v49373392" class="anchor"></span><div class="para"> <p>Unknown HIV plasma viral load near delivery </p></div></li><li class="topic__listitem"><span id="v49373394" class="anchor"></span><div class="para"> <p>Are thought to have had incomplete adherence to ART</p></div></li></ul></div><span id="v49373395" class="anchor"></span><div class="para"> <p>Many experts now believe that IV ZDV is not required during labor for women receiving combination ART who have achieved HIV plasma viral loads < 50 copies/mL near delivery. However, IV ZDV should be considered for women with a viral load of 50 to 999 copies/mL at or near delivery; it may provide additional protection against perinatal transmission. </p></div><span id="v49373396" class="anchor"></span><div class="para"> <p><b>After delivery,</b> combination ART is continued for all women, even those who had not previously received ART.</p></div><span id="v49373397" class="anchor"></span><div class="para"> <p><b><i>All newborns exposed to HIV</i></b> should receive a postpartum ARV regimen to reduce the risk of HIV infection. Treatment should begin as soon as possible, preferably within 6 to 12 hours of delivery. The ARV regimen is determined by maternal and infant risk factors for perinatal HIV transmission (see the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV's <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/maternal-hiv-testing-and-identification-perinatal-hiv-exposure?view=full">Maternal HIV Testing and Identification of Perinatal HIV Exposure</a> recommendations). </p></div><span id="v49373399" class="anchor"></span><div class="para"> <p>Preventive regimens are categorized as</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v49373402" class="anchor"></span><div class="para"> <p>ARV prophylaxis</p></div></li><li class="topic__listitem"><span id="v49373404" class="anchor"></span><div class="para"> <p>Presumptive HIV therapy </p></div></li></ul></div><span id="v9141123" class="anchor"></span><div class="para"> <p><b>Low-risk infants</b> are candidates for ARV prophylaxis. They include full-term neonates born to women who have had sustained virologic suppression with ART (as shown by an HIV plasma viral load < 50 copies/mL) near delivery and in whom there are no concerns related to adherence to ART. </p></div><span id="v77995772" class="anchor"></span><div class="para"> <p>Low-risk infants should be given ARV prophylaxis with ZDV 4 mg/kg orally twice daily for the first 4 weeks of life. ZDV is the backbone of infant prophylaxis and is used for all infants born to women with HIV infection regardless of the risk factors.</p></div><span id="v77995773" class="anchor"></span><div class="para"> <p>Some experts advise ZDV may be given for 2 weeks to select infants born at ≥ 37 weeks gestation to women who meet low-risk criteria, who have been given ART for more than 10 consecutive weeks, and who have maintained viral suppression for the duration of the pregnancy (see the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV's <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/management-infants-arv-hiv-exposure-infection?view=full">Management of Infants Born to People with HIV Infection</a>). </p></div><span id="v37571410" class="anchor"></span><div class="para"> <p><b>High-risk infants</b> are given presumptive HIV therapy (see table <span class="multimedia__link mlinkBlock" data-bind="component: { name: 'm-link-text', params: $data }" data-popup-model='{"ItemId":"74086197-3239-4f45-b530-4a7161fe8cda","Title":"Neonatal%20Antiretroviral%20Management%20According%20to%20Risk%20of%20HIV%20Infection","ShareUrlTitle":"neonatal-antiretroviral-management-according-to-risk-of-hiv-infection","Description":"","ImageUrl":null,"ThumbnailUrl":"/Content/Images/Redesign/table/icon_table_red.png","MediaType":"table","MediaNameTranslated":"Table","UniqueId":"v49373411","Placement":null,"IsInCarousel":false,"Edition":0,"ImageWidth":null,"ImageHeight":null,"IframeSrc":null,"Target":null,"Alt":null}' data-popup-options='{"ListName":"TopicMultimedia","LinkText":"%3Cspan%20%3ENeonatal%20Antiretroviral%20Management%20According%20to%20Risk%20of%20HIV%20Infection%3C%2Fspan%3E","CssClass":null,"LoadLocations":true,"ShowTooltip":true,"SingleItem":true,"ExcludeFromBrand":"","ShowCredits":true,"ShowDescription":true,"PopupTitle":"Table","ShowTitle":true,"ShowIcon":false,"ShowModalIndicator":false,"ShowTitleInHeader":false,"HideCarousel":false,"Target":"modal","Url":null,"HideMainArrows":false}'></span>) with a three-drug regimen of <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>zidovudine</span>, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>lamivudine</span>, and either <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>nevirapine</span> or <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>raltegravir</span> (for dosing, see table <span class="multimedia__link mlinkBlock" data-bind="component: { name: 'm-link-text', params: $data }" data-popup-model='{"ItemId":"e0b2fa81-954d-4b00-931e-d0584b768e9a","Title":"Antiretroviral%20Dosing%20for%20Neonates%20With%20Perinatal%20HIV%20Exposure","ShareUrlTitle":"antiretroviral-dosing-for-neonates-with-perinatal-hiv-exposure","Description":"","ImageUrl":null,"ThumbnailUrl":"/Content/Images/Redesign/table/icon_table_red.png","MediaType":"table","MediaNameTranslated":"Table","UniqueId":"v49373475","Placement":null,"IsInCarousel":false,"Edition":0,"ImageWidth":null,"ImageHeight":null,"IframeSrc":null,"Target":null,"Alt":null}' data-popup-options='{"ListName":"TopicMultimedia","LinkText":"%3Cspan%20%3EAntiretroviral%20Dosing%20for%20Neonates%20with%20Perinatal%20HIV%20Exposure%3C%2Fspan%3E","CssClass":null,"LoadLocations":true,"ShowTooltip":true,"SingleItem":true,"ExcludeFromBrand":"","ShowCredits":true,"ShowDescription":true,"PopupTitle":"Table","ShowTitle":true,"ShowIcon":false,"ShowModalIndicator":false,"ShowTitleInHeader":false,"HideCarousel":false,"Target":"modal","Url":null,"HideMainArrows":false}'></span>) for up to 6 weeks or, rarely, longer. This therapy initially serves as prophylaxis but also as preliminary treatment for those later confirmed to have HIV. </p></div><span id="v77995777" class="anchor"></span><div class="para"> <p>Very few ARV medications (notably ZDV, <span class="genericDrug" data-showrollover="false">nevirapine</span>, <span class="genericDrug" data-showrollover="false">lamivudine</span>, <span class="genericDrug" data-showrollover="false">abacavir</span>, and <span class="genericDrug" data-showrollover="false">raltegravir</span>) are considered safe and effective for infants < 14 days postnatal age, and fewer still (only <span class="genericDrug" data-showrollover="false">zidovudine</span>, <span class="genericDrug" data-showrollover="false">lamivudine</span>, <span class="genericDrug" data-showrollover="false">nevirapine</span>, and, for late preterm infants, <span class="genericDrug" data-showrollover="false">raltegravir</span>) have dosing data available for preterm infants. The optimal ARV regimen for neonates born to women with ARV drug-resistant virus is unknown.</p></div><span id="v49373407" class="anchor"></span><div class="para"> <p>Infants who subsequently have a positive HIV virologic test are given ART with three medications as appropriate for treatment of known HIV infection. An expert in pediatric or maternal HIV infection should be immediately consulted (see information at <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en">ClinicalInfo.HIV.gov</a> or at the <a rel="nofollow" target="_blank" href="http://nccc.ucsf.edu/">National Clinician Consultation Center</a>). Clinicians also can call the Perinatal HIV Consultation and Referral Services Hotline at 1-888-HIV-8765 (1-888-448-8765) for questions regarding interventions to decrease vertical HIV transmission and neonatal diagnosis.</p></div> <span id="v49373410"></span> <div data-mmanualobjecttype="illustrativeMaterial" class="inlinebox--full inlinebox--table inlinebox--clickable illustrativeMaterialTable "> <div class="inlinebox__wrapper" id="v49373412"> <div class="inlinebox__header">Table</div> <div class="inlinebox__content"> <div class="multimedia__link" data-bind="component: { name: 'multimedia-link-text', params: $data }" data-popup-model='{"ItemId":"74086197-3239-4f45-b530-4a7161fe8cda","Title":"Neonatal%20Antiretroviral%20Management%20According%20to%20Risk%20of%20HIV%20Infection","ShareUrlTitle":"neonatal-antiretroviral-management-according-to-risk-of-hiv-infection","Description":"","ImageUrl":null,"ThumbnailUrl":"./Content/Images/Redesign/table/icon_table_red.png","MediaType":"table","MediaNameTranslated":"Table","UniqueId":"v49373411","Placement":null,"IsInCarousel":false,"Edition":0,"ImageWidth":null,"ImageHeight":null,"IframeSrc":null,"Target":null,"Alt":null}' data-popup-options='{"ListName":"","LinkText":"Neonatal%20Antiretroviral%20Management%20According%20to%20Risk%20of%20HIV%20Infection","CssClass":null,"LoadLocations":false,"ShowTooltip":false,"SingleItem":true,"ExcludeFromBrand":null,"ShowCredits":true,"ShowDescription":true,"PopupTitle":"Table","ShowTitle":true,"ShowIcon":false,"ShowModalIndicator":false,"ShowTitleInHeader":false,"HideCarousel":true,"Target":null,"Url":null,"HideMainArrows":false}'> </div> <div class="inlinebox__button"> <img src="./Content/Images/Redesign/table/icon_table_red.png" alt="" loading="lazy" width="55" height="42"> </div> <div class="inlinebox__content--print" id="74086197-3239-4f45-b530-4a7161fe8cda"> </div> </div> </div> <!-- Type: Table --> </div> <script type="text/javascript"> $(document).ready(function () { var url = window.location; if (url.search.includes("media=print")) { $.ajax({ url: '/Redesign/Topic/GetTableBody', type: "GET", dataType: "json", data: { tableId: '74086197-3239-4f45-b530-4a7161fe8cda' }, async: true, success: function (data) { $('#74086197-3239-4f45-b530-4a7161fe8cda').html('<div class="modaldialog">'+ data.TableBody + '</div>'); }, error: function (jqxhr, textStatus, errorThrown) { console.error(errorThrown); } }); } }); </script> <span id="v49373474"></span> <div data-mmanualobjecttype="illustrativeMaterial" class="inlinebox--full inlinebox--table inlinebox--clickable illustrativeMaterialTable "> <div class="inlinebox__wrapper" id="v49373476"> <div class="inlinebox__header">Table</div> <div class="inlinebox__content"> <div class="multimedia__link" data-bind="component: { name: 'multimedia-link-text', params: $data }" data-popup-model='{"ItemId":"e0b2fa81-954d-4b00-931e-d0584b768e9a","Title":"Antiretroviral%20Dosing%20for%20Neonates%20With%20Perinatal%20HIV%20Exposure","ShareUrlTitle":"antiretroviral-dosing-for-neonates-with-perinatal-hiv-exposure","Description":"","ImageUrl":null,"ThumbnailUrl":"./Content/Images/Redesign/table/icon_table_red.png","MediaType":"table","MediaNameTranslated":"Table","UniqueId":"v49373475","Placement":null,"IsInCarousel":false,"Edition":0,"ImageWidth":null,"ImageHeight":null,"IframeSrc":null,"Target":null,"Alt":null}' data-popup-options='{"ListName":"","LinkText":"Antiretroviral%20Dosing%20for%20Neonates%20With%20Perinatal%20HIV%20Exposure","CssClass":null,"LoadLocations":false,"ShowTooltip":false,"SingleItem":true,"ExcludeFromBrand":null,"ShowCredits":true,"ShowDescription":true,"PopupTitle":"Table","ShowTitle":true,"ShowIcon":false,"ShowModalIndicator":false,"ShowTitleInHeader":false,"HideCarousel":true,"Target":null,"Url":null,"HideMainArrows":false}'> </div> <div class="inlinebox__button"> <img src="./Content/Images/Redesign/table/icon_table_red.png" alt="" loading="lazy" width="55" height="42"> </div> <div class="inlinebox__content--print" id="e0b2fa81-954d-4b00-931e-d0584b768e9a"> </div> </div> </div> <!-- Type: Table --> </div> <script type="text/javascript"> $(document).ready(function () { var url = window.location; if (url.search.includes("media=print")) { $.ajax({ url: '/Redesign/Topic/GetTableBody', type: "GET", dataType: "json", data: { tableId: 'e0b2fa81-954d-4b00-931e-d0584b768e9a' }, async: true, success: function (data) { $('#e0b2fa81-954d-4b00-931e-d0584b768e9a').html('<div class="modaldialog">'+ data.TableBody + '</div>'); }, error: function (jqxhr, textStatus, errorThrown) { console.error(errorThrown); } }); } }); </script><span id="v77995788" class="anchor"></span><div class="para"> <p>Some mothers with HIV infection who live in the United States or in other countries where safe, affordable, and alternative sources of feeding are available may choose to breastfeed if they are receiving ART and have a sustained, undetectable viral load. The decision to breastfeed should be made only after counseling and shared decision-making discussions. Some recommendations for continuing neonatal ARV prophylaxis and using an increased diagnostic testing frequency in this situation have been suggested, but a consensus has not yet been reached because data are incomplete. An expert in pediatric HIV infection should be consulted (see Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV's <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/infant-feeding-individuals-hiv-united-states?view=full">Infant Feeding for Individuals with HIV in the United States</a>).</p></div><span id="v77995790" class="anchor"></span><div class="para"> <p>Additionally, in countries where infectious diseases and undernutrition are major causes of early childhood mortality and safe, affordable infant formula is not available, the protection breastfeeding offers against the mortality risks of respiratory and gastrointestinal infections may counterbalance the risk of HIV transmission. In these countries, the World Health Organization (WHO) recommends mothers with HIV infection continue to breastfeed for at least 12 months of the infant's life (see the WHO's <a rel="nofollow" target="_blank" href="https://www.who.int/publications/i/item/9789241549707">Guideline: Updates on HIV and Infant Feeding</a>).</p></div><span id="v77995792" class="anchor"></span><div class="para"> <p><b>Donating to milk banks</b> is contraindicated for women with HIV infection in the United States and in other countries where safe and affordable alternative sources of feeding are readily available.</p></div><span id="v37571413" class="anchor"></span><div class="para"> <p><b>Premastication (prechewing)</b> of food, practiced by some mothers of young infants, is also contraindicated for women with HIV infection.</p></div> </div> </section> <section id="v1108240" class="topic__section GHead"> <span itemscope="" itemtype="http://schema.org/MedicalTherapy"></span> <h3 id="Prevention_v1108219_v1108241" class="topic__header--subsection"> <span itemprop="name" id="v1108241" class="anchor"></span> Prevention of adolescent transmission </h3> <div class="topic__content"> <span id="v1108244" class="anchor"></span><div class="para"> <p>Because adolescents are at special risk of HIV infection, they should receive education, have access to HIV testing, and know their serostatus. Education should include information about transmission, implications of infection, and strategies for prevention, including abstaining from high-risk behaviors and engaging in safe sex practices (eg, correct and consistent <a href="./{CAA6B443-6711-4A27-AAB3-8A0A91E86C81}.html#v8579821" data-toggle="tooltip" title="Condoms" data-id="b4b478a1-9cff-4372-ab12-884c7be72c52" data-itemid="caa6b443-6711-4a27-aab3-8a0a91e86c81">use of condoms</a><span id="b4b478a1-9cff-4372-ab12-884c7be72c52" class="d-none xref"> <span class="tooltip-container"> <a href="./{CAA6B443-6711-4A27-AAB3-8A0A91E86C81}.html#v8579821"> <span class="tooltip-content"> <span class="tooltip-heading"> Condoms </span> Barrier contraceptives include condoms, diaphragms, cervical caps, and contraceptive sponges. Other pericoital contraceptives include vaginal spermicides (foams, creams, gels, suppositories)... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>) for those who are sexually active. Efforts should especially target adolescents at high risk of HIV infection, in particular, Black and Hispanic adolescent men who have sex with other men because these are the fastest-growing US demographics of new HIV infections among youth; however, all adolescents should receive risk-reduction education.</p></div><span id="v1108246" class="anchor"></span><div class="para"> <p>In most US states, informed consent is necessary for testing and the release of information regarding HIV serostatus. Decisions regarding disclosure of HIV status to a sex partner without the patient’s consent should be based on the following: </p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v77995795" class="anchor"></span><div class="para"> <p>Possibility of intimate partner violence to the patient after disclosure to the partner</p></div></li><li class="topic__listitem"><span id="v77995797" class="anchor"></span><div class="para"> <p>Likelihood that the partner is at risk</p></div></li><li class="topic__listitem"><span id="v77995799" class="anchor"></span><div class="para"> <p>Whether the partner has reasonable cause to suspect the risk and to take precautions</p></div></li><li class="topic__listitem"><span id="v77995801" class="anchor"></span><div class="para"> <p>Presence of a legal requirement to withhold or disclose such information</p></div></li></ul></div> </div> </section> <section id="v77995802" class="topic__section GHead"> <span></span> <h3 id="Prevention_v1108219_v77995803" class="topic__header--subsection"> <span id="v77995803" class="anchor"></span> Pre-exposure prophylaxis (PrEP) </h3> <div class="topic__content"> <span id="v77995804" class="anchor"></span><div class="para"> <p>PrEP is the use of ARV medications by people who are not infected with HIV but who are at high risk of becoming infected (eg, by having a sex partner with HIV infection). Commonly, PrEP is a combination of <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>tenofovir disoproxil fumarate</span>/<span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>emtricitabine</span> (TDF/FTC); less commonly, PrEP is a combination of <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>tenofovir alafenamide</span>/<span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>emtricitabine</span> (TAF/FTC), which still has very high efficacy. PrEP does not eliminate the need to use other methods of reducing risk of HIV infection, including using condoms correctly and avoiding high-risk behaviors (eg, needle sharing). </p></div><span id="v77995805" class="anchor"></span><div class="para"> <p>Data regarding infants of HIV-negative mothers taking TDF/FTC PrEP during pregnancy are incomplete, but, currently, no adverse effects have been reported in children born to women with HIV infection treated with TDF/FTC. Use of PrEP to reduce the risk of HIV infection in injection drug users is being studied. </p></div><span id="v77995806" class="anchor"></span><div class="para"> <p>Adolescents in the United States often face a barrier to seeking sexually transmitted infection and HIV services partly because they fear breach of confidentiality (that is, that their parents or guardians will be told). This has been a barrier to administration of PrEP to adolescents as well. Issues of cost (with possible lack of insurance reimbursement) also may be more complex for adolescents receiving PrEP than for adults receiving PrEP. Despite these potential barriers, PrEP for sexually active adolescents, particularly those with high-risk sexual behavior, should be strongly considered. A recent compendium of minor consent laws for sexually transmitted infections and HIV services is available to help guide clinicians (<a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v77995812" data-toggle="tooltip" title="PrEP reference" data-id="4eafefe5-9290-4e76-b794-9c674c6e2778" data-itemid="6ea530b9-c85e-4653-b466-245f2a0e10ea">1</a><span id="4eafefe5-9290-4e76-b794-9c674c6e2778" class="d-none xref"> <span class="tooltip-container"> <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v77995812"> <span class="tooltip-content"> <span class="tooltip-heading"> PrEP reference </span> Human immunodeficiency virus (HIV) infection is caused by the retrovirus HIV-1 (and less commonly by the related retrovirus HIV-2). Infection leads to progressive immunologic deterioration and... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/4/1/5/415-candidiasis-tongue-slide-25-springer-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="PrEP reference" loading="lazy"> </span> </a> </span> </span>). </p></div><span id="v77995808" class="anchor"></span><div class="para"> <p>Long-acting injectable ARV medications such as <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>cabotegravir</span> are also being studied to further improve PrEP in high-risk populations with poor medication adherence. For current CDC recommendations, see <a rel="nofollow" target="_blank" href="https://www.cdc.gov/hiv/guidelines/preventing.html">Pre-Exposure Prophylaxis (PrEP)</a>. For further discussion, see <a rel="nofollow" target="_blank" href="https://www.hivguidelines.org/prep-for-prevention/">PrEP to Prevent HIV and Promote Sexual Health</a> from the New York State Department of Health AIDS Institute.</p></div> </div> </section> <section id="v77995811" class="topic__section GHead"> <span></span> <h3 id="Prevention_v1108219_v77995812" class="topic__header--subsection"> <span id="v77995812" class="anchor"></span> PrEP reference </h3> <div class="topic__content"> <div class="list"> <ul data-mmanualobjecttype="List" class="nobulleted"><li class="topic__listitem"><span id="v77995815" class="anchor"></span><div class="para"> <p>1. <a rel="nofollow" target="_blank" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382446/">Nelson KM, Skinner A, Underhill K</a>: Minor consent laws for sexually transmitted infection and HIV services. <i>JAMA</i> 328(7):674–676, 2022. doi: 10.1001/jama.2022.10777</p></div></li></ul></div> </div> </section> </div> </section> <section id="v9141133" class="topic__section topic__section--keypoints FHead"> <h2 id="KeyPoints_v9141134" class="topic__header--section"> <span id="v9141134" class="anchor"></span> Key Points <span class="topic__keypoints--icon"></span> </h2> <div class="topic__content--keypoints"> <div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v9141137" class="anchor"></span><div class="para"> <p>Most HIV cases in infants and children result from mother-to-child transmission (MTCT) before or during birth, or from breastfeeding in countries where safe and affordable infant formula is not available.</p></div></li><li class="topic__listitem"><span id="v9141139" class="anchor"></span><div class="para"> <p>Maternal antiretroviral therapy (ART) can reduce incidence of MTCT from about 25% to < 1%.</p></div></li><li class="topic__listitem"><span id="v77995818" class="anchor"></span><div class="para"> <p>Neonates born to women living with HIV infection are treated for a short time with antiretroviral (ARV) medications to interrupt MTCT.</p></div></li><li class="topic__listitem"><span id="v9141141" class="anchor"></span><div class="para"> <p>Diagnose children < 18 months using qualitative HIV RNA or RNA/DNA assays (eg, transcription-mediated amplification of RNA). </p></div></li><li class="topic__listitem"><span id="v9141143" class="anchor"></span><div class="para"> <p>Diagnose children > 18 months using a 4th-generation HIV-1/2 antigen/antibody combination immunoassay followed by a 2nd-generation HIV-1/2 antibody differentiation assay and, if required, an HIV-1 qualitative RNA assay.</p></div></li><li class="topic__listitem"><span id="v9141145" class="anchor"></span><div class="para"> <p>Urgently treat (using rapid initiation) all infants with HIV infection < 12 months of age; those 1 to < 6 years of age who have stage 3–defining opportunistic infections or CD4 counts < 500 cells/mcL; and those ≥ 6 years of age who have stage 3–defining opportunistic infections or CD4 counts < 200 cells/mcL. </p></div></li><li class="topic__listitem"><span id="v37571418" class="anchor"></span><div class="para"> <p>Treat all other children and adolescents with HIV infection as soon as issues of adherence are more fully assessed and addressed with the children and their caretakers.</p></div></li><li class="topic__listitem"><span id="v9141147" class="anchor"></span><div class="para"> <p>Combination ART is given, preferably using a fixed-dose combination product if feasible, for increased adherence.</p></div></li><li class="topic__listitem"><span id="v77995820" class="anchor"></span><div class="para"> <p>Adolescents who do not have HIV infection may be given PrEP to prevent acquisition of HIV infection, but issues of confidentiality and cost may be more problematic than for adults receiving PrEP.</p></div></li><li class="topic__listitem"><span id="v9141149" class="anchor"></span><div class="para"> <p>Give prophylaxis for opportunistic infections based on age and CD4+ count.</p></div></li></ul></div> </div> </section> <section id="v37571419" class="topic__section FHead"> <h2 id="Further_v37571420" class="topic__header--section"> <span id="v37571420" class="anchor"></span> More Information </h2> <div class="topic__content"> <span id="v49373608" class="anchor"></span><div class="para"> <p>The following English-language resources may be useful. Please note that THE MANUAL is not responsible for the content of these resources.</p></div><span id="v49373609" class="anchor"></span><div class="para"> <p>See the following US government sites for information on drug treatment, including adverse effects, dosing (especially for information on fixed-dose combination products), and drug interactions, educational materials, and quick links to related topics:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="nobulleted"><li class="topic__listitem"><span id="v49373612" class="anchor"></span><div class="para"> <p>ClinicalInfo.HIV.gov/Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV: <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines">Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection</a></p></div></li><li class="topic__listitem"><span id="v77995822" class="anchor"></span><div class="para"> <p>ClinicalInfo.HIV.gov: <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new-guidelines">Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States</a></p></div></li><li class="topic__listitem"><span id="v77995825" class="anchor"></span><div class="para"> <p>ClinicalInfo.HIV.gov: <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/appendix-c-cdc-pediatric-hiv-cd4-cell?view=full">Appendix C: CDC Pediatric HIV CD4 Cell Count/Percentage and HIV-Related Diseases Categorization</a></p></div></li><li class="topic__listitem"><span id="v77995828" class="anchor"></span><div class="para"> <p>ClinicalInfo.HIV.gov: <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/diagnosis-hiv-infection-infants-and-children?view=full">Diagnosis of HIV Infection in Infants and Children</a></p></div></li><li class="topic__listitem"><span id="v77995831" class="anchor"></span><div class="para"> <p>ClinicalInfo.HIV.gov: <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/maternal-hiv-testing-and-identification-perinatal-hiv-exposure?view=full">Maternal HIV Testing and Identification of Perinatal HIV Exposure</a></p></div></li><li class="topic__listitem"><span id="v77995834" class="anchor"></span><div class="para"> <p>ClinicalInfo.HIV.gov: <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/overview-0?view=full">Appendix A: Pediatric Antiretroviral Drug Information</a></p></div></li><li class="topic__listitem"><span id="v77995837" class="anchor"></span><div class="para"> <p>ClinicalInfo.HIV.gov: <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/management-infants-arv-hiv-exposure-infection?view=full">Management of Infants Born to People with HIV Infection</a></p></div></li><li class="topic__listitem"><span id="v49373615" class="anchor"></span><div class="para"> <p>ClinicalInfo.HIV.gov: <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new-guidelines">Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV</a></p></div></li><li class="topic__listitem"><span id="v77995840" class="anchor"></span><div class="para"> <p>ClinicalInfo.HIV.gov: <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new-guidelines">Guidelines for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV</a></p></div></li><li class="topic__listitem"><span id="v49373618" class="anchor"></span><div class="para"> <p>ClinicalInfo.HIV.gov: <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new">Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV</a></p></div></li><li class="topic__listitem"><span id="v77995843" class="anchor"></span><div class="para"> <p>ClinicalInfo.HIV.gov: <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/infant-feeding-individuals-hiv-united-states?view=full">Infant Feeding for Individuals with HIV in the United States</a></p></div></li><li class="topic__listitem"><span id="v77995846" class="anchor"></span><div class="para"> <p>World Health Organization: <a rel="nofollow" target="_blank" href="https://www.who.int/publications/i/item/9789241549707">Guideline: Updates on HIV and Infant Feeding</a></p></div></li><li class="topic__listitem"><span id="v49373621" class="anchor"></span><div class="para"> <p>Centers for Disease Control and Prevention (CDC): <a rel="nofollow" target="_blank" href="https://www.cdc.gov/hiv/guidelines/preventing.html">Pre-Exposure Prophylaxis (PrEP)</a></p></div></li><li class="topic__listitem"><span id="v77995849" class="anchor"></span><div class="para"> <p>U.S. Preventive Services Task Force (USPSTF): <a rel="nofollow" target="_blank" href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/human-immunodeficiency-virus-hiv-infection-screening">Human Immunodeficiency Virus (HIV) Infection: Screening</a>recommendation statement (2019)</p></div></li></ul></div><span id="v49373623" class="anchor"></span><div class="para"> <p>The following resources provide information about various other prevention, treatment, and education aspects of HIV/AIDS:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="nobulleted"><li class="topic__listitem"><span id="v37571429" class="anchor"></span><div class="para"> <p><a rel="nofollow" target="_blank" href="https://www.hivguidelines.org/">New York State Department of Health AIDS Institute HIV Clinical Guidelines Program:</a> Disseminates practical, evidence-based clinical guidelines that promote quality medical care for people in New York who are living with and/or are at risk of acquiring HIV and certain other illnesses</p></div></li><li class="topic__listitem"><span id="v49373625" class="anchor"></span><div class="para"> <p><a rel="nofollow" target="_blank" href="https://www.hivguidelines.org/prep-for-prevention/">New York State Department of Health AIDS Institute:</a> Pre-exposure prophylaxis (PrEP) guidelines, education, and training for HIV prevention</p></div></li><li class="topic__listitem"><span id="v49373628" class="anchor"></span><div class="para"> <p><a rel="nofollow" target="_blank" href="https://www.health.ny.gov/diseases/aids/">New York State Department of Health AIDS Institute:</a> Comprehensive information regarding all aspects of HIV/AIDS, including treatment, social awareness, resources for consumers, and training for professionals</p></div></li><li class="topic__listitem"><span id="v37571432" class="anchor"></span><div class="para"> <p><a rel="nofollow" target="_blank" href="http://www.unaids.org/en/">UNAIDS:</a> Comprehensive information on how the organization directs, advocates, coordinates, and provides technical support needed to connect leadership from governments, the private sector, and communities to deliver life-saving HIV services</p></div></li><li class="topic__listitem"><span id="v37571435" class="anchor"></span><div class="para"> <p><a rel="nofollow" target="_blank" href="http://nccc.ucsf.edu/clinical-resources/hiv-aids-resources/hiv-aids-guidelines/">National Clinician Consultation Center:</a> Up-to-date HIV/AIDS guidelines and key treatment protocols for HIV/AIDS treatment, prevention, and exposure</p></div></li><li class="topic__listitem"><span id="v77995852" class="anchor"></span><div class="para"> <p>American Academy of Pediatrics: <a rel="nofollow" target="_blank" href="https://pubmed.ncbi.nlm.nih.gov/23796739/">Transitioning HIV-Infected Youth Into Adult Health Care</a></p></div></li><li class="topic__listitem"><span id="v37571447" class="anchor"></span><div class="para"> <p>Perinatal HIV Consultation and Referral Services Hotline 1-888-HIV-8765 (1-888-448-8765): Free 24-hour clinical consultation and advice on treating pregnant women with HIV infection and their infants</p></div></li></ul></div> </div> </section>
 
 <section class="topic__section">
 <div class="topicswitch topic__patient-education topic__patient-education--bottom hide-on-print" data-icd9="042;795.71">
 <div class="topic__patient-education--container">
 <div class="topic__patient-education--icon"></div>
 <div class="topic__patient-education--text">
 View PATIENT EDUCATION
 </div>
 </div>
 </div>
 </section>
</div>
<script type="text/javascript">
 $(document).ready(function () {
 $(document).on('click', '.topicswitch', function (e) {
 e.preventDefault();
 $.ajax({
 url: '/Custom/Edition/GetSwitchUrl',
 type: "GET",
 dataType: "json",
 data: {
 icd9: '042;795.71',
 title: 'Human Immunodeficiency Virus (HIV) Infection in Infants and Children',
 itemGuid: '6ea530b9-c85e-4653-b466-245f2a0e10ea'
 }
 }).done(function (data) {
 
 // redirect
 location.href = data.href;
 }).fail(function (jqxhr, textStatus, errorThrown) {
 console.error(errorThrown);
 });
 });
 });
</script>
 </article>
 <div class="copyright-print">
 <div class="copyright-print--logo">
<img src="./Content/Images/msd_foot_logo.png" alt="" class="badge msd" loading="lazy" width="240" height="71">
 </div>
 <div class="copyright-print--text">
 Copyright © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
 </div>
 </div>
 <section class="bottomnav__wrapper hide-on-print" style="display:none">
 
<div class="bottomnav no-print side-by-side">
 <div class="bottomnav__gotolink bottomnav__gotolink--previous">
 <a href="./{DD0853E8-46C1-40A1-82F8-CCB793B61953}.html">
 <div class="bottomnav__gotolink--content">
 <div class="bottomnav__icon bottomnav__icon--previous"></div>
 <div class="bottomnav__linktext">How To Do Suprapubic Aspiration of the Bladder in a Child</div>
 </div>
 </a>
 </div>
 
 <div class="bottomnav__gotolink bottomnav__gotolink--next">
 <a href="./{74B30271-8B50-4566-A065-33B80B68A8EF}.html">
 <div class="bottomnav__gotolink--content">
 <div class="bottomnav__linktext">Antiretroviral Therapy in Children</div>
 <div class="bottomnav__icon bottomnav__icon--next"></div>
 </div>
 </a>
 </div>
</div>
 </section>
</div>
<span id="showpopup"></span>
<span id="showchildpopup"></span>
<div class="box box--marketing marketing-block orderize__candidate hide-on-print" data-orderize="1301">
 <div class="marketing-block-wrapper">
 <div class="box__header">
 <div class="box__headertext"></div>
 </div>
 <div class="box__content">
<div class="marketingblock-quiz hide-on-print">
<div class="marketingblock-quiz-img">
<img alt="quiz link" src="./Content/Images/Redesign/quizzes_lightbulb_red.png" loading="lazy" width="64" height="52">
</div>
<div class="marketingblock-quiz-desc">
<h4>Test your knowledge</h4>
<a href="./{976709AA-1FDC-4953-8B32-2A9E9973AC21}.html">Take a Quiz! </a></div>
</div> </div>
 </div>
</div>
<script type="text/javascript">
 $('img[usemap]').rwdImageMaps();
</script>
<div class="box box--marketing marketing-block orderize__candidate hide-on-print" data-orderize="1550">
 <div class="marketing-block-wrapper">
 <div class="box__header">
 <div class="box__headertext"></div>
 </div>
 <div class="box__content">
 <div class="box__content--mobile">
 <img loading="lazy" src="./~/media/manual/marketing/mobileqr/en_msd_mobile_pro_326.gif" alt="" id="daf16074-3747-4d09-8115-96262b6e790b_mobile" usemap="#daf16074-3747-4d09-8115-96262b6e790b_mobile" width="326" height="90">
 <map name="daf16074-3747-4d09-8115-96262b6e790b_mobile">
 <area shape="RECT" coords="176,79,90,53" href="https://play.google.com/store/apps/details?id=com.msd.professional&referrer=utm_source%3DMMWeb%26utm_medium%3Dbanner%26utm_content%3DTopic1Vertical%26utm_campaign%3DWebAppAds" target="_blank" alt="iOS">
<area shape="RECT" coords="202,51,297,80" href="https://apps.apple.com/app/msd-professional-version/id1123678257" target="_blank" alt="ANDROID">
 </map>
 </div>
 <div class="box__content--tablet">
 <img loading="lazy" src="./~/media/manual/marketing/mobileqr/en_msd_mobile_pro_326.gif" alt="" id="daf16074-3747-4d09-8115-96262b6e790b_tablet" usemap="#daf16074-3747-4d09-8115-96262b6e790b_tablet" width="326" height="90">
 <map name="daf16074-3747-4d09-8115-96262b6e790b_tablet">
 <area shape="RECT" coords="176,79,90,53" href="https://play.google.com/store/apps/details?id=com.msd.professional&referrer=utm_source%3DMMWeb%26utm_medium%3Dbanner%26utm_content%3DTopic1Vertical%26utm_campaign%3DWebAppAds" target="_blank" alt="iOS">
<area shape="RECT" coords="202,51,297,80" href="https://apps.apple.com/app/msd-professional-version/id1123678257" target="_blank" alt="ANDROID">
 </map>
 </div>
 <div class="box__content--desktop">
 <img loading="lazy" src="./~/media/manual/marketing/mobileqr/en_msd_mobile_qr_pro_326.gif" alt="" id="daf16074-3747-4d09-8115-96262b6e790b_desktop" usemap="#daf16074-3747-4d09-8115-96262b6e790b_desktop" width="326" height="90">
 <map name="daf16074-3747-4d09-8115-96262b6e790b_desktop">
 <area shape="RECT" coords="176,79,90,53" href="https://apps.apple.com/app/msd-professional-version/id1123678257" target="_blank" alt="iOS">
<area shape="RECT" coords="202,51,297,80" href="https://play.google.com/store/apps/details?id=com.msd.professional&referrer=utm_source%3DMMWeb%26utm_medium%3Dbanner%26utm_content%3DTopic1Vertical%26utm_campaign%3DWebAppAds" target="_blank" alt="ANDROID">
 </map>
 </div>
 </div>
 </div>
</div>
<script type="text/javascript">
 $('img[usemap]').rwdImageMaps();
</script>
<a id="autoload" role="button" tabindex="-1"></a>
 <div class="autoload-placeholder hide-on-print" name="Up Next:"></div>
 <a class="next-topic hide-on-print" role="button" aria-hidden="true"></a>
 </div>
</div>
 </section>
 
 </main>
 
 <div class="l-layer l-layer--topscroll">
 <div class="topscroll topscroll--hidden">
 <div class="topscroll__container">
 <div class="topscroll__button">
 <div class="topscroll__content">
 <i class="topscroll__arrow"></i>
 TOP
 </div>
 </div>
 </div>
 <div class="topscroll__bar"></div>
</div>
 </div>
 </div>
 
 <div class="flyout hide-on-print" tabindex="0">
 <nav class="flyout__menu" role="application" aria-label="Menu">
 </nav>
 </div>
 <div class="print">
 <div id="print__content">
 </div>
 </div>
 <div class="multimedia__popup l-viewport" data-bind="component: { name: 'multimedia-popup'}">
 <!-- Placeholder for media players. -->
</div>
 <script type="text/javascript">
 //global value for translating the 'Read More' value
 var MMReadMore = "read more";
 var MMMaxTeaseCount = 250;
 </script>
 
 
<div class="sticky-footer hide-on-print">
 <ul>
 <li class="sticky-footer--topic">
 <button aria-label="Topic" class="sticky-footer-topicmenu" aria-expanded="false">
 <span class="footer-bar__icon topic-ico"></span>
 </button>
 <div class="footer-expand-cont footer-parent-cont topicList">
 <button aria-label="close" class="footer-expand-cont__close"></button>
 <div class="footer-topicList-wrapper">
 <div class="in-this-topic-sidebar">
 <div class="box__header">
 <span>IN THIS TOPIC</span>
 <span class="in-this-topic-togggle-btn" aria-label="IN THIS TOPIC" aria-expanded="false"></span>
 </div>
 </div>
 </div>
 </div>
 </li>
 <li class="sticky-footer--version-switcher nontopicpage">
 <a data-id="HE" href="/home" target="_self" aria-label="Version Switch">
 <span class="footer-bar__icon versionSwitcher-ico"></span>
 </a>
 </li>
 <li class="sticky-footer--version-switcher topicpage">
 <a class="topicswitch" href="#" target="_self" aria-label="Version Switch">
 <span class="footer-bar__icon versionSwitcher-ico"></span>
 </a>
 </li>
 <li class="sticky-footer--vetFilter"></li>
 <li>
 <a href="./{218352E5-01E6-4C81-9542-33CF998B22E9}.html" target="_self" aria-label="Resources">
 <span class="footer-bar__icon resources-ico"></span>
 </a>
 </li>
 <li class="sticky-footer--social">
 <aside class="actiontoolbar hide-on-print">
 <!--<a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--bookmark" onclick="bookmarkPage(this);" href="#"></a>-->
 <a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--download" style="display: none" href="#"></a>
 
 <ul>
 <li class="a2a_kit a2a_kit_size_32 a2a_default_style" data-a2a-icon-color="transparent,transparent">
 <a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--share a2a_dd" href="https://www.addtoany.com/share" rel="noopener" role="button" aria-expanded="false" aria-label="Share in"></a>
 </li>
 <li>
 <a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--print" href="#" onclick="window.print(); MManual.analytics.notifyOpenModal(MManual.analytics.eventPrintAnArticle);" role="button" title="print"></a>
 </li>
 <li class="a2a_kit a2a_kit_size_32 a2a_default_style" data-a2a-icon-color="transparent,transparent">
 <a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--email a2a_button_email" href="#" role="button" title="Mail"></a>
 </li>
 <li class="scroll-to-top">
 <a href="#top" role="button" aria-label="Go To Top" title="Go To Top"><span class="scroll-to-top-img"></span></a>
 </li>
 <li class="scroll-to-bottom">
 <a href="#" role="button" aria-label="Go To Top"><span class="scroll-to-bottom-img"></span></a>
 </li>
 </ul>
 </aside>
 </li>
 <li class="sticky-footer--moreCont">
 <button aria-label="More" class="sticky-footer--more" aria-expanded="false">
 <span class="footer-bar__icon more-ico"></span>
 </button>
 <div class="footer-expand-cont more-footer-container">
 <ul>
 <li>
 <a href="./{F01A9F26-96C0-45E2-8ACC-403ACDB78022}.html" target="_self" aria-label="Home">
 <span class="footer-bar__icon home-ico"></span>
 </a>
 </li>
 <li>
 <a href="./{FF41B506-E267-4A7F-8357-F8C0474115E2}.html" target="_self" aria-label="info">
 <span class="footer-bar__icon info-ico"></span>
 </a>
 </li>
 <li>
 <button aria-label="Settings" aria-expanded="false">
 <span class="footer-bar__icon settings-ico"></span>
 </button>
 <div class="footer-sub-cont settings-footer-cont"></div>
 </li>
 <li class="language-footer">
 <button aria-label="Select Language" aria-expanded="false">
 <span class="footer-bar__icon language-ico"></span>
 </button>
 <div class="footer-sub-cont language-footer-cont"></div>
 </li>
 </ul>
 </div>
 </li>
 </ul>
</div>
 
 
 
<!--[if (gte IE 9)|!(IE)]><!-->
<script type="text/javascript">
 function downloadJSAtOnload() {
 
 MManual.deferredScripts.push("./bundles/redesign/libsdeferredjsv4.1.2.2-13178e13ca.js?v=0HKp-yFnKaDEueCLP27J6D4rHb3-AAxm6cmzEE3Gmb41");
 
 
 MManual.deferredScripts.push("./bundles/redesign/mmanualdeferredjsv4.1.2.2-13178e13ca.js?v=-hMvtQA9NJy1WdyRhBfBFzrPaWL44SkinQI4pIY9AWk1");
 
 
 MManual.deferredScripts.push("./bundles/redesign/mmanualTopicdeferredjsv4.1.2.2-13178e13ca.js?v=wDzP134aC3i-5gwHvRAsARMyhcs_em3XWcSsRyzYpYQ1");
 
 MManual.utils.loadScripts(MManual.deferredScripts);
 }
 $(document).ready(downloadJSAtOnload);
</script>
<!--<![endif]-->
<!--[if lt IE 9]>
 
 <script src="/Content/Scripts/Lib/mediaelement-and-player.min.js?v4.1.2.2-13178e13ca" type="text/javascript"></script>
 <script src="/Content/Scripts/Lib/zoomerang.js?v4.1.2.2-13178e13ca" type="text/javascript"></script>
 <script type="text/javascript">
 function downloadJSAtOnload() {
 
 MManual.deferredScripts.push("/bundles/redesign/mmanualdeferredjsv4.1.2.2-13178e13ca.js?v=-hMvtQA9NJy1WdyRhBfBFzrPaWL44SkinQI4pIY9AWk1");
 
 
 MManual.deferredScripts.push("/bundles/redesign/ie8libsdeferredjsv4.1.2.2-13178e13ca.js?v=0HKp-yFnKaDEueCLP27J6D4rHb3-AAxm6cmzEE3Gmb41");
 
 
 MManual.deferredScripts.push("/bundles/redesign/mmanualTopicdeferredjsv4.1.2.2-13178e13ca.js?v=wDzP134aC3i-5gwHvRAsARMyhcs_em3XWcSsRyzYpYQ1");
 
 for (var i = 0; i < MManual.deferredScripts.length; i++) {
 var element = document.createElement("script");
 element.src = MManual.deferredScripts[i];
 element.classList.add("optanon-category-C0002");
 document.body.appendChild(element);
 }
 }
 $(document).ready(downloadJSAtOnload);
 </script>
<![endif]-->
 <!-- Current instance name : ue-p-sc-cd01
 Current application version : 4.1.2.2-13178e13ca
 -->
 <!--[if (gte IE 9)|!(IE)]><!-->
<script src="./bundles/redesign/libsEndjsv4.1.2.2-13178e13ca.js?v=NWrOPHpqntlKhYlvryw8nEPZpRaWQrScEY3i127KnfI1"></script>
<!--<![endif]-->
<input id="MediaFramework_ItemId" name="MediaFramework_ItemId" type="hidden" value="6EA530B9C85E4653B466245F2A0E10EA">
<div id="hiddentblcontents" style="display:none"><div id='hidden_v49373475'> <div data-mmanualobjecttype="Table" class="table-box"> <span id="v49373476"></span> <div class="TableFullPage" id="v49373475"> <h3 class="title">Antiretroviral Dosing for Neonates With Perinatal HIV Exposure</h3> <div class="tableWrapper"> <table> <tbody><tr class="odd" tablehead1=""><td><p class="tableHead1"><span id="v49373508" class="anchor"></span><div class="para"> <p><b>Medication (Oral)*</b></p></div></p></td><td><p class="tableHead1"><span id="v49373511" class="anchor"></span><div class="para"> <p><b>Low-Risk Prophylaxis (4 Weeks Total Treatment)</b></p></div></p></td><td><p class="tableHead1"><span id="v49373514" class="anchor"></span><div class="para"> <p><b>High-Risk Therapy (6 Weeks Total Treatment)‡</b></p></div></p></td></tr><tr class="even"><td><span id="v49373517" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Zidovudine</span> (ZDV)†</p></div></td><td><span id="v49373519" class="anchor"></span><div class="para"> <p>≥ 35 weeks gestation at birth: ZDV 4 mg/kg twice daily</p></div></td><td><span id="v49373521" class="anchor"></span><div class="para"> <p>≥ 35 weeks gestation at birth: ZDV 4 mg/kg twice daily</p></div></td></tr><tr class="odd"><td><span id="v49373524" class="anchor"></span><div class="para"> <p></div></td><td><span id="v49373526" class="anchor"></span><div class="para"> <p>≥ 30 to < 35 weeks gestation at birth:></p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v49373529" class="anchor"></span><div class="para"> <p>Birth to age 2 weeks: ZDV 2 mg/kg twice daily</p></div></li><li class="topic__listitem"><span id="v49373531" class="anchor"></span><div class="para"> <p>Age 2−4 weeks: ZDV 3 mg/kg twice daily</p></div></li></ul></div></td><td><span id="v49373533" class="anchor"></span><div class="para"> <p>≥ 30 to < 35 weeks gestation at></p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v49373536" class="anchor"></span><div class="para"> <p>Birth to age 2 weeks: ZDV 2 mg/kg twice daily</p></div></li><li class="topic__listitem"><span id="v49373538" class="anchor"></span><div class="para"> <p>Age 2–6 weeks: ZDV 3 mg/kg twice daily</p></div></li></ul></div></td></tr><tr class="even"><td><span id="v49373541" class="anchor"></span><div class="para"> <p></div></td><td><span id="v49373543" class="anchor"></span><div class="para"> <p>< 30 weeks gestation at birth:></p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v49373546" class="anchor"></span><div class="para"> <p>ZDV 2 mg/kg twice daily</p></div></li></ul></div></td><td><span id="v49373548" class="anchor"></span><div class="para"> <p>< 30 weeks gestation at birth:></p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v49373551" class="anchor"></span><div class="para"> <p>Birth to age 4 weeks: ZDV 2 mg/kg twice daily for 4 weeks</p></div></li><li class="topic__listitem"><span id="x000389" class="anchor"></span><div class="para"> <p>Age 4–6 weeks: ZDV 3 mg/kg twice daily</p></div></li></ul></div></td></tr><tr class="odd"><td><span id="v49373554" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Lamivudine</span> (3TC)</p></div></td><td><span id="v49373556" class="anchor"></span><div class="para"> <p>Not applicable</p></div></td><td><span id="v49373558" class="anchor"></span><div class="para"> <p>≥ 32 weeks gestation at birth:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v49373561" class="anchor"></span><div class="para"> <p>Birth to age 4 weeks: 3TC 2 mg/kg twice daily</p></div></li><li class="topic__listitem"><span id="v49373563" class="anchor"></span><div class="para"> <p>Age 4–6 weeks: 3TC 4 mg/kg twice daily</p></div></li></ul></div></td></tr><tr class="even"><td><span id="v49373578" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Nevirapine</span> (NVP)</p></div></td><td><span id="v49373580" class="anchor"></span><div class="para"> <p>Not applicable</p></div></td><td><span id="v49373582" class="anchor"></span><div class="para"> <p>≥ 37 weeks gestation at birth: </p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v49373585" class="anchor"></span><div class="para"> <p>NVP 6 mg/kg twice daily</p></div></li></ul></div><span id="v49373586" class="anchor"></span><div class="para"> <p>34 to < 37 weeks gestation at birth:></p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v49373589" class="anchor"></span><div class="para"> <p>Birth to age 1 week: NVP 4 mg/kg twice daily </p></div></li><li class="topic__listitem"><span id="v49373591" class="anchor"></span><div class="para"> <p>Age 1–6 weeks: NVP 6 mg/kg twice daily</p></div></li></ul></div><span id="x000548" class="anchor"></span><div class="para"> <p>32 to 34 weeks gestation at birth:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="x000549" class="anchor"></span><div class="para"> <p>Birth to age 2 weeks: NVP 2 mg/kg twice daily</p></div></li><li class="topic__listitem"><span id="x000550" class="anchor"></span><div class="para"> <p>Age 2–4 weeks: NVP 4 mg/kg twice daily</p></div></li><li class="topic__listitem"><span id="x000551" class="anchor"></span><div class="para"> <p>Age 4–6 weeks: NVP 6 mg/kg twice daily </p></div></li></ul></div></td></tr><tr class="odd"><td><span id="v49373594" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Raltegravir</span> (RAL)</p></div></td><td><span id="v49373596" class="anchor"></span><div class="para"> <p>Not applicable</p></div></td><td><span id="v49373598" class="anchor"></span><div class="para"> <p>≥ 37 weeks gestation at birth and weighing ≥ 2 kg: </p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v49373601" class="anchor"></span><div class="para"> <p>Birth to age 1 week: About 1.5 mg/kg once a day</p></div></li><li class="topic__listitem"><span id="v49373603" class="anchor"></span><div class="para"> <p>Age 1–4 weeks: About 3 mg/kg twice daily </p></div></li><li class="topic__listitem"><span id="v49373605" class="anchor"></span><div class="para"> <p>Age 4–6 weeks: About 6 mg/kg twice daily</p></div></li></ul></div></td></tr></tbody> <tfoot><tr><td colspan="3"><span id="v49373484" class="anchor"></span><div class="para"> <p>* ARV medications should begin as soon as possible, preferably within 6 to 12 hours of delivery. See table <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v49373412" data-toggle="tooltip" title="Neonatal Antiretroviral Management According to Risk of HIV Infection" data-id="a3325a6a-73d3-46ce-8654-9730de11e2ca" data-itemid="6ea530b9-c85e-4653-b466-245f2a0e10ea">Neonatal Antiretroviral Management According to Risk of HIV Infection</a><span id="a3325a6a-73d3-46ce-8654-9730de11e2ca" class="d-none xref"> <span class="tooltip-container"> <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v49373412"> <span class="tooltip-content"> <span class="tooltip-heading"> Neonatal Antiretroviral Management According to Risk of HIV Infection </span> <span class="tooltip-readmore"> </span> </span> <span class="tooltip-img"> <img src="/Content/Images/Redesign/table/icon_table_red.png?mh=160&mw=160" class="tooltip-Preview" alt="Neonatal Antiretroviral Management According to Risk of HIV Infection" loading="lazy"> </span> </a> </span> </span> for details regarding risk of perinatal transmission. Consulting an expert in pediatric HIV is recommended when selecting a therapy duration based on case-specific risk factors and interim HIV test results. For ARV management after the neonatal period, see the <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines">Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection</a> from the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV.</p></div></td></tr><tr><td colspan="3"><span id="x000552" class="anchor"></span><div class="para"> <p>† For neonates who cannot tolerate oral medications, ZDV can be given IV at 75% of the oral dose, using the same dosing interval.</p></div></td></tr><tr><td colspan="3"><span id="v49373492" class="anchor"></span><div class="para"> <p>‡ Further increases in ZDV and NVP doses are used for infants proved to have HIV infection and for infants receiving longer prophylaxis because of HIV exposure via breastfeeding, depending on their gestational and chronologic ages; an expert in pediatric HIV medicine should be consulted.</p></div></td></tr><tr><td colspan="3"><span id="v49373498" class="anchor"></span><div class="para"> <p>ART = antiretroviral therapy; ARV = antiretroviral.</p></div></td></tr><tr><td colspan="3"><span id="x000544" class="anchor"></span><div class="para"> <p>Adapted from the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV: <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines">Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection</a>. Accessed 02/08/2023.</p></div></td></tr></tfoot> </table> </div> </div> <button class="btn print" onclick="printPopupContent();"><i class="fa fa-print"></i></button> <button class="btn show-tab"><i class="fa fa-arrows-alt"></i><i class="fa fa-times"></i></button> </div></div><div id='hidden_v1108117'> <div data-mmanualobjecttype="Table" class="table-box"> <span id="v1108119"></span> <div class="TableHalfPage" id="v1108117"> <h3 class="title">Considerations for Use of Live Vaccines in Children With HIV Infection</h3> <div class="tableWrapper"> <table> <thead><tr tablehead1=""><th style='text-align:left' rowspan="2" scope='col'><p class="tableHead1"><span id="v1284771" class="anchor"></span><div class="para"> <p>Live Vaccine</p></div></p></th><th style='text-align:left' rowspan="2" scope='col'><p class="tableHead1"><span id="v1284774" class="anchor"></span><div class="para"> <p>Comments</p></div></p></th></tr></thead> <tbody><tr class="odd"><td><span id="v1108140" class="anchor"></span><div class="para"> <p>Bacille Calmette–Guérin (BCG)</p></div></td><td><span id="v9141104" class="anchor"></span><div class="para"> <p>Not recommended in United States; internationally, may be given to HIV-exposed neonates of unknown HIV infection status</p></div></td></tr><tr class="even"><td><span id="v1108151" class="anchor"></span><div class="para"> <p> <a href="./{B1673C7B-7F18-40EA-B742-954408B58A4A}.html" data-toggle="tooltip" title="Poliomyelitis Vaccine" data-id="801797e7-aeca-4bf7-9e6c-c01d285e1757" data-itemid="b1673c7b-7f18-40ea-b742-954408b58a4a">Oral poliovirus</a><span id="801797e7-aeca-4bf7-9e6c-c01d285e1757" class="d-none xref"> <span class="tooltip-container"> <a href="./{B1673C7B-7F18-40EA-B742-954408B58A4A}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Poliomyelitis Vaccine </span> Extensive vaccination has almost eradicated polio worldwide. But cases still occur in areas with incomplete immunization, such as sub-Saharan Africa and southern Asia. There are 3 serotypes... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span></p></div></td><td><span id="v1108153" class="anchor"></span><div class="para"> <p>Not available in United States but available in other parts of the world; inactivated polio vaccine given instead according to routine schedule*</p></div></td></tr><tr class="odd"><td><span id="v1108164" class="anchor"></span><div class="para"> <p> <a href="./{C3C97683-4BCF-46EE-9AAF-16CD253B0B2D}.html" data-toggle="tooltip" title="Influenza Vaccine" data-id="a1391377-0fe4-4dd4-a835-4ddd257cb0b9" data-itemid="c3c97683-4bcf-46ee-9aaf-16cd253b0b2d">Live-attenuated influenza</a><span id="a1391377-0fe4-4dd4-a835-4ddd257cb0b9" class="d-none xref"> <span class="tooltip-container"> <a href="./{C3C97683-4BCF-46EE-9AAF-16CD253B0B2D}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Influenza Vaccine </span> Based on recommendations by the World Health Organization and the Centers for Disease Control and Prevention (CDC), vaccines for influenza are modified annually to include the most prevalent... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span> (LAI)</p></div></td><td><span id="v1108166" class="anchor"></span><div class="para"> <p>Not recommended; inactivated vaccine given instead according to routine schedule*</p></div></td></tr><tr class="even"><td><span id="v1108177" class="anchor"></span><div class="para"> <p> <a href="./{9B13E380-5C42-4321-9C85-6675F98829E3}.html" data-toggle="tooltip" title="Measles, Mumps, and Rubella (MMR) Vaccine" data-id="0ad925da-228d-4512-a1ae-05aa042644ab" data-itemid="9b13e380-5c42-4321-9c85-6675f98829e3">Measles-mumps-rubella</a><span id="0ad925da-228d-4512-a1ae-05aa042644ab" class="d-none xref"> <span class="tooltip-container"> <a href="./{9B13E380-5C42-4321-9C85-6675F98829E3}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Measles, Mumps, and Rubella (MMR) Vaccine </span> The measles/mumps/rubella vaccines (MMR vaccines) effectively protect against all 3 infections ( measles, mumps, rubella). Historically, people who are given the MMR vaccine according to the... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span> (MMR)</p></div></td><td><span id="v1108179" class="anchor"></span><div class="para"> <p>Can be given to children whose CD4+ T-cell percentage is <span class='symbol'>≥</span> 15%</p></div><span id="v9141109" class="anchor"></span><div class="para"> <p>Administration at 12 months of age followed by second dose within 1–3 months enhances likelihood of response before HIV-induced immunologic decline occurs</p></div><span id="v9141110" class="anchor"></span><div class="para"> <p>MMR plus separate varicella-zoster virus (VZV) vaccine preferred over combined MMRV vaccine to minimize adverse effects</p></div><span id="v9141111" class="anchor"></span><div class="para"> <p>If risk of exposure to measles is increased (eg, during an outbreak), give at a younger age (eg, 6–9 months); however, this dose not considered part of routine schedule (ie, restart at 12 months)</p></div></td></tr><tr class="odd"><td><span id="v1108189" class="anchor"></span><div class="para"> <p>Rotavirus, live-attenuated</p></div></td><td><span id="v1108191" class="anchor"></span><div class="para"> <p>Limited evidence to date suggests that benefits of vaccine very likely outweigh its risks</p></div></td></tr><tr class="even"><td><span id="v1108200" class="anchor"></span><div class="para"> <p> <a href="./{41F4A30E-1F06-47DD-9164-627B28C74977}.html" data-toggle="tooltip" title="Varicella Vaccine" data-id="ce300d1f-d55b-4c4d-99ec-1e56b8f1ae1e" data-itemid="41f4a30e-1f06-47dd-9164-627b28c74977">Varicella-zoster virus</a><span id="ce300d1f-d55b-4c4d-99ec-1e56b8f1ae1e" class="d-none xref"> <span class="tooltip-container"> <a href="./{41F4A30E-1F06-47DD-9164-627B28C74977}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Varicella Vaccine </span> Varicella vaccination provides effective protection against varicella (chickenpox). It is not known how long protection against varicella lasts. But, live-virus vaccines, like the varicella... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span> (VZV)</p></div></td><td><span id="v1108202" class="anchor"></span><div class="para"> <p>Can be given to children whose CD4+ T-cell percentage is <span class='symbol'>≥</span> 15%</p></div><span id="v9141112" class="anchor"></span><div class="para"> <p>Administration at 12 months of age followed by second dose within 1–3 months enhances likelihood of response before HIV-induced immunologic decline occurs</p></div><span id="v9141113" class="anchor"></span><div class="para"> <p>MMR plus separate VZV vaccine preferred over combined MMRV vaccine to minimize adverse effects</p></div></td></tr></tbody> <tfoot><tr><td colspan="2"><span id="v37571393" class="anchor"></span><div class="para"> <p>* Given according to the usual <a href="./{4B587529-6EBC-4349-ABC8-3F78E4E81AE9}.html#v82347972" data-toggle="tooltip" title="Childhood Vaccination Schedules" data-id="f3fefe39-447d-4b6b-bbbe-8c94d6aa1849" data-itemid="4b587529-6ebc-4349-abc8-3f78e4e81ae9">pediatric immunization schedule</a><span id="f3fefe39-447d-4b6b-bbbe-8c94d6aa1849" class="d-none xref"> <span class="tooltip-container"> <a href="./{4B587529-6EBC-4349-ABC8-3F78E4E81AE9}.html#v82347972"> <span class="tooltip-content"> <span class="tooltip-heading"> Childhood Vaccination Schedules </span> Vaccination has been extremely effective in preventing serious disease and in improving health worldwide. Because of vaccines, infections that were once very common and/or fatal (eg, smallpox... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>.</p></div></td></tr><tr><td colspan="2"><span id="v37571398" class="anchor"></span><div class="para"> <p>MMRV = measles-mumps-rubella-varicella.</p></div></td></tr></tfoot> </table> </div> </div> <button class="btn print" onclick="printPopupContent();"><i class="fa fa-print"></i></button> <button class="btn show-tab"><i class="fa fa-arrows-alt"></i><i class="fa fa-times"></i></button> </div></div><div id='hidden_v49373218'> <div data-mmanualobjecttype="Table" class="table-box"> <span id="v49373219"></span> <div class="TableHalfPage" id="v49373218"> <h3 class="title">Immunologic Categories (HIV Infection Stages) for Children <span class='symbol'></span> 13 Years With HIV Infection Based on Age-Specific CD4+ T-Cell Count or Percentage</h3> <div class="tableWrapper"> <table> <thead><tr tablehead1=""><th style='text-align:left' rowspan="2" scope='col'><p class="tableHead1"><span id="v49373232" class="anchor"></span><div class="para"> <p>Immunologic Categories (Stages)*</p></div></p></th><th style='text-align:left' colspan="2" scope='col'><p class="tableHead1"><span id="v49373235" class="anchor"></span><div class="para"> <p>< 1="" year=""></p></div></p></th><th style='text-align:left' colspan="2" scope='col'><p class="tableHead1"><span id="v49373238" class="anchor"></span><div class="para"> <p>1 to < 6=""></p></div></p></th><th style='text-align:left' colspan="2" scope='col'><p class="tableHead1"><span id="v49373241" class="anchor"></span><div class="para"> <p> ≥ 6 years</p></div></p></th></tr><tr tablehead1=""><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373245" class="anchor"></span><div class="para"> <p>Cells/mcL</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373248" class="anchor"></span><div class="para"> <p>%</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373251" class="anchor"></span><div class="para"> <p>Cells/mcL</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373254" class="anchor"></span><div class="para"> <p>%</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373257" class="anchor"></span><div class="para"> <p>Cells/mcL</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373260" class="anchor"></span><div class="para"> <p>%</p></div></p></th></tr></thead> <tbody><tr class="odd"><td><span id="v49373271" class="anchor"></span><div class="para"> <p>1</p></div></td><td><span id="v49373273" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 1500</p></div></td><td><span id="v49373275" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 34</p></div></td><td><span id="v49373277" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 1000</p></div></td><td><span id="v49373279" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 30</p></div></td><td><span id="v49373281" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 500</p></div></td><td><span id="v49373283" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 26</p></div></td></tr><tr class="even"><td><span id="v49373286" class="anchor"></span><div class="para"> <p>2</p></div></td><td><span id="v49373288" class="anchor"></span><div class="para"> <p>750–1499</p></div></td><td><span id="v49373290" class="anchor"></span><div class="para"> <p>26–33</p></div></td><td><span id="v49373292" class="anchor"></span><div class="para"> <p>500–999</p></div></td><td><span id="v49373294" class="anchor"></span><div class="para"> <p>22–29</p></div></td><td><span id="v49373296" class="anchor"></span><div class="para"> <p>200–499</p></div></td><td><span id="v49373298" class="anchor"></span><div class="para"> <p>14–25</p></div></td></tr><tr class="odd"><td><span id="v49373301" class="anchor"></span><div class="para"> <p>3</p></div></td><td><span id="v49373303" class="anchor"></span><div class="para"> <p><span class='symbol'></span> 750</p></div></td><td><span id="v49373305" class="anchor"></span><div class="para"> <p><span class='symbol'></span> 26</p></div></td><td><span id="v49373307" class="anchor"></span><div class="para"> <p><span class='symbol'></span> 500</p></div></td><td><span id="v49373309" class="anchor"></span><div class="para"> <p><span class='symbol'></span> 22</p></div></td><td><span id="v49373311" class="anchor"></span><div class="para"> <p><span class='symbol'></span> 200</p></div></td><td><span id="v49373313" class="anchor"></span><div class="para"> <p><span class='symbol'></span> 14</p></div></td></tr></tbody> <tfoot><tr><td colspan="7"><span id="v49373264" class="anchor"></span><div class="para"> <p>* The stage is based primarily on the CD4 cell count. The CD4 cell count takes precedence over the CD4 percentage, and the percentage is considered only if the count is missing. If a stage 3–defining opportunistic infection has been diagnosed, the stage is 3 regardless of CD4 test results.</p></div></td></tr><tr><td colspan="7"><span id="v49373265" class="anchor"></span><div class="para"> <p>Adapted from <a rel="nofollow" target="_blank" href="https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6303a1.htm">Centers for Disease Control and Prevention</a>: Revised surveillance case definitions for HIV infection—United States, 2014. <i>Morbidity and Mortality Weekly Report</i> 63(RR–3):1–10, 2014.</p></div></td></tr></tfoot> </table> </div> </div> <button class="btn print" onclick="printPopupContent();"><i class="fa fa-print"></i></button> <button class="btn show-tab"><i class="fa fa-arrows-alt"></i><i class="fa fa-times"></i></button> </div></div><div id='hidden_v49373411'> <div data-mmanualobjecttype="Table" class="table-box"> <span id="v49373412"></span> <div class="TableFullPage" id="v49373411"> <h3 class="title">Neonatal Antiretroviral Management According to Risk of HIV Infection</h3> <div class="tableWrapper"> <table> <thead><tr tablehead1=""><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373421" class="anchor"></span><div class="para"> <p><b>Perinatal HIV Transmission Risk</b></p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373424" class="anchor"></span><div class="para"> <p><b>Maternal/Neonatal Factors</b></p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373427" class="anchor"></span><div class="para"> <p><b>Neonatal HIV Management*</b></p></div></p></th></tr></thead> <tbody><tr class="odd"><td><span id="v49373453" class="anchor"></span><div class="para"> <p>Low</p></div></td><td><span id="v49373455" class="anchor"></span><div class="para"> <p>Mother received ART during pregnancy. </p></div><span id="v49373456" class="anchor"></span><div class="para"> <p>Mother had sustained virologic suppression (as shown by HIV plasma viral load of < 50="" copies/ml)="" near="" delivery.=""></p></div><span id="v49373457" class="anchor"></span><div class="para"> <p>There were no concerns about mother's adherence to ART.</p></div></td><td><span id="v49373459" class="anchor"></span><div class="para"> <p><b>ARV prophylaxis:</b> ZDV for 4 weeks†</p></div></td></tr><tr class="even"><td><span id="v49373462" class="anchor"></span><div class="para"> <p>High</p></div></td><td><span id="v49373464" class="anchor"></span><div class="para"> <p>Mother did not receive ART during pregnancy.</p></div><span id="v49373465" class="anchor"></span><div class="para"> <p>Mother did not receive antepartum or intrapartum ARV medications.</p></div><span id="v49373466" class="anchor"></span><div class="para"> <p>Mother received only intrapartum ARV medications.</p></div><span id="v49373467" class="anchor"></span><div class="para"> <p>Mother received antepartum and intrapartum ARV medications but had an unknown or a detectable (≥ 50 copies/mL) HIV plasma viral load near delivery (particularly when delivery was vaginal).</p></div><span id="v49373468" class="anchor"></span><div class="para"> <p>Mother had acute or primary HIV infection during pregnancy or breastfeeding in which case breastfeeding should be stopped immediately.</p></div><span id="v49373469" class="anchor"></span><div class="para"> <p>Mother had unconfirmed HIV status with ≥ 1 positive HIV test at delivery or postpartum.‡</p></div></td><td><span id="v49373471" class="anchor"></span><div class="para"> <p><b>Three-drug presumptive HIV therapy:</b> ZDV, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>lamivudine</span>, and either <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>nevirapine</span> <i>or</i> <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>raltegravir</span> (combination given from birth to age 6 weeks)</p></div></td></tr></tbody> <tfoot><tr><td colspan="3"><span id="v49373431" class="anchor"></span><div class="para"> <p>* ARV medications should begin as soon as possible, preferably within 6 to 12 hours of delivery. See table <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v49373476" data-toggle="tooltip" title="Antiretroviral Dosing for Neonates With Perinatal HIV Exposure" data-id="9ffc9ca4-7061-470a-a9c2-c818db27f6f1" data-itemid="6ea530b9-c85e-4653-b466-245f2a0e10ea">Antiretroviral Dosing for Neonates With Perinatal HIV Exposure</a><span id="9ffc9ca4-7061-470a-a9c2-c818db27f6f1" class="d-none xref"> <span class="tooltip-container"> <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v49373476"> <span class="tooltip-content"> <span class="tooltip-heading"> Antiretroviral Dosing for Neonates With Perinatal HIV Exposure </span> <span class="tooltip-readmore"> </span> </span> <span class="tooltip-img"> <img src="/Content/Images/Redesign/table/icon_table_red.png?mh=160&mw=160" class="tooltip-Preview" alt="Antiretroviral Dosing for Neonates With Perinatal HIV Exposure" loading="lazy"> </span> </a> </span> </span> for dosing specifics.</p></div></td></tr><tr><td colspan="3"><span id="UniqueID_ehb_13l_lwb" class="anchor"></span><div class="para"> <p>† Some experts advise ZDV may be given for 2 weeks to select infants born at ≥ 37 weeks gestation to women who meet low-risk criteria, who have been given ART for more than 10 consecutive weeks, and who have maintained viral suppression for the duration of the pregnancy (see the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV's <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/management-infants-arv-hiv-exposure-infection?view=full">Management of Infants Born to People with HIV Infection</a>). </p></div></td></tr><tr><td colspan="3"><span id="v49373435" class="anchor"></span><div class="para"> <p>‡ Stop neonatal treatment if later testing confirms mother does not have HIV infection.</p></div></td></tr><tr><td colspan="3"><span id="v49373444" class="anchor"></span><div class="para"> <p>ART = antiretroviral therapy; ARV = antiretroviral; ZDV = <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>zidovudine</span>.</p></div></td></tr><tr><td colspan="3"><span id="v49373447" class="anchor"></span><div class="para"> <p>Adapted from the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV: <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines">Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection</a>. Accessed 02/08/2023.</p></div></td></tr></tfoot> </table> </div> </div> <button class="btn print" onclick="printPopupContent();"><i class="fa fa-print"></i></button> <button class="btn show-tab"><i class="fa fa-arrows-alt"></i><i class="fa fa-times"></i></button> </div></div></div></div><div id="hiddentblcontents" style="display:none"><div id='hidden_v49373218'> <div data-mmanualobjecttype="Table" class="table-box"> <span id="v49373219"></span> <div class="TableHalfPage" id="v49373218"> <h3 class="title">Immunologic Categories (HIV Infection Stages) for Children <span class='symbol'></span> 13 Years With HIV Infection Based on Age-Specific CD4+ T-Cell Count or Percentage</h3> <div class="tableWrapper"> <table> <thead><tr tablehead1=""><th style='text-align:left' rowspan="2" scope='col'><p class="tableHead1"><span id="v49373232" class="anchor"></span><div class="para"> <p>Immunologic Categories (Stages)*</p></div></p></th><th style='text-align:left' colspan="2" scope='col'><p class="tableHead1"><span id="v49373235" class="anchor"></span><div class="para"> <p>< 1="" year=""></p></div></p></th><th style='text-align:left' colspan="2" scope='col'><p class="tableHead1"><span id="v49373238" class="anchor"></span><div class="para"> <p>1 to < 6=""></p></div></p></th><th style='text-align:left' colspan="2" scope='col'><p class="tableHead1"><span id="v49373241" class="anchor"></span><div class="para"> <p> ≥ 6 years</p></div></p></th></tr><tr tablehead1=""><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373245" class="anchor"></span><div class="para"> <p>Cells/mcL</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373248" class="anchor"></span><div class="para"> <p>%</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373251" class="anchor"></span><div class="para"> <p>Cells/mcL</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373254" class="anchor"></span><div class="para"> <p>%</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373257" class="anchor"></span><div class="para"> <p>Cells/mcL</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373260" class="anchor"></span><div class="para"> <p>%</p></div></p></th></tr></thead> <tbody><tr class="odd"><td><span id="v49373271" class="anchor"></span><div class="para"> <p>1</p></div></td><td><span id="v49373273" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 1500</p></div></td><td><span id="v49373275" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 34</p></div></td><td><span id="v49373277" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 1000</p></div></td><td><span id="v49373279" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 30</p></div></td><td><span id="v49373281" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 500</p></div></td><td><span id="v49373283" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 26</p></div></td></tr><tr class="even"><td><span id="v49373286" class="anchor"></span><div class="para"> <p>2</p></div></td><td><span id="v49373288" class="anchor"></span><div class="para"> <p>750–1499</p></div></td><td><span id="v49373290" class="anchor"></span><div class="para"> <p>26–33</p></div></td><td><span id="v49373292" class="anchor"></span><div class="para"> <p>500–999</p></div></td><td><span id="v49373294" class="anchor"></span><div class="para"> <p>22–29</p></div></td><td><span id="v49373296" class="anchor"></span><div class="para"> <p>200–499</p></div></td><td><span id="v49373298" class="anchor"></span><div class="para"> <p>14–25</p></div></td></tr><tr class="odd"><td><span id="v49373301" class="anchor"></span><div class="para"> <p>3</p></div></td><td><span id="v49373303" class="anchor"></span><div class="para"> <p><span class='symbol'></span> 750</p></div></td><td><span id="v49373305" class="anchor"></span><div class="para"> <p><span class='symbol'></span> 26</p></div></td><td><span id="v49373307" class="anchor"></span><div class="para"> <p><span class='symbol'></span> 500</p></div></td><td><span id="v49373309" class="anchor"></span><div class="para"> <p><span class='symbol'></span> 22</p></div></td><td><span id="v49373311" class="anchor"></span><div class="para"> <p><span class='symbol'></span> 200</p></div></td><td><span id="v49373313" class="anchor"></span><div class="para"> <p><span class='symbol'></span> 14</p></div></td></tr></tbody> <tfoot><tr><td colspan="7"><span id="v49373264" class="anchor"></span><div class="para"> <p>* The stage is based primarily on the CD4 cell count. The CD4 cell count takes precedence over the CD4 percentage, and the percentage is considered only if the count is missing. If a stage 3–defining opportunistic infection has been diagnosed, the stage is 3 regardless of CD4 test results.</p></div></td></tr><tr><td colspan="7"><span id="v49373265" class="anchor"></span><div class="para"> <p>Adapted from <a rel="nofollow" target="_blank" href="https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6303a1.htm">Centers for Disease Control and Prevention</a>: Revised surveillance case definitions for HIV infection—United States, 2014. <i>Morbidity and Mortality Weekly Report</i> 63(RR–3):1–10, 2014.</p></div></td></tr></tfoot> </table> </div> </div> <button class="btn print" onclick="printPopupContent();"><i class="fa fa-print"></i></button> <button class="btn show-tab"><i class="fa fa-arrows-alt"></i><i class="fa fa-times"></i></button> </div></div></div><div id="hiddentblcontents" style="display:none"><div id='hidden_v49373218'> <div data-mmanualobjecttype="Table" class="table-box"> <span id="v49373219"></span> <div class="TableHalfPage" id="v49373218"> <h3 class="title">Immunologic Categories (HIV Infection Stages) for Children <span class='symbol'></span> 13 Years With HIV Infection Based on Age-Specific CD4+ T-Cell Count or Percentage</h3> <div class="tableWrapper"> <table> <thead><tr tablehead1=""><th style='text-align:left' rowspan="2" scope='col'><p class="tableHead1"><span id="v49373232" class="anchor"></span><div class="para"> <p>Immunologic Categories (Stages)*</p></div></p></th><th style='text-align:left' colspan="2" scope='col'><p class="tableHead1"><span id="v49373235" class="anchor"></span><div class="para"> <p>< 1="" year=""></p></div></p></th><th style='text-align:left' colspan="2" scope='col'><p class="tableHead1"><span id="v49373238" class="anchor"></span><div class="para"> <p>1 to < 6=""></p></div></p></th><th style='text-align:left' colspan="2" scope='col'><p class="tableHead1"><span id="v49373241" class="anchor"></span><div class="para"> <p> ≥ 6 years</p></div></p></th></tr><tr tablehead1=""><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373245" class="anchor"></span><div class="para"> <p>Cells/mcL</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373248" class="anchor"></span><div class="para"> <p>%</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373251" class="anchor"></span><div class="para"> <p>Cells/mcL</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373254" class="anchor"></span><div class="para"> <p>%</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373257" class="anchor"></span><div class="para"> <p>Cells/mcL</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373260" class="anchor"></span><div class="para"> <p>%</p></div></p></th></tr></thead> <tbody><tr class="odd"><td><span id="v49373271" class="anchor"></span><div class="para"> <p>1</p></div></td><td><span id="v49373273" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 1500</p></div></td><td><span id="v49373275" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 34</p></div></td><td><span id="v49373277" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 1000</p></div></td><td><span id="v49373279" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 30</p></div></td><td><span id="v49373281" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 500</p></div></td><td><span id="v49373283" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 26</p></div></td></tr><tr class="even"><td><span id="v49373286" class="anchor"></span><div class="para"> <p>2</p></div></td><td><span id="v49373288" class="anchor"></span><div class="para"> <p>750–1499</p></div></td><td><span id="v49373290" class="anchor"></span><div class="para"> <p>26–33</p></div></td><td><span id="v49373292" class="anchor"></span><div class="para"> <p>500–999</p></div></td><td><span id="v49373294" class="anchor"></span><div class="para"> <p>22–29</p></div></td><td><span id="v49373296" class="anchor"></span><div class="para"> <p>200–499</p></div></td><td><span id="v49373298" class="anchor"></span><div class="para"> <p>14–25</p></div></td></tr><tr class="odd"><td><span id="v49373301" class="anchor"></span><div class="para"> <p>3</p></div></td><td><span id="v49373303" class="anchor"></span><div class="para"> <p><span class='symbol'></span> 750</p></div></td><td><span id="v49373305" class="anchor"></span><div class="para"> <p><span class='symbol'></span> 26</p></div></td><td><span id="v49373307" class="anchor"></span><div class="para"> <p><span class='symbol'></span> 500</p></div></td><td><span id="v49373309" class="anchor"></span><div class="para"> <p><span class='symbol'></span> 22</p></div></td><td><span id="v49373311" class="anchor"></span><div class="para"> <p><span class='symbol'></span> 200</p></div></td><td><span id="v49373313" class="anchor"></span><div class="para"> <p><span class='symbol'></span> 14</p></div></td></tr></tbody> <tfoot><tr><td colspan="7"><span id="v49373264" class="anchor"></span><div class="para"> <p>* The stage is based primarily on the CD4 cell count. The CD4 cell count takes precedence over the CD4 percentage, and the percentage is considered only if the count is missing. If a stage 3–defining opportunistic infection has been diagnosed, the stage is 3 regardless of CD4 test results.</p></div></td></tr><tr><td colspan="7"><span id="v49373265" class="anchor"></span><div class="para"> <p>Adapted from <a rel="nofollow" target="_blank" href="https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6303a1.htm">Centers for Disease Control and Prevention</a>: Revised surveillance case definitions for HIV infection—United States, 2014. <i>Morbidity and Mortality Weekly Report</i> 63(RR–3):1–10, 2014.</p></div></td></tr></tfoot> </table> </div> </div> <button class="btn print" onclick="printPopupContent();"><i class="fa fa-print"></i></button> <button class="btn show-tab"><i class="fa fa-arrows-alt"></i><i class="fa fa-times"></i></button> </div></div></div><div id="hiddentblcontents" style="display:none"><div id='hidden_v1108117'> <div data-mmanualobjecttype="Table" class="table-box"> <span id="v1108119"></span> <div class="TableHalfPage" id="v1108117"> <h3 class="title">Considerations for Use of Live Vaccines in Children With HIV Infection</h3> <div class="tableWrapper"> <table> <thead><tr tablehead1=""><th style='text-align:left' rowspan="2" scope='col'><p class="tableHead1"><span id="v1284771" class="anchor"></span><div class="para"> <p>Live Vaccine</p></div></p></th><th style='text-align:left' rowspan="2" scope='col'><p class="tableHead1"><span id="v1284774" class="anchor"></span><div class="para"> <p>Comments</p></div></p></th></tr></thead> <tbody><tr class="odd"><td><span id="v1108140" class="anchor"></span><div class="para"> <p>Bacille Calmette–Guérin (BCG)</p></div></td><td><span id="v9141104" class="anchor"></span><div class="para"> <p>Not recommended in United States; internationally, may be given to HIV-exposed neonates of unknown HIV infection status</p></div></td></tr><tr class="even"><td><span id="v1108151" class="anchor"></span><div class="para"> <p> <a href="./{B1673C7B-7F18-40EA-B742-954408B58A4A}.html" data-toggle="tooltip" title="Poliomyelitis Vaccine" data-id="801797e7-aeca-4bf7-9e6c-c01d285e1757" data-itemid="b1673c7b-7f18-40ea-b742-954408b58a4a">Oral poliovirus</a><span id="801797e7-aeca-4bf7-9e6c-c01d285e1757" class="d-none xref"> <span class="tooltip-container"> <a href="./{B1673C7B-7F18-40EA-B742-954408B58A4A}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Poliomyelitis Vaccine </span> Extensive vaccination has almost eradicated polio worldwide. But cases still occur in areas with incomplete immunization, such as sub-Saharan Africa and southern Asia. There are 3 serotypes... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span></p></div></td><td><span id="v1108153" class="anchor"></span><div class="para"> <p>Not available in United States but available in other parts of the world; inactivated polio vaccine given instead according to routine schedule*</p></div></td></tr><tr class="odd"><td><span id="v1108164" class="anchor"></span><div class="para"> <p> <a href="./{C3C97683-4BCF-46EE-9AAF-16CD253B0B2D}.html" data-toggle="tooltip" title="Influenza Vaccine" data-id="a1391377-0fe4-4dd4-a835-4ddd257cb0b9" data-itemid="c3c97683-4bcf-46ee-9aaf-16cd253b0b2d">Live-attenuated influenza</a><span id="a1391377-0fe4-4dd4-a835-4ddd257cb0b9" class="d-none xref"> <span class="tooltip-container"> <a href="./{C3C97683-4BCF-46EE-9AAF-16CD253B0B2D}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Influenza Vaccine </span> Based on recommendations by the World Health Organization and the Centers for Disease Control and Prevention (CDC), vaccines for influenza are modified annually to include the most prevalent... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span> (LAI)</p></div></td><td><span id="v1108166" class="anchor"></span><div class="para"> <p>Not recommended; inactivated vaccine given instead according to routine schedule*</p></div></td></tr><tr class="even"><td><span id="v1108177" class="anchor"></span><div class="para"> <p> <a href="./{9B13E380-5C42-4321-9C85-6675F98829E3}.html" data-toggle="tooltip" title="Measles, Mumps, and Rubella (MMR) Vaccine" data-id="0ad925da-228d-4512-a1ae-05aa042644ab" data-itemid="9b13e380-5c42-4321-9c85-6675f98829e3">Measles-mumps-rubella</a><span id="0ad925da-228d-4512-a1ae-05aa042644ab" class="d-none xref"> <span class="tooltip-container"> <a href="./{9B13E380-5C42-4321-9C85-6675F98829E3}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Measles, Mumps, and Rubella (MMR) Vaccine </span> The measles/mumps/rubella vaccines (MMR vaccines) effectively protect against all 3 infections ( measles, mumps, rubella). Historically, people who are given the MMR vaccine according to the... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span> (MMR)</p></div></td><td><span id="v1108179" class="anchor"></span><div class="para"> <p>Can be given to children whose CD4+ T-cell percentage is <span class='symbol'>≥</span> 15%</p></div><span id="v9141109" class="anchor"></span><div class="para"> <p>Administration at 12 months of age followed by second dose within 1–3 months enhances likelihood of response before HIV-induced immunologic decline occurs</p></div><span id="v9141110" class="anchor"></span><div class="para"> <p>MMR plus separate varicella-zoster virus (VZV) vaccine preferred over combined MMRV vaccine to minimize adverse effects</p></div><span id="v9141111" class="anchor"></span><div class="para"> <p>If risk of exposure to measles is increased (eg, during an outbreak), give at a younger age (eg, 6–9 months); however, this dose not considered part of routine schedule (ie, restart at 12 months)</p></div></td></tr><tr class="odd"><td><span id="v1108189" class="anchor"></span><div class="para"> <p>Rotavirus, live-attenuated</p></div></td><td><span id="v1108191" class="anchor"></span><div class="para"> <p>Limited evidence to date suggests that benefits of vaccine very likely outweigh its risks</p></div></td></tr><tr class="even"><td><span id="v1108200" class="anchor"></span><div class="para"> <p> <a href="./{41F4A30E-1F06-47DD-9164-627B28C74977}.html" data-toggle="tooltip" title="Varicella Vaccine" data-id="ce300d1f-d55b-4c4d-99ec-1e56b8f1ae1e" data-itemid="41f4a30e-1f06-47dd-9164-627b28c74977">Varicella-zoster virus</a><span id="ce300d1f-d55b-4c4d-99ec-1e56b8f1ae1e" class="d-none xref"> <span class="tooltip-container"> <a href="./{41F4A30E-1F06-47DD-9164-627B28C74977}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Varicella Vaccine </span> Varicella vaccination provides effective protection against varicella (chickenpox). It is not known how long protection against varicella lasts. But, live-virus vaccines, like the varicella... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span> (VZV)</p></div></td><td><span id="v1108202" class="anchor"></span><div class="para"> <p>Can be given to children whose CD4+ T-cell percentage is <span class='symbol'>≥</span> 15%</p></div><span id="v9141112" class="anchor"></span><div class="para"> <p>Administration at 12 months of age followed by second dose within 1–3 months enhances likelihood of response before HIV-induced immunologic decline occurs</p></div><span id="v9141113" class="anchor"></span><div class="para"> <p>MMR plus separate VZV vaccine preferred over combined MMRV vaccine to minimize adverse effects</p></div></td></tr></tbody> <tfoot><tr><td colspan="2"><span id="v37571393" class="anchor"></span><div class="para"> <p>* Given according to the usual <a href="./{4B587529-6EBC-4349-ABC8-3F78E4E81AE9}.html#v82347972" data-toggle="tooltip" title="Childhood Vaccination Schedules" data-id="f3fefe39-447d-4b6b-bbbe-8c94d6aa1849" data-itemid="4b587529-6ebc-4349-abc8-3f78e4e81ae9">pediatric immunization schedule</a><span id="f3fefe39-447d-4b6b-bbbe-8c94d6aa1849" class="d-none xref"> <span class="tooltip-container"> <a href="./{4B587529-6EBC-4349-ABC8-3F78E4E81AE9}.html#v82347972"> <span class="tooltip-content"> <span class="tooltip-heading"> Childhood Vaccination Schedules </span> Vaccination has been extremely effective in preventing serious disease and in improving health worldwide. Because of vaccines, infections that were once very common and/or fatal (eg, smallpox... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>.</p></div></td></tr><tr><td colspan="2"><span id="v37571398" class="anchor"></span><div class="para"> <p>MMRV = measles-mumps-rubella-varicella.</p></div></td></tr></tfoot> </table> </div> </div> <button class="btn print" onclick="printPopupContent();"><i class="fa fa-print"></i></button> <button class="btn show-tab"><i class="fa fa-arrows-alt"></i><i class="fa fa-times"></i></button> </div></div></div><div id="hiddentblcontents" style="display:none"><div id='hidden_v49373218'> <div data-mmanualobjecttype="Table" class="table-box"> <span id="v49373219"></span> <div class="TableHalfPage" id="v49373218"> <h3 class="title">Immunologic Categories (HIV Infection Stages) for Children <span class='symbol'></span> 13 Years With HIV Infection Based on Age-Specific CD4+ T-Cell Count or Percentage</h3> <div class="tableWrapper"> <table> <thead><tr tablehead1=""><th style='text-align:left' rowspan="2" scope='col'><p class="tableHead1"><span id="v49373232" class="anchor"></span><div class="para"> <p>Immunologic Categories (Stages)*</p></div></p></th><th style='text-align:left' colspan="2" scope='col'><p class="tableHead1"><span id="v49373235" class="anchor"></span><div class="para"> <p>< 1="" year=""></p></div></p></th><th style='text-align:left' colspan="2" scope='col'><p class="tableHead1"><span id="v49373238" class="anchor"></span><div class="para"> <p>1 to < 6=""></p></div></p></th><th style='text-align:left' colspan="2" scope='col'><p class="tableHead1"><span id="v49373241" class="anchor"></span><div class="para"> <p> ≥ 6 years</p></div></p></th></tr><tr tablehead1=""><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373245" class="anchor"></span><div class="para"> <p>Cells/mcL</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373248" class="anchor"></span><div class="para"> <p>%</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373251" class="anchor"></span><div class="para"> <p>Cells/mcL</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373254" class="anchor"></span><div class="para"> <p>%</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373257" class="anchor"></span><div class="para"> <p>Cells/mcL</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373260" class="anchor"></span><div class="para"> <p>%</p></div></p></th></tr></thead> <tbody><tr class="odd"><td><span id="v49373271" class="anchor"></span><div class="para"> <p>1</p></div></td><td><span id="v49373273" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 1500</p></div></td><td><span id="v49373275" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 34</p></div></td><td><span id="v49373277" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 1000</p></div></td><td><span id="v49373279" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 30</p></div></td><td><span id="v49373281" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 500</p></div></td><td><span id="v49373283" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 26</p></div></td></tr><tr class="even"><td><span id="v49373286" class="anchor"></span><div class="para"> <p>2</p></div></td><td><span id="v49373288" class="anchor"></span><div class="para"> <p>750–1499</p></div></td><td><span id="v49373290" class="anchor"></span><div class="para"> <p>26–33</p></div></td><td><span id="v49373292" class="anchor"></span><div class="para"> <p>500–999</p></div></td><td><span id="v49373294" class="anchor"></span><div class="para"> <p>22–29</p></div></td><td><span id="v49373296" class="anchor"></span><div class="para"> <p>200–499</p></div></td><td><span id="v49373298" class="anchor"></span><div class="para"> <p>14–25</p></div></td></tr><tr class="odd"><td><span id="v49373301" class="anchor"></span><div class="para"> <p>3</p></div></td><td><span id="v49373303" class="anchor"></span><div class="para"> <p><span class='symbol'></span> 750</p></div></td><td><span id="v49373305" class="anchor"></span><div class="para"> <p><span class='symbol'></span> 26</p></div></td><td><span id="v49373307" class="anchor"></span><div class="para"> <p><span class='symbol'></span> 500</p></div></td><td><span id="v49373309" class="anchor"></span><div class="para"> <p><span class='symbol'></span> 22</p></div></td><td><span id="v49373311" class="anchor"></span><div class="para"> <p><span class='symbol'></span> 200</p></div></td><td><span id="v49373313" class="anchor"></span><div class="para"> <p><span class='symbol'></span> 14</p></div></td></tr></tbody> <tfoot><tr><td colspan="7"><span id="v49373264" class="anchor"></span><div class="para"> <p>* The stage is based primarily on the CD4 cell count. The CD4 cell count takes precedence over the CD4 percentage, and the percentage is considered only if the count is missing. If a stage 3–defining opportunistic infection has been diagnosed, the stage is 3 regardless of CD4 test results.</p></div></td></tr><tr><td colspan="7"><span id="v49373265" class="anchor"></span><div class="para"> <p>Adapted from <a rel="nofollow" target="_blank" href="https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6303a1.htm">Centers for Disease Control and Prevention</a>: Revised surveillance case definitions for HIV infection—United States, 2014. <i>Morbidity and Mortality Weekly Report</i> 63(RR–3):1–10, 2014.</p></div></td></tr></tfoot> </table> </div> </div> <button class="btn print" onclick="printPopupContent();"><i class="fa fa-print"></i></button> <button class="btn show-tab"><i class="fa fa-arrows-alt"></i><i class="fa fa-times"></i></button> </div></div></div><div id="hiddentblcontents" style="display:none"><div id='hidden_v49373411'> <div data-mmanualobjecttype="Table" class="table-box"> <span id="v49373412"></span> <div class="TableFullPage" id="v49373411"> <h3 class="title">Neonatal Antiretroviral Management According to Risk of HIV Infection</h3> <div class="tableWrapper"> <table> <thead><tr tablehead1=""><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373421" class="anchor"></span><div class="para"> <p><b>Perinatal HIV Transmission Risk</b></p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373424" class="anchor"></span><div class="para"> <p><b>Maternal/Neonatal Factors</b></p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v49373427" class="anchor"></span><div class="para"> <p><b>Neonatal HIV Management*</b></p></div></p></th></tr></thead> <tbody><tr class="odd"><td><span id="v49373453" class="anchor"></span><div class="para"> <p>Low</p></div></td><td><span id="v49373455" class="anchor"></span><div class="para"> <p>Mother received ART during pregnancy. </p></div><span id="v49373456" class="anchor"></span><div class="para"> <p>Mother had sustained virologic suppression (as shown by HIV plasma viral load of < 50="" copies/ml)="" near="" delivery.=""></p></div><span id="v49373457" class="anchor"></span><div class="para"> <p>There were no concerns about mother's adherence to ART.</p></div></td><td><span id="v49373459" class="anchor"></span><div class="para"> <p><b>ARV prophylaxis:</b> ZDV for 4 weeks†</p></div></td></tr><tr class="even"><td><span id="v49373462" class="anchor"></span><div class="para"> <p>High</p></div></td><td><span id="v49373464" class="anchor"></span><div class="para"> <p>Mother did not receive ART during pregnancy.</p></div><span id="v49373465" class="anchor"></span><div class="para"> <p>Mother did not receive antepartum or intrapartum ARV medications.</p></div><span id="v49373466" class="anchor"></span><div class="para"> <p>Mother received only intrapartum ARV medications.</p></div><span id="v49373467" class="anchor"></span><div class="para"> <p>Mother received antepartum and intrapartum ARV medications but had an unknown or a detectable (≥ 50 copies/mL) HIV plasma viral load near delivery (particularly when delivery was vaginal).</p></div><span id="v49373468" class="anchor"></span><div class="para"> <p>Mother had acute or primary HIV infection during pregnancy or breastfeeding in which case breastfeeding should be stopped immediately.</p></div><span id="v49373469" class="anchor"></span><div class="para"> <p>Mother had unconfirmed HIV status with ≥ 1 positive HIV test at delivery or postpartum.‡</p></div></td><td><span id="v49373471" class="anchor"></span><div class="para"> <p><b>Three-drug presumptive HIV therapy:</b> ZDV, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>lamivudine</span>, and either <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>nevirapine</span> <i>or</i> <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>raltegravir</span> (combination given from birth to age 6 weeks)</p></div></td></tr></tbody> <tfoot><tr><td colspan="3"><span id="v49373431" class="anchor"></span><div class="para"> <p>* ARV medications should begin as soon as possible, preferably within 6 to 12 hours of delivery. See table <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v49373476" data-toggle="tooltip" title="Antiretroviral Dosing for Neonates With Perinatal HIV Exposure" data-id="9ffc9ca4-7061-470a-a9c2-c818db27f6f1" data-itemid="6ea530b9-c85e-4653-b466-245f2a0e10ea">Antiretroviral Dosing for Neonates With Perinatal HIV Exposure</a><span id="9ffc9ca4-7061-470a-a9c2-c818db27f6f1" class="d-none xref"> <span class="tooltip-container"> <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v49373476"> <span class="tooltip-content"> <span class="tooltip-heading"> Antiretroviral Dosing for Neonates With Perinatal HIV Exposure </span> <span class="tooltip-readmore"> </span> </span> <span class="tooltip-img"> <img src="/Content/Images/Redesign/table/icon_table_red.png?mh=160&mw=160" class="tooltip-Preview" alt="Antiretroviral Dosing for Neonates With Perinatal HIV Exposure" loading="lazy"> </span> </a> </span> </span> for dosing specifics.</p></div></td></tr><tr><td colspan="3"><span id="UniqueID_ehb_13l_lwb" class="anchor"></span><div class="para"> <p>† Some experts advise ZDV may be given for 2 weeks to select infants born at ≥ 37 weeks gestation to women who meet low-risk criteria, who have been given ART for more than 10 consecutive weeks, and who have maintained viral suppression for the duration of the pregnancy (see the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV's <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/management-infants-arv-hiv-exposure-infection?view=full">Management of Infants Born to People with HIV Infection</a>). </p></div></td></tr><tr><td colspan="3"><span id="v49373435" class="anchor"></span><div class="para"> <p>‡ Stop neonatal treatment if later testing confirms mother does not have HIV infection.</p></div></td></tr><tr><td colspan="3"><span id="v49373444" class="anchor"></span><div class="para"> <p>ART = antiretroviral therapy; ARV = antiretroviral; ZDV = <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>zidovudine</span>.</p></div></td></tr><tr><td colspan="3"><span id="v49373447" class="anchor"></span><div class="para"> <p>Adapted from the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV: <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines">Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection</a>. Accessed 02/08/2023.</p></div></td></tr></tfoot> </table> </div> </div> <button class="btn print" onclick="printPopupContent();"><i class="fa fa-print"></i></button> <button class="btn show-tab"><i class="fa fa-arrows-alt"></i><i class="fa fa-times"></i></button> </div></div></div><div id="hiddentblcontents" style="display:none"><div id='hidden_v49373475'> <div data-mmanualobjecttype="Table" class="table-box"> <span id="v49373476"></span> <div class="TableFullPage" id="v49373475"> <h3 class="title">Antiretroviral Dosing for Neonates With Perinatal HIV Exposure</h3> <div class="tableWrapper"> <table> <tbody><tr class="odd" tablehead1=""><td><p class="tableHead1"><span id="v49373508" class="anchor"></span><div class="para"> <p><b>Medication (Oral)*</b></p></div></p></td><td><p class="tableHead1"><span id="v49373511" class="anchor"></span><div class="para"> <p><b>Low-Risk Prophylaxis (4 Weeks Total Treatment)</b></p></div></p></td><td><p class="tableHead1"><span id="v49373514" class="anchor"></span><div class="para"> <p><b>High-Risk Therapy (6 Weeks Total Treatment)‡</b></p></div></p></td></tr><tr class="even"><td><span id="v49373517" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Zidovudine</span> (ZDV)†</p></div></td><td><span id="v49373519" class="anchor"></span><div class="para"> <p>≥ 35 weeks gestation at birth: ZDV 4 mg/kg twice daily</p></div></td><td><span id="v49373521" class="anchor"></span><div class="para"> <p>≥ 35 weeks gestation at birth: ZDV 4 mg/kg twice daily</p></div></td></tr><tr class="odd"><td><span id="v49373524" class="anchor"></span><div class="para"> <p></div></td><td><span id="v49373526" class="anchor"></span><div class="para"> <p>≥ 30 to < 35="" weeks="" gestation="" at="" birth:=""></p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v49373529" class="anchor"></span><div class="para"> <p>Birth to age 2 weeks: ZDV 2 mg/kg twice daily</p></div></li><li class="topic__listitem"><span id="v49373531" class="anchor"></span><div class="para"> <p>Age 2−4 weeks: ZDV 3 mg/kg twice daily</p></div></li></ul></div></td><td><span id="v49373533" class="anchor"></span><div class="para"> <p>≥ 30 to < 35="" weeks="" gestation="" at=""></p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v49373536" class="anchor"></span><div class="para"> <p>Birth to age 2 weeks: ZDV 2 mg/kg twice daily</p></div></li><li class="topic__listitem"><span id="v49373538" class="anchor"></span><div class="para"> <p>Age 2–6 weeks: ZDV 3 mg/kg twice daily</p></div></li></ul></div></td></tr><tr class="even"><td><span id="v49373541" class="anchor"></span><div class="para"> <p></div></td><td><span id="v49373543" class="anchor"></span><div class="para"> <p>< 30="" weeks="" gestation="" at="" birth:=""></p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v49373546" class="anchor"></span><div class="para"> <p>ZDV 2 mg/kg twice daily</p></div></li></ul></div></td><td><span id="v49373548" class="anchor"></span><div class="para"> <p>< 30="" weeks="" gestation="" at="" birth:=""></p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v49373551" class="anchor"></span><div class="para"> <p>Birth to age 4 weeks: ZDV 2 mg/kg twice daily for 4 weeks</p></div></li><li class="topic__listitem"><span id="x000389" class="anchor"></span><div class="para"> <p>Age 4–6 weeks: ZDV 3 mg/kg twice daily</p></div></li></ul></div></td></tr><tr class="odd"><td><span id="v49373554" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Lamivudine</span> (3TC)</p></div></td><td><span id="v49373556" class="anchor"></span><div class="para"> <p>Not applicable</p></div></td><td><span id="v49373558" class="anchor"></span><div class="para"> <p>≥ 32 weeks gestation at birth:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v49373561" class="anchor"></span><div class="para"> <p>Birth to age 4 weeks: 3TC 2 mg/kg twice daily</p></div></li><li class="topic__listitem"><span id="v49373563" class="anchor"></span><div class="para"> <p>Age 4–6 weeks: 3TC 4 mg/kg twice daily</p></div></li></ul></div></td></tr><tr class="even"><td><span id="v49373578" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Nevirapine</span> (NVP)</p></div></td><td><span id="v49373580" class="anchor"></span><div class="para"> <p>Not applicable</p></div></td><td><span id="v49373582" class="anchor"></span><div class="para"> <p>≥ 37 weeks gestation at birth: </p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v49373585" class="anchor"></span><div class="para"> <p>NVP 6 mg/kg twice daily</p></div></li></ul></div><span id="v49373586" class="anchor"></span><div class="para"> <p>34 to < 37="" weeks="" gestation="" at="" birth:=""></p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v49373589" class="anchor"></span><div class="para"> <p>Birth to age 1 week: NVP 4 mg/kg twice daily </p></div></li><li class="topic__listitem"><span id="v49373591" class="anchor"></span><div class="para"> <p>Age 1–6 weeks: NVP 6 mg/kg twice daily</p></div></li></ul></div><span id="x000548" class="anchor"></span><div class="para"> <p>32 to 34 weeks gestation at birth:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="x000549" class="anchor"></span><div class="para"> <p>Birth to age 2 weeks: NVP 2 mg/kg twice daily</p></div></li><li class="topic__listitem"><span id="x000550" class="anchor"></span><div class="para"> <p>Age 2–4 weeks: NVP 4 mg/kg twice daily</p></div></li><li class="topic__listitem"><span id="x000551" class="anchor"></span><div class="para"> <p>Age 4–6 weeks: NVP 6 mg/kg twice daily </p></div></li></ul></div></td></tr><tr class="odd"><td><span id="v49373594" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Raltegravir</span> (RAL)</p></div></td><td><span id="v49373596" class="anchor"></span><div class="para"> <p>Not applicable</p></div></td><td><span id="v49373598" class="anchor"></span><div class="para"> <p>≥ 37 weeks gestation at birth and weighing ≥ 2 kg: </p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v49373601" class="anchor"></span><div class="para"> <p>Birth to age 1 week: About 1.5 mg/kg once a day</p></div></li><li class="topic__listitem"><span id="v49373603" class="anchor"></span><div class="para"> <p>Age 1–4 weeks: About 3 mg/kg twice daily </p></div></li><li class="topic__listitem"><span id="v49373605" class="anchor"></span><div class="para"> <p>Age 4–6 weeks: About 6 mg/kg twice daily</p></div></li></ul></div></td></tr></tbody> <tfoot><tr><td colspan="3"><span id="v49373484" class="anchor"></span><div class="para"> <p>* ARV medications should begin as soon as possible, preferably within 6 to 12 hours of delivery. See table <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v49373412" data-toggle="tooltip" title="Neonatal Antiretroviral Management According to Risk of HIV Infection" data-id="a3325a6a-73d3-46ce-8654-9730de11e2ca" data-itemid="6ea530b9-c85e-4653-b466-245f2a0e10ea">Neonatal Antiretroviral Management According to Risk of HIV Infection</a><span id="a3325a6a-73d3-46ce-8654-9730de11e2ca" class="d-none xref"> <span class="tooltip-container"> <a href="./{6EA530B9-C85E-4653-B466-245F2A0E10EA}.html#v49373412"> <span class="tooltip-content"> <span class="tooltip-heading"> Neonatal Antiretroviral Management According to Risk of HIV Infection </span> <span class="tooltip-readmore"> </span> </span> <span class="tooltip-img"> <img src="/Content/Images/Redesign/table/icon_table_red.png?mh=160&mw=160" class="tooltip-Preview" alt="Neonatal Antiretroviral Management According to Risk of HIV Infection" loading="lazy"> </span> </a> </span> </span> for details regarding risk of perinatal transmission. Consulting an expert in pediatric HIV is recommended when selecting a therapy duration based on case-specific risk factors and interim HIV test results. For ARV management after the neonatal period, see the <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines">Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection</a> from the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV.</p></div></td></tr><tr><td colspan="3"><span id="x000552" class="anchor"></span><div class="para"> <p>† For neonates who cannot tolerate oral medications, ZDV can be given IV at 75% of the oral dose, using the same dosing interval.</p></div></td></tr><tr><td colspan="3"><span id="v49373492" class="anchor"></span><div class="para"> <p>‡ Further increases in ZDV and NVP doses are used for infants proved to have HIV infection and for infants receiving longer prophylaxis because of HIV exposure via breastfeeding, depending on their gestational and chronologic ages; an expert in pediatric HIV medicine should be consulted.</p></div></td></tr><tr><td colspan="3"><span id="v49373498" class="anchor"></span><div class="para"> <p>ART = antiretroviral therapy; ARV = antiretroviral.</p></div></td></tr><tr><td colspan="3"><span id="x000544" class="anchor"></span><div class="para"> <p>Adapted from the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV: <a rel="nofollow" target="_blank" href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines">Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection</a>. Accessed 02/08/2023.</p></div></td></tr></tfoot> </table> </div> </div> <button class="btn print" onclick="printPopupContent();"><i class="fa fa-print"></i></button> <button class="btn show-tab"><i class="fa fa-arrows-alt"></i><i class="fa fa-times"></i></button> </div></div></div></body>
<div class="bottomnav__gotolink bottomnav__gotolink--next"></div>  <div class="fixed-footer fixed-width" align="right" id="setbackgrnd"><table class="fixed-width"><tr class="fixed-width"><td id="tdsearch" align="right" class="tdsearch"><input type="text" id="search" onkeyup="search(id)" placeholder="Find on page..." class="form-control search"></td><td id="tdbtn" align="left" class="tdbtn"><button onclick="myFunction()" id="button" class="button"></button></td></tr></table></div>
</html>